Antibodies, pharmaceutical compositions and methods
By developing pH-dependent antibodies with replacement and blocking functions, the problems of high dose and high cost in the treatment of complement-mediated diseases by existing antibodies are solved, and efficient complement activity neutralization and side effects are achieved, and the therapeutic effect is improved.
Patent Information
- Application Number
- CN202080085493.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-16
- Filing Date
- 2020-10-15
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-10-15
AI Technical Summary
When treating complement-mediated diseases, existing antibodies have high doses and high costs, and are difficult to effectively neutralize the hemolytic activity of human serum. The existing pH-dependent antibodies have low dissociation efficiency under acidic pH conditions, which affects the therapeutic effect.
An isolated antibody has been developed that comprises an antigen binding region and an antibody constant region with a substitution function and/or a blocking function, capable of binding to Cls in a pH-dependent manner, promoting dissociation of Clq from the Clqrs complex or inhibiting Clq. The binding to Clr2s2 specifically binds to Clqrs complex and promotes the dissociation of Clq, with efficient substitution or blocking functions.
By surface plasmon resonance measurement, the antibody shows reliable binding activity in the neutral pH range, while the low binding activity in the acidic pH range reduces therapeutic dose and side effects and improves the speed and efficiency of neutralizing complement activity.
Smart Images

Figure BDA0003685714400000731 
Figure BDA0003685714400001051 
Figure BDA0003685714400001061
Abstract
Description
Technical Field
[0001] The present invention relates to antibodies, such as anti-Cls antibodies, and methods of using the same. Background Art
[0002] The C1 complex is a large protein complex that functions as a key initiator of the classical pathway cascade. The C1 complex consists of three components, Clq, Clr, and Cls, in a molar ratio of 1:2:2 (NPL 1). The classical pathway is initiated when the C1 complex binds to an antibody-bound target. Clq has six globular heads that mediate the binding of the C1 complex to the antibody through avidity interactions with the Fc region. Once tightly bound to the target, the Clr in the C1 complex automatically activates and becomes enzymatically active. The activated Clr then cleaves and activates the zymogen Cls in the C1 complex (NPL 2). Subsequently, the active Cls cleaves its substrate complement components C2 and C4 into C2a / C2b and C4a / C4b fragments, respectively. This leads to the assembly of C4b2a (a C3 convertase) on the target surface, which cleaves C3 to form C3b. C3b in turn cleaves C5 to initiate the formation of the terminal membrane attack complex, C5b, C6, C7, C8, and C9, which lyse the target through pore formation.
[0003] Both Cls and Clr proteins have the same domain organization, namely CUB1-EGF-CUB2-CCP1-CCP2-serine protease (NPL 3). The CUB1-EGF-CUB2 domain mediates the interaction between Clr and Cls to form the Clr2s2 tetramer (NPL 4), as well as the interaction between Clr2s2 and Clq (NPL 5). In contrast, the CCP1-CCP2-serine protease domains of Clr and Cls are responsible for the proteolytic cleavage of their respective substrates (NPL 6, NPL 7). The Clr2s2 tetramer interacts with the six stems in Clq through six binding sites within the CUB1-EGF-CUB2 domain of the tetramer (NPL 5).
[0004] While a properly functioning complement system protects the host from pathogens, dysregulation or inappropriate activation of the classical pathway can lead to various complement-mediated disorders, such as, but not limited to, autoimmune hemolytic anemia (AIHA), Behcet's disease, bullous pemphigus (BP), immune thrombocytopenic purpura (ITP), etc. Therefore, inhibiting excessive or uncontrolled activation of the classical pathway may provide clinical benefits to patients suffering from such disorders.
[0005] HI532 is an antibody that binds to the β domain of Cls and is reported to inhibit the interaction of Clr2s2 with Clq (NPL 8). However, this antibody was unable to completely neutralize the hemolytic activity of human serum, with 30% activity remaining even after 24 h of incubation of serum with the antibody.
[0006] Antibodies are attractive drugs because they are stable in plasma, highly specific for their targets, and generally exhibit favorable pharmacokinetic profiles. However, due to their large molecular size, the dose of therapeutic antibodies is often high. In cases where the target is present in large quantities, the required antibody therapeutic dose is even higher. Therefore, methods to improve the pharmacokinetics, pharmacodynamics, and antigen-binding properties of antibodies are attractive approaches to reduce the dose and high production costs associated with therapeutic antibodies.
[0007] It has been reported that antibodies that bind to antigens in a pH-dependent manner (hereinafter also referred to as "pH-dependent antibodies" or "pH-dependent binding antibodies") enable a single antibody molecule to neutralize multiple antigen molecules (NPL 9, PTL 1). pH-dependent antibodies strongly bind to their antigens under neutral pH conditions in plasma, but dissociate from the antigens under acidic pH conditions in endosomes. Once dissociated from the antigen, the antibody circulates back to the plasma through the FcRn receptor, and the dissociated antigen is degraded in the lysosomes of the cell. The recirculating antibody is then free to bind to and neutralize the antigen molecule again, and this process continues to repeat as long as the antibody is still in circulation.
[0008] Reference List
[0009] Patent Literature
[0010] [PTL 1] WO2009 / 125825
[0011] Non-patent literature
[0012] [NPL 1]Wang et.al.Mol Cell.2016 Jul 7;63(1):135-45
[0013] [NPL2]Mortensen et.al.Proc Natl Acad Sci US A.2017 Jan 31;114(5):986-991
[0014] [NPL 3]Gal et.al.Mol Immunol.2009 Sep; 46(14): 2745-52
[0015] [NPL4]Almitairi et.al.Proc Natl Acad Sci US A.2018 Jan 23;115(4):768-773
[0016] [NPL 5]Bally et.al.J Biol Chem.2009Jul 17;284(29):19340-8
[0017] [NPL 6]Rossi et.al.1998 J Biol Chem.1998 Jan 9;273(2):1232-9
[0018] [NPL 7]Lacroix et.al.J Biol Chem.2001 Sep 28;276(39):36233-40
[0019] [NPL 8]Tseng et.al.Mol Immunol.1997 Jun; 34(8-9): 671-9
[0020] [NPL 9]Igawa et.al.Nat Biotechnol.2010 Nov; 28(11): 1203-7 Summary of the invention
[0021] Technical issues
[0022] The present invention provides anti-complement component antibodies, such as anti-Cls antibodies, pharmaceutical compositions comprising the same, and methods of using the same.
[0023] Solution to the problem
[0024] The present invention provides an isolated antibody comprising an antigen binding region and an antibody constant region, having a displacement function and / or a blocking function and binding to Cls in a pH-dependent manner, wherein the displacement function enables the antibody to bind to the Clqrs complex and promote the dissociation of Clq from the lqrs complex, and the blocking function enables the antibody to bind to Clr2s2 and inhibit the binding of Clq to Clr2s2.
[0025] Specifically, the present invention relates to the following:
[0026] [1] An isolated antibody comprising an antigen binding region and an antibody constant region, wherein
[0027] The antibody promotes the dissociation of Clq from the Clqrs complex and / or inhibits the binding of Clq to Clr2s2, wherein
[0028] In the case where the binding activity of the antibody to human and / or cynomolgus monkey Cls is measured by surface plasmon resonance,
[0029] i) the dissociation constant (KD) values in the neutral pH range can be reliably calculated, whereas the KD values in the acidic pH range cannot be reliably calculated due to the absence of binding activity or very low binding activity, or
[0030] ii) Under the premise that both the KD values in the neutral pH range and the acidic pH range can be reliably calculated, the ratio of the KD value in the acidic pH range to the KD value in the neutral pH range, i.e. the acidic KD / neutral KD ratio, is greater than 10.
[0031] [2] The antibody described in [1], wherein the binding activity is measured by surface plasmon resonance using a sensor chip and a running buffer at 37 degrees Celsius, each antibody is captured on the sensor chip at 50 resonance units by human Igκ light chain, and the running buffer contains 20mM ACES (N-(2-acetylamino)-2-aminoethanesulfonic acid), 150mM NaCl, 1.2mM CaCl2, 1mg / mL bovine serum albumin (BSA), 1mg / mL CM-dextran sodium salt (CMD), 0.05% polysorbate 20, and 0.005% NaN3.
[0032] [3] The antibody of [1] or [2], wherein the pI of the antibody is less than 9.00, less than 8.90, less than 8.80 or 8.78 or less, and 4.28 or more.
[0033] [4] The antibody described in [3], wherein the pI is measured by capillary isoelectric focusing, wherein a solution containing 0.08 M phosphoric acid in 0.1% m / v methylcellulose (MC) is used as the anolyte solution, a solution containing 0.1 M sodium hydroxide in 0.1% m / v MC is used as the catholyte solution, and a solution containing 0.5 mg / mL antibody, 0.3% m / v MC, 6.0 mM iminodiacetic acid (IDA), 10 mM arginine, 4 M urea and pI markers (7.65 and 9.77) is used as the working solution for the cleaved antibody.
[0034] [5] The antibody according to any one of [1] to [4], wherein the antigen-binding region is capable of specifically binding to the CUB1-EGF-CUB2 domain of human Cls.
[0035] [6] The antibody of any one of [1] to [5], wherein the antigen-binding region comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HVR-H1, HVR-H2 and HVR-H3, the HVR-H1 comprises an amino acid sequence consisting of AYAMN (SEQ ID No. 1), the HVR-H2 comprises an amino acid sequence consisting of LIYGX1X2X3X4FYASWAX5X6 (SEQ ID No. 2), the HVR-H3 comprises an amino acid sequence consisting of GRSX7NYX8SX9FHL (SEQ ID No. 3), and the light chain variable region comprises HVR-L1, HVR-L2 and HVR-L3, the HVR-L1 comprises an amino acid sequence consisting of QAX 10 X 11 X 12 LHD 13 NLA (SEQ ID No. 4), wherein HVR-L2 comprises X 14 ASX 15 X 16 ES (SEQ ID No. 5), wherein the HVR-L3 comprises X 17 GEFX 18 X 19 X 20 X 21 ADX 22 NX 23 (SEQ ID No.6), wherein X1 to X 23 Each of which is selected from naturally occurring amino acids.
[0036] [7] An isolated anti-Cls antibody comprising a heavy chain variable region, a light chain variable region and an antibody constant region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2 and HVR-H3, the HVR-H1 comprises an amino acid sequence consisting of AYAMN (SEQ ID No. 1), the HVR-H2 comprises an amino acid sequence consisting of LIYGX1X2X3X4FYASWAX5X6 (SEQ ID No. 2), the HVR-H3 comprises an amino acid sequence consisting of GRSX7NYX8SX9FHL (SEQ ID No. 3), the light chain variable region comprises HVR-L1, HVR-L2 and HVR-L3, the HVR-L1 comprises an amino acid sequence consisting of QAX 10 X 11 X 12 LHD 13 NLA (SEQ ID No. 4), wherein HVR-L2 comprises X 14 ASX 15 X16 ES (SEQ ID No. 5), wherein the HVR-L3 comprises X 17 GEFX 18 X 19 X 20 X 21 ADX 22 NX 23 (SEQ ID No.6), wherein X1 to X 23 Each of which is selected from naturally occurring amino acids.
[0037] [8] The antibody described in [6] or [7], wherein
[0038] X1 is Lys or Ser,
[0039] X2 is Gly or Lys,
[0040] X3 is His or Ser,
[0041] X4 is Glu or Thr,
[0042] X5 is Glu or Lys,
[0043] X6 is Glu or Gly,
[0044] X7 is Lys or Val,
[0045] X8 is Asn or Val,
[0046] X9 is Asp or Gly,
[0047] X 10 is Asn, Gln or Ser,
[0048] X 11 is Gly or Gln,
[0049] X 12 It is Ile or Ser,
[0050] X 13 is Lys or Arg,
[0051] X 14 is Gly or Gln,
[0052] X 15 is Gln or Thr,
[0053] X 16 is Leu or Arg,
[0054] X 17 is His or Gln,
[0055] X 18 Is Pro or Ser,
[0056] X 19 is Cys or Tyr,
[0057] X 20 is Glu or Ser,
[0058] X 21 is Glu or Ser,
[0059] X 22 is Cys or Leu, and
[0060] X 23 It is Gln or Thr.
[0061] [9] The antibody of any one of [6] to [8], wherein HVR-H1 comprises the amino acid sequence consisting of SEQ ID No.7, HVR-H2 comprises any one of the amino acid sequences consisting of SEQ ID Nos.8 to 10, HVR-H3 comprises any one of the amino acid sequences consisting of SEQ ID Nos.11 to 13, HVR-L1 comprises any one of the amino acid sequences consisting of SEQ ID Nos.14 to 18, HVR-L2 comprises any one of the amino acid sequences consisting of SEQ ID Nos.19 to 22, and HVR-L3 comprises any one of the amino acid sequences consisting of SEQ ID Nos.23 to 28.
[0062]
[10] The antibody of any one of [6] to [9], wherein the combination of amino acid sequences of HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3 is selected from the group consisting of 1) to 9) below;
[0063] 1) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0064] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 8,
[0065] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0066] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 14,
[0067] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0068] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 23;
[0069] 2) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0070] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 9,
[0071] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 12,
[0072] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 14,
[0073] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0074] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 23;
[0075] 3) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0076] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0077] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0078] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. o15,
[0079] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0080] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0081] 4) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0082] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0083] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0084] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0085] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0086] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0087] 5) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0088] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0089] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0090] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 16,
[0091] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 21, and
[0092] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 25;
[0093] 6) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0094] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0095] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0096] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 17,
[0097] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0098] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 26;
[0099] 7) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0100] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0101] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0102] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0103] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0104] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 27;
[0105] 8) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0106] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0107] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0108] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0109] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0110] HVR-L3, which comprises the amino acid sequence consisting of SEQ ID No. 27, and
[0111] 9) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0112] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0113] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0114] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0115] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 22, and
[0116] HVR-L3 comprises the amino acid sequence consisting of SEQ ID No.28.
[0117]
[11] The antibody described in [6] or [7], wherein X 19 and / or X 22 Not Cys.
[0118]
[12] The antibody of
[11] , wherein X 19 is Trp or Tyr, and X22 It is Leu or Met.
[0119]
[13] The antibody described in
[11] or
[12] , wherein
[0120] X1 is Ser,
[0121] X2 is Gly,
[0122] X3 is His,
[0123] X4 is Glu,
[0124] X5 is Glu,
[0125] X6 is Glu,
[0126] X7 is Lys,
[0127] X8 is Asn or Val,
[0128] X9 is Asp or Gly,
[0129] X 10 is Asn, Gln or Ser,
[0130] X 11 is Gly or Gln,
[0131] X 12 It's Ile.
[0132] X 13 is Lys or Arg,
[0133] X14 is Gly or Gln,
[0134] X 15 is Gln or Thr,
[0135] X 16 is Leu or Arg,
[0136] X 17 It's His,
[0137] X 18 Is Pro or Ser,
[0138] X 19 It's Tyr.
[0139] X 20 is Glu or Ser,
[0140] X 21 is Glu or Ser,
[0141] X 22 is Leu, and
[0142] X 23 It is Gln or Thr.
[0143]
[14] The antibody of any one of
[11] to
[13] , wherein HVR-H1 comprises an amino acid sequence consisting of SEQ ID No.7, HVR-H2 comprises an amino acid sequence consisting of SEQ ID No.10, HVR-H3 comprises an amino acid sequence consisting of SEQ ID No.11 or 13, HVR-L1 comprises any one of the amino acid sequences consisting of SEQ ID Nos.15 to 18, HVR-L2 comprises any one of the amino acid sequences consisting of SEQ ID Nos.19 to 22, and HVR-L3 comprises any one of the amino acid sequences consisting of SEQ ID Nos.24 to 28.
[0144]
[15] The antibody of any one of
[11] to
[14] , wherein the combination of amino acid sequences of HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3 is selected from the group consisting of the following 3) to 9);
[0145] 3) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0146] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0147] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0148] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0149] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0150] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0151] 4) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0152] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0153] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0154] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0155] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0156] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0157] 5) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0158] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0159] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0160] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 16,
[0161] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 21, and
[0162] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 25;
[0163] 6) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0164] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0165] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0166] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 17,
[0167] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0168] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 26;
[0169] 7) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0170] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0171] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0172] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0173] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0174] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 27;
[0175] 8) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0176] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0177] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0178] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0179] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0180] HVR-L3, which comprises the amino acid sequence consisting of SEQ ID No. 27, and
[0181] 9) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0182] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0183] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0184] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0185] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 22, and
[0186] HVR-L3 comprises the amino acid sequence consisting of SEQ ID No.28.
[0187]
[16] The antibody of any one of [1] to
[15] , wherein the antibody constant region is a constant region of a human antibody including a heavy chain and a light chain.
[0188]
[17] The antibody described in
[16] , wherein the human antibody is human IgG1.
[0189]
[18] The antibody of
[16] or
[17] , wherein the constant region in the heavy chain comprises at least one amino acid which reduces the ability to bind to C1q compared to the constant region of a human antibody without the at least one amino acid.
[0190]
[19] The antibody described in
[18] , wherein the amino acid that reduces the ability to bind to C1q is Asp at position 238 in the EU numbering system.
[0191]
[20] The antibody of any one of
[16] to
[19] , wherein the constant region in the heavy chain comprises at least one amino acid that selectively binds to FcγRIIb compared to a constant region of a human antibody without the at least one amino acid.
[0192]
[21] The antibody described in
[20] , wherein the ratio of the KD value of the constant region in the heavy chain to human FcγRIIa to the KD value of the constant region in the heavy chain to human FcγRIIb (KD(hFcβRIIa / KD(hFcγRIIb)) is higher than the human antibody constant region without the at least one amino acid in
[20] .
[0193]
[22] The antibody of
[20] or
[21] , wherein the constant region in the heavy chain comprises Tyr at position 234 in the EU numbering system, Asp at position 238 in the EU numbering system, Ile at position 264 in the EU numbering system, and Lys at position 330 in the EU numbering system.
[0194]
[23] The antibody of any one of
[20] to
[22] , wherein the constant region in the heavy chain comprises at least one selected from the group consisting of Arg at position 214 in the EU numbering system, Val at position 250 in the EU numbering system, Pro at position 307 in the EU numbering system, Arg at position 311 in the EU numbering system, Arg at position 343 in the EU numbering system, Leu at position 428 in the EU numbering system, Ala at position 434 in the EU numbering system, Thr at position 436 in the EU numbering system, Arg at position 438 in the EU numbering system, and Glu at position 440 in the EU numbering system.
[0195]
[24] The antibody according to any one of
[16] to
[23] , wherein amino acids 446 and 447 according to the EU numbering system of the constant region are deleted.
[0196]
[25] The antibody of any one of
[16] to
[24] , wherein the antigen-binding region is a humanized antibody variable region.
[0197]
[26] A pharmaceutical composition comprising the antibody according to any one of [1] to
[25] and at least one pharmaceutically acceptable carrier.
[0198]
[27] The pharmaceutical composition of
[26] , for treating an individual suffering from a complement-mediated disease or condition, or preventing an individual at risk of suffering from a complement-mediated disease or condition.
[0199]
[28] A method for treating an individual suffering from a complement-mediated disease or condition, or preventing an individual at risk of suffering from a complement-mediated disease or condition, comprising administering to the individual an effective amount of the antibody of any one of [1] to
[25] . BRIEF DESCRIPTION OF THE DRAWINGS
[0200] [ Figure 1 ]
[0201] Figure 1 The binding ability of anti-Cls antibodies to human Clr2s2 protein is illustrated. The BIACORE (registered trademark) sensorgram of anti-Cls antibodies against 100nM recombinant human Clr2s2 protein is shown. The antibody variant is generated by a single amino acid substitution at position 94 (kabat numbering) in the COS0637temp light chain. The COS0637temp data is also shown as a control.
[0202] [ Figure 2 ]
[0203] Figure 2 The binding ability of anti-Cls antibodies to human Clr2s2 protein is illustrated. The BIACORE (registered trademark) sensorgram of anti-Cls antibodies against 100nM recombinant human Clr2s2 protein is shown. The antibody variant is generated by a single amino acid substitution at position 95d (kabat numbering) in the COS0637temp light chain. The COS0637temp data is also shown as a control.
[0204] [ Figure 3 ]
[0205] Figure 3 The binding ability of anti-Cls antibodies to human Clr2s2 protein is illustrated. The BIACORE (registered trademark) sensorgram of anti-Cls antibodies against 100nM recombinant human Clr2s2 protein is shown. The antibody variants are produced by double amino acid substitutions at positions 94 and 95d (kabat numbering) in the COS0637temp light chain. The COS0637temp data are also shown as a control. Variants showing slight binding reactions are highlighted with arrows.
[0206] [ Figure 4-1 ]
[0207] Figure 4-1 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637cc-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0208] [ Figure 4-2 ]
[0209] Figure 4-2 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637h-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0210] [ Figure 4-3 ]
[0211] Figure 4-3BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637temp-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0212] [ Figure 4-4 ]
[0213] Figure 4-4 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHvl-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0214] [ Figure 4-5 ]
[0215] Figure 4-5 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv2-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0216] [ Figure 4-6 ]
[0217] Figure 4-6BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv3-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0218] [ Figure 4-7 ]
[0219] Figure 4-7 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv4-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0220] [ Figure 4-8 ]
[0221] Figure 4-8 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv5-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0222] [ Figure 4-9 ]
[0223] Figure 4-9BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv6-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0224] [ Figure 4-10 ]
[0225] Figure 4-10 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv7-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0226] [ Figure 4-11 ]
[0227] Figure 4-11 BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv8-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0228] [ Figure 4-12 ]
[0229] Figure 4-12BIACORE (registered trademark) sensorgrams are illustrated, showing the interaction of COS0637pHv9-TT91R with human Clr2s2 and cynomolgus monkey Clr2s2 to evaluate pH dependence and cross-reactivity against cynomolgus monkey and human Clr2s2, as described in Example 3.2. Sensorgrams were obtained by injecting human Clr2s2 (solid line [pH7.4], dotted line [pH5.8]), cynomolgus monkey Clr2s2 (short dash line [pH7.4], dotted line [pH5.8]) on the sensor surface immobilized with anti-Cls antibody, respectively. The antibody / antigen complex formed at pH7.4 was allowed to dissociate at pH7.4, and the antibody / antigen complex formed at pH5.8 was allowed to dissociate at pH5.8.
[0230] [ Figure 5-1 ]
[0231] Figure 5-1 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637cc-SG1148 is depicted by overlaying three sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dotted lines) depict antibody binding to Clqrs and displacement of Clq from Clr2s2. Figure 3 (Dashed line) depicts the baseline when only the antibody binds to Clr2s2 in the absence of any Clq. To compare these sensorgrams, the binging response of Clr2s2 was normalized to 100RU.
[0232] [ Figure 5-2 ]
[0233] Figure 5-2 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637pHv3-TT91R is depicted by overlaying three sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dotted lines) depict antibody binding to Clqrs and displacement of Clq from Clr2s2. Figure 3 (Dashed line) depicts the baseline when only the antibody binds to Clr2s2 in the absence of any Clq. To compare these sensorgrams, the binging response of Clr2s2 was normalized to 100RU.
[0234] [ Figure 5-3]
[0235] Figure 5-3 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637pHv8-TT91R is depicted by overlaying three sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dotted lines) depict antibody binding to Clqrs and displacement of Clq from Clr2s2. Figure 3 (Dashed line) depicts the baseline when only the antibody binds to Clr2s2 in the absence of any Clq. To compare these sensorgrams, the binging response of Clr2s2 was normalized to 100RU.
[0236] [ Figure 5-4 ]
[0237] Figure 5-4 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637pHv9-TT91R is depicted by overlaying three sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dotted lines) depict antibody binding to Clqrs and displacement of Clq from Clr2s2. Figure 3 (Dashed line) depicts the baseline when only the antibody binds to Clr2s2 in the absence of any Clq. To compare these sensorgrams, the binging response of Clr2s2 was normalized to 100RU.
[0238] [ Figure 6-1 ]
[0239] Figure 6-1 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637cc-SG1148 is depicted by overlaying two sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dot line) depicts the binding of the antibody to Clqrs and the displacement of Clq from Clr2s2. To compare these sensorgrams, the baseline (before antibody injection) was adjusted to 0 RU.
[0240] [ Figure 6-2 ]
[0241] Figure 6-2 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637pHv3-TT91R is depicted by overlaying two sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dot line) depicts the binding of the antibody to Clqrs and the displacement of Clq from Clr2s2. To compare these sensorgrams, the baseline (before antibody injection) was adjusted to 0 RU.
[0242] [ Figure 6-3 ]
[0243] Figure 6-3 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637pHv8-TT91R is depicted by overlaying two sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dot line) depicts the binding of the antibody to Clqrs and the displacement of Clq from Clr2s2. To compare these sensorgrams, the baseline (before antibody injection) was adjusted to 0 RU.
[0244] [ Figure 6-4 ]
[0245] Figure 6-4 The antibody-mediated dissociation of native human Clq from recombinant human Clr2s2 tetramer immobilized on the BIACORE (registered trademark) sensor surface is illustrated. The replacement of native human Clq by COS0637pHv9-TT91R is depicted by overlaying two sensorgrams. Figure 1 (Solid line) depicts the stable capture of Clqrs on the sensor surface. Figure 2 (Dash-dot line) depicts the binding of the antibody to Clqrs and the displacement of Clq from Clr2s2. To compare these sensorgrams, the baseline (before antibody injection) was adjusted to 0 RU.
[0246] [ Figure 7 ]
[0247] Figure 7 Results of determining the proportion of IL-2 secreting cells in a cultured cell population are shown. Each marker shows the results for a tested donor.
[0248] [ Figure 8-1 ]
[0249] Figure 8-1 Results of mean values of cell areas are illustrated. Statistical significance was assessed by Wilcoxon rank sum test (*p<0.05, **p<0.01). Each marker shows the results of the tested samples.
[0250] [ Figure 8-2 ]
[0251] Figure 8-2 Results of mean values of cell perimeter are illustrated. Statistical significance was assessed by Wilcoxon rank sum test (*p<0.05, **p<0.01). Each marker shows the results of the tested samples.
[0252] [ Figure 8-3 ]
[0253] Figure 8-3 The results of determining the proportion of cells secreting IL-2 in a cultured cell population are illustrated. Each marker shows the result of a test sample.
[0254] Description of Implementation Methods
[0255] The techniques and procedures described or referenced herein are generally well understood by those skilled in the art and are routinely used using conventional methodology, such as, for example, the widely used methods described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd Edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Current Protocols in Molecular Biology (FM Ausubel et al., eds., (2003)); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (MJ MacPherson, BD Hames and GR Taylor, eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual and Animal Cell Culture (RI Freshney, ed. (1987)); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Manual, ed. Notebook (JECellis, 1998) Academic Press; Animal Cell Culture (RIFreshney), 1987); Introduction to Cell and Tissue Culture (JPMather and PERoberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A.Doyle, JBGriffiths and DG Newell, 1993-8) J.Wiley and Sons; Handbook of ExperimentalImmunology (eds. DMWeir and CC Blackwell); Gene Transfer Vectors for Mammalian Cells (JMMiller and MPCalos, 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., 1994); Current Protocols in Immunology (JEColigan et al., 1991); ShortProtocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (CA Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (edited by D. Catty., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (edited by P. Shepherd and C. Dean, Oxford University Press, 2000); Using Antibodies: ALaboratory Manual (E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and JD Capra, Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (VT DeVita et al., JS Lippincott Company, 1993).
[0256] I. Definitions
[0257] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd Edition, J. Wiley & Sons (New York, NY 1994) and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th Edition, John Wiley & Sons (New York, NY 1992), provide a general guide to many of the terms used in this application for those skilled in the art. All references cited herein, including patent applications and publications, are incorporated by reference in their entirety.
[0258] For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural, and vice versa. It should be understood that the terms used herein are for the purpose of describing specific embodiments only and are not intended to be limiting. If any definition listed below conflicts with any document incorporated herein by reference, the definition listed below shall prevail.
[0259] "Acceptor human framework" for the purposes of this article is a framework comprising an amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework can include the same amino acid sequence, or it can include amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to a VL human immunoglobulin framework sequence or a human consensus framework sequence.
[0260] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by a dissociation constant (Kd or KD). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below. "Affinity", "binding affinity", "binding ability" and "binding activity" can be used interchangeably. The term "binding activity" refers to the strength of the sum of non-covalent interactions between a single or multiple binding sites of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Here, binding activity is not strictly limited to reflecting the activity of a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). When members of a binding pair can bind to each other in a monovalent and multivalent binding manner, the binding activity is the strength of the sum of these bindings. The binding activity of a molecule X to its partner Y can generally be represented by a dissociation constant (KD). Alternatively, the association rate and dissociation rate (Kon and Koff) can be used to assess binding. Binding activity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.
[0261] An "affinity matured" antibody is one with one or more alterations in one or more hypervariable regions (HVRs) which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess such alterations.
[0262] The terms "anti-Cls antibody" and "antibody that binds to Cls" refer to an antibody that is capable of binding to Cls with sufficient affinity so that the antibody can be used as a diagnostic and / or therapeutic agent targeting Cls. In one embodiment, the extent of binding of the anti-Cls antibody to unrelated, non-Cls proteins is less than about 10% of the binding of the antibody to Cls, as measured by, for example, radioimmunoassay (RIA). In certain embodiments, the dissociation constant (Kd) of the antibody that binds to Cls is 1 micromolar (microM) or less, 100 nM or less, 10 nM or less, 1 nM or less, 0.1 nM or less, 0.01 nM or less, or 0.001 nM or less (e.g., 10 -8 M or smaller, for example, from 10 -8 M to 10 -13 M, for example, from 10 -9 M to 10 -13 M). In certain embodiments, an anti-Cls antibody binds to a Cls epitope that is conserved among Cls from different species.
[0263] The term "antibody" is used herein in the broadest sense and includes various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0264] "Antibody fragment" refers to a molecule other than an intact antibody, which comprises a portion of an intact antibody that binds to an antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
[0265] An "antibody that binds to the same epitope as a reference antibody" is one that blocks the binding of the reference antibody to its antigen by 50% or more in a competition assay, whereas the reference antibody blocks the binding of the antibody to its antigen by 50% or more in a competition assay. Exemplary competition assays are provided herein.
[0266] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0267] The "class" of an antibody refers to the type of constant domain or region that its heavy chain possesses. There are five main classes of antibodies: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0268] As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents cellular function and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., 211 At 131 I. 125 I. 90 Y. 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P. 212 radioactive isotopes of Pb and Lu); chemotherapeutic agents or drugs (e.g., methotrexate, doxorubicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitors; enzymes and fragments thereof, such as nucleolytic enzymes; antibiotics; toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof; and various anti-tumor or anti-cancer agents disclosed below.
[0269] "Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation.
[0270] An "effective amount" of an agent (eg, a pharmaceutical agent) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
[0271] The term "epitope" includes any determinant that can be bound by an antibody. An epitope is a region of an antigen that is bound by an antibody that targets the antigen and includes specific amino acids that directly contact the antibody. Epitope determinants can include chemically active surface clusters of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and can have specific three-dimensional structural characteristics and / or specific charge characteristics. Typically, antibodies specific for a particular target antigen will preferentially recognize epitopes on the target antigen in a complex mixture of proteins and / or macromolecules.
[0272] The term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain comprising at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) or glycine-lysine (residues 446-447) in the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0273] "Framework" or "FR" refers to the variable domain residues other than the hypervariable region (HVR) residues. The FR of a variable domain is generally composed of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, HVR and FR sequences generally appear in the following order in VH (or VL): FR1-H1 (L1)-FR2-H2 (L2)-FR3-H3 (L3)-FR4.
[0274] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that comprise an Fc region as defined herein.
[0275] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably to refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", which include the primary transformed cell and the progeny derived therefrom, without regard to the number of passages. The progeny may not be completely identical to the parent cell in nucleic acid content, but may contain mutations. Mutant progeny screened or selected for the same function or biological activity as the initially transformed cell are included herein.
[0276] A "human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human or human cell or derived from a non-human source utilizing a human antibody library or other human antibody encoding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0277] "Human consensus framework" is a framework that represents the most common amino acid residues in the selection of human immunoglobulin VL or VH framework sequences. Typically, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Typically, the subgroup of sequences is the subgroup in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1-3. In one embodiment, for VL, the subgroup is the subgroup κI in the above-mentioned Kabat et al. In one embodiment, for VH, the subgroup is the subgroup III in the above-mentioned Kabat et al.
[0278] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one and usually two variable domains, wherein all or substantially all of the HVRs (e.g., CDRs) correspond to those of non-human antibodies, and all or substantially all of the FRs correspond to those of human antibodies. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. An antibody, for example, a "humanized form" of a non-human antibody refers to a humanized antibody.
[0279] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is hypervariable in sequence ("complementarity determining region" or "CDR") and / or forms structurally defined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contacts"). Typically, an antibody comprises six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). Exemplary HVRs herein include:
[0280] (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));
[0281] (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991));
[0282] (c) antigenic contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); and
[0283] (d) a combination of (a), (b) and / or (c), comprising HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3) and 94-102 (H3).
[0284] Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.
[0285] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules including, but not limited to, a cytotoxic agent.
[0286] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
[0287] An "isolated" antibody is one that has been separated from components of its natural environment. In some embodiments, the antibody is purified to a purity greater than 95% or 99%, for example as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0288] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0289] "Isolated nucleic acid encoding an anti-Cls antibody" or "isolated nucleic acid encoding an anti-Clr antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecules in a single vector or separate vectors and such nucleic acid molecules present in one or more locations in a host cell.
[0290] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, that is, the individual antibodies that make up the population are identical and / or bind to the same epitope, except for possible variant antibodies, for example, containing naturally occurring mutations or occurring during the production process of monoclonal antibody preparations, and such variants are generally present in small amounts. Contrary to the polyclonal antibody preparations that generally include different antibodies for different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed to a single determinant on an antigen. Therefore, the modifier "monoclonal" represents the characteristics of the antibody obtained from a substantially homogeneous antibody population, and should not be construed as requiring antibody to be produced by any ad hoc method. For example, the monoclonal antibody used according to the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of human immunoglobulin loci, and such methods and other exemplary methods for preparing monoclonal antibodies are described herein.
[0291] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies can be present in pharmaceutical formulations.
[0292] "Native antibodies" refer to naturally occurring immunoglobulin molecules with different structures. For example, natural IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains bonded by disulfide bonds. From N-terminus to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N-terminus to C-terminus, each light chain has a variable region (VL), also called a variable light chain domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody can be assigned to one of two types, called κ and λ, based on the amino acid sequence of its constant domain.
[0293] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications, and / or warnings concerning the use of such therapeutic products.
[0294] "Percentage (%) amino acid sequence identity" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence after the sequences are aligned and, if necessary, gaps are introduced to achieve maximum percentage sequence identity without any conservative substitutions being considered as part of sequence identity. Alignment for determining amino acid sequence identity percentage can be achieved in various ways within the skill of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR) software, or GENETYX (registered trademark) (Genetyx Co., Ltd.). Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequence.
[0295] The ALIGN-2 sequence comparison computer program is written by Genentech, Inc., and the source code has been submitted to the U.S. Copyright Office, Washington, D.C., 20559, with user documentation, and the copyright registration number in the United States is TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. in South San Francisco, California, or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and will not change. In the case of using ALIGN-2 for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A with, and or for a given amino acid sequence B (which can be optionally expressed as a given amino acid A with, and or for a given amino acid sequence B having or including a specific % amino acid sequence identity) is calculated as follows:
[0296] Multiply 100 by the fraction X / Y
[0297] Where X is the number of amino acid residues whose sequences are scored as identical matches by the alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be understood that the length of amino acid sequence A is not equal to the length of amino acid sequence B, and the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0298] The term "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient contained therein to be effective, and that contains no additional components that are unacceptably toxic to a subject to which the formulation would be administered.
[0299] "Pharmaceutically acceptable carrier" refers to a component of a pharmaceutical preparation other than the active ingredient that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
[0300] As used herein, the phrase "specific binding" refers to the activity or feature of an antibody that binds to a non-target antigen at a binding level that includes background (i.e., non-specific) binding but does not include significant (i.e., specific) binding. In other words, "specific binding" refers to the activity or feature of an antibody that binds to a target antigen at a certain binding level that includes significant (i.e., specific) binding in addition to background or in place of background (i.e., non-specific) binding. Specificity can be measured by any method mentioned in this specification or known in the art. The level of the above-mentioned non-specific or background binding can be zero, or may not be zero but close to zero, or may be low enough to be technically ignored by those skilled in the art. For example, when a technician cannot detect or observe any significant (or relatively strong) signal of binding between an antibody and a non-target antigen in a suitable binding assay, it can be said that the antibody "does not specifically bind" the non-target antigen. On the contrary, when a technician can detect or observe any significant (or relatively strong) signal of binding between an antibody and a target antigen in a suitable binding assay, it can be said that the antibody "specifically binds" the target antigen.
[0301] Unless otherwise indicated, the term "Cls" as used herein refers to any native Cls from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed Cls as well as any form of Cls produced by processing in cells. The term also includes naturally occurring Cls variants, such as splice variants or allelic variants. The amino acid sequence of an exemplary human Cls is shown in SEQ ID NO: 1. The amino acid sequences of exemplary cynomolgus monkey and rat Cls are shown in SEQ ID No: 3 and 2, respectively.
[0302] Unless otherwise indicated, the term "Clr" as used herein refers to any native Clr from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed Clr as well as any form of Clr produced by processing in cells. The term also includes naturally occurring Clr variants, such as splice variants or allelic variants. The amino acid sequence of an exemplary human Clr is shown in SEQ ID NO: 4. The amino acid sequences of exemplary cynomolgus monkey and rat Clr are shown in SEQ ID No: 5 and 6.
[0303] As used herein, "treatment" (and grammatical variations thereof, e.g., "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prevention or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the occurrence or recurrence of disease, alleviating symptoms, alleviating any direct or indirect pathological consequences of disease, preventing metastasis, reducing the rate of disease progression, ameliorating or relieving the disease state, alleviating or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the development of disease or slow the progression of disease.
[0304] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al., Kuby Immunology, 6th edition, WH Freeman and Co., p. 91 (2007)). A single VH or VL domain may be sufficient to confer antigen binding specificity. In addition, the VH or VL domains from antibodies that bind to an antigen can be used to screen libraries of complementary VL or VH domains, respectively, to isolate antibodies that bind to a specific antigen. See, e.g., Portolano et al., J. Immunol. 150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).
[0305] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures, as well as vectors that integrate into the genome of a host cell into which they have been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."
[0306] II. Antibodies
[0307] On the one hand, the present invention is based in part on antibodies comprising an antigen binding region and an antibody constant region. In certain embodiments, antibodies that bind to C1s are provided. In certain embodiments, antibodies that specifically bind to C1s are provided. The antibodies of the present invention can be used, for example, to diagnose or treat complement-mediated diseases or conditions.
[0308] In one embodiment, the species of C1s can be selected from one or more species. In a specific embodiment, the species is human and non-human animals. In a specific embodiment, the species is human, rat and monkey (e.g., cynomolgus monkey, rhesus monkey, marmoset, chimpanzee and baboon). In a specific embodiment, the species is human and monkey (e.g., cynomolgus monkey, rhesus monkey, marmoset, chimpanzee and baboon). In a specific embodiment, the species is human and cynomolgus monkey.
[0309] In embodiments, antibodies include various types of antibodies, including antibody fragments, chimeric and humanized antibodies, human antibodies, library-derived antibodies, and multispecific antibodies. In embodiments, antibodies can be full-length antibodies, such as complete IgG1, IgG2, IgG3, or IgG4 antibodies, or other antibody classes or isotypes defined herein.
[0310] (Antibody fragment)
[0311] In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv and scFv fragments, as well as other fragments described below. For a review of certain antibody fragments, see Hudson et al., Nat. Med. 9: 129-134 (2003). For a review of scFv fragments, see, for example, Pluckthun, in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.
[0312] Diabodies are antibody fragments with two antigen-binding sites and can be bivalent or bispecific. See, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
[0313] A single domain antibody is an antibody fragment comprising all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, a single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Pat. No. 6,248,516 Bl).
[0314] As described herein, antibody fragments can be prepared by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (eg, E. coli or bacteriophage).
[0315] (Chimeric and humanized antibodies)
[0316] In certain embodiments, the antibodies provided herein are chimeric antibodies. Certain chimeric antibodies are described, for example, in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class switching" antibody, in which the class or subclass has been changed from the class or subclass of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
[0317] In certain embodiments, chimeric antibodies are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity to people while retaining the specificity and affinity of the parent non-human antibody. Typically, humanized antibodies include one or more variable domains, wherein HVR, such as CDR, (or a portion thereof) is derived from non-human antibodies, and FR (or a portion thereof) is derived from human antibody sequences. Humanized antibodies are optionally also comprised of at least a portion of a human constant region. In some embodiments, some FR residues in humanized antibodies are replaced by corresponding residues from non-human antibodies (e.g., antibodies from which HVR residues originate), for example, to restore or improve antibody specificity or affinity.
[0318] Humanized antibodies and methods for their preparation are reviewed, for example, in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described, for example, in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) transplantation); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "surface resurfacing"); Dall'Acqua et al., Methods 36:43-60 (2005) (describing "FR rearrangement"); and Osboum et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the "guided selection" method of FR rearrangement).
[0319] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best fit" method (see, e.g., Sims et al. J. Immunol. 151: 2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular light chain or heavy chain variable region subgroup (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89: 4285 (1992); and Presta et al. J. Immunol., 151: 2623 (1993); Human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).
[0320] (Human Antibody)
[0321] In certain embodiments, the antibodies provided herein are human antibodies. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
[0322] Human antibodies can be prepared by administering an immunogen to a transgenic animal that has been modified to produce a complete human antibody or a complete antibody with a human variable region that responds to antigen stimulation. Such animals typically contain all or part of a human immunoglobulin locus that replaces an endogenous immunoglobulin locus, or it is present outside the chromosome or randomly integrated into an animal chromosome. In such transgenic mice, the endogenous immunoglobulin locus is usually inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23: 1117-1125 (2005). See also, for example, U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSE (registered trademark) technology; U.S. Patent No. 5,770,429 describing HUMAB (registered trademark) technology; U.S. Patent No. 7,041,870 describing KM MOUSE (registered trademark) technology and U.S. Patent Application Publication No. US 2007 / 0061900 describing VELOCIMOUSE (registered trademark) technology. The human variable regions from intact antibodies produced by such animals can be further modified, for example, by combining with a different human constant region.
[0323] Human antibodies can also be prepared by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for producing human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boemer et al., J. Immunol., 147: 86 (1991)). Human antibodies produced by human B cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103: 3557-3562 (2006). Other methods include, for example, U.S. Pat. No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26 (4): 265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20 (3): 927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27 (3): 185-91 (2005).
[0324] Human antibodies can also be produced by isolating Fv clone variable domain sequences selected from human phage display libraries. Such variable domain sequences can then be combined with desired human constant domains. The technology of selecting human antibodies from antibody libraries is described below.
[0325] (Library-derived antibodies)
[0326] The antibodies of the present invention can be isolated by screening combinatorial libraries for antibodies with the desired activity. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies with the desired binding properties. For example, these methods are reviewed in Hoogenboom et al., Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed. Human Press, Totowa, NJ, 2001), and further described in, for example, McCafferty et al., Nature 348: 552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and Bradbury, Methods in Molecular Biology 248: 161-175 (Lo ed. Human Press, Totowa, NJ, 2001). Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004).
[0327] In certain phage display methods, the VH and VL gene repertoires are cloned separately by polymerase chain reaction (PCR) and randomly recombined in a phage library, and then the phage can be screened for antigen binding, as described in Winter et al., Ann. Rev. Immunol., 12: 433-455 (1994). Phage typically display antibody fragments in the form of single-chain Fv (scFv) fragments or Fab fragments. Libraries from immune sources provide high-affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, as described in Griffiths et al., EMBO J, 12: 725-734 (1993), naive libraries (e.g., from humans) can be cloned to provide a single source of antibodies to a wide range of non-self and self antigens without any immunization. Finally, naive libraries can also be prepared synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and rearrangement in vitro, as described in Hoogenboom and Winter, J. Mol. Biol., 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373 and U.S. Pat. Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0290236 and 2009 / 0002360.
[0328] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
[0329] (Multispecific Antibodies)
[0330] In certain embodiments, the antibodies provided herein are multispecific antibodies, such as bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificity to at least two different sites. In certain embodiments, one binding specificity is for Cls, and the other is for any other antigen. In certain embodiments, bispecific antibodies can bind to two different epitopes of Cls. Bispecific antibodies can also be used to localize cytotoxic agents to cells expressing Cls. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0331] Techniques for preparing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93 / 08829, and Traunecker et al., EMBO J. 10: 3655 (1991)) and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be prepared by designing electrostatic steering effects for making antibody Fc-heterodimer molecules (WO 93 / 08829, and Traunecker et al., EMBO J. 10: 3655 (1991)). 2009 / 089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al., Science, 229:81 (1985)); using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody" technology to prepare bispecific antibody fragments fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and use of single-chain Fv (scFv) dimers (see, e.g., Gruber et al., J. Immunol., 152:5368 (1994)); and preparation of trispecific antibodies, e.g., as described in Tutt et al., J. Immunol. 147:60 (1991).
[0332] Also included herein are engineered antibodies having three or more functional antigen binding sites, including "octopus antibodies" (see, e.g., US 2006 / 0025576A1).
[0333] The antibodies or fragments herein also include "dual-acting Fabs" or "DAFs," which comprise an antigen binding site that binds to both Cls and another, different antigen (see, e.g., US 2008 / 0069820).
[0334] A. Isolated Antibodies
[0335] In certain embodiments, the antibody is an isolated antibody. In embodiments, the isolated antibody comprises an antigen binding region and an antibody constant region.
[0336] In an embodiment, the isolated antibody may have a substitution function, so that the antibody specifically binds to Cls and promotes the dissociation of Clq from the Clqrs complex. In an embodiment, the isolated antibody may have a blocking function, so that the antibody specifically binds to Cls and inhibits the binding of Clq to Clr2s2. The isolated antibody may have one or both of the substitution function and the blocking function. The antibody preferably has these two functions.
[0337] In one embodiment, the isolated antibody specifically binds to Cls in a pH-dependent manner. As a specific example of the embodiment, when the binding activity of the antibody to human and / or cynomolgus monkey Cls is determined by surface plasmon resonance,
[0338] i) the dissociation constant (KD) values in the neutral pH range can be reliably calculated, whereas the KD values in the acidic pH range cannot be reliably calculated due to the absence of binding activity or very low binding activity, or
[0339] ii) Under the premise that both the KD values in the neutral pH range and the acidic pH range can be reliably calculated, the ratio of the KD value in the acidic pH range to the KD value in the neutral pH range, i.e. the acidic KD / neutral KD ratio, is greater than 10.
[0340] Such antibodies are expected to be particularly superior as drugs because the dosage and frequency of administration to patients can be reduced, thereby reducing the total dose. Anti-Cls antibodies are expected to have a higher safety profile than antibodies that bind to and remove the Clqrs complex from plasma because they only remove Clr2s2 from plasma (by binding to Cls) rather than removing Clq from plasma. Therefore, side effects associated with Clq depletion can be avoided. In addition, antibodies with rapid replacement of Clq are expected to neutralize complement activity more quickly, which can translate into a faster onset of therapeutic effect.
[0341] (a1) BIACORE (registered trademark) / replacement concept
[0342] In one embodiment, the isolated antibody that inhibits the interaction between Clq and the Clr2s2 complex is an antibody that binds to the Clqrs complex on a chip for surface plasmon resonance assay, such as a BIACORE (registered trademark) chip and promotes the dissociation of Clq from the Clqrs complex. In some embodiments, the above-mentioned function of binding to the Clqrs complex and promoting the dissociation of Clq from the Clqrs complex is referred to herein as "substitution function / activity" or "Clq substitution function / activity". The function / activity can be appropriately qualitatively or quantitatively evaluated using a surface plasmon resonance assay, such as the BIACORE (registered trademark) assay described herein. In a further embodiment, when the response unit (RU) value in the presence of the antibody is lower than the response unit (RU) value in the absence of the antibody, the antibody can be determined as an antibody having a substitution function, such as when a sufficient time has passed, by a surface plasmon resonance assay, such as a BIACORE (registered trademark) assay. In the sensorgram obtained from such an assay, a "crossing time point" can be identified, where the curve in the presence of Clq and the absence of the antibody crosses the curve in the presence of Clq and the antibody (see Examples for details). Strictly speaking, even in a single sensorgram, multiple crossing time points may be observed due to noise or oscillation of the latter curve when crossing the previous curve. In this case, any one of the multiple crossing time points can be selected as the "crossing time point". "After enough time" means that the measurement time point of the response unit (RU) value is sufficient for measurement purposes after the "crossing time point". In some embodiments, the measurement time point of the response unit (RU) value is at least 60s, 100s, 150s, 200s, 500s, 700s, 1000s, 1500s or 2000s after the antibody injection start time point. Alternatively, the measured time point can be at least 100s, 200s, 300s, 400s, 500s, 600s, 700s, 800s, 900s, 1000s, 3000s, 5000s, 7000s or 10000s after the crossing time point.
[0343] In one embodiment, when the crossing time point (e.g., in BIACORE (registered trademark) assay) is 60s, 100s, 150s, 200s, 500s, 700s, 1000s, 1500s or 2000s after the time point of starting antibody injection, the isolated antibody that inhibits the interaction between Clq and the Clr2s2 complex can be determined as an antibody with a replacement function, as determined by, for example, BIACORE (registered trademark) assay using the following conditions: the capture levels of the Clr2s2 complex and Clq are 200 resonance units (RU) and 200 resonance units (RU), respectively, and the antibody as the analyte is injected at 500nM, 10 microliters (μL) / min.
[0344] In one embodiment, when almost all (or all) Clq dissociates from the Clqrs complex within 100s, 300s, 500s, 700s, 1000s, 1500s, 2000s, 3000s, 5000s, 7000s or 10000s after the time point of starting antibody injection, the isolated antibody that inhibits the interaction between Clq and the Clr2s2 complex can be determined as an antibody with a replacement function, such as determined by, for example, BIACORE (registered trademark) assay using the following conditions: the capture levels of Clr2s2 complex and Clq are 200 resonance units (RU) and 200 resonance units (RU), respectively, and the antibody as an analyte is injected at 500nM, 10 microliters / minute. For example, in the sensorgram obtained from such an assay, when the value (RU) in the presence of Clq and the antibody approaches or reaches the value (RU) reached in the presence of the antibody without Clq, it can be determined that "almost all (or all) Clq is dissociated from the Clqrs complex". Herein, "substantially all (Clq)" refers to percentages of 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more; and "all (Clq)" refers to a percentage of 100%. The percentage of dissociated Clq can be quantitatively determined by any assay described herein. In some embodiments, the present invention provides a method for screening antibodies that replace Clq from the Clr2s2 complex using the above-mentioned method for measuring the "replacement function / activity" of such antibodies. In one embodiment, the screening method includes selecting an antibody that inhibits the interaction between Clq and the Clr2s2 complex; that is, selecting an antibody that binds to the Clqrs complex and promotes the dissociation of Clq from the Clqrs complex. Antibodies with replacement function / activity can be appropriately selected using a surface plasmon resonance assay, for example, a BIACORE (registered trademark) assay as described herein. In some embodiments, the screening method includes determining by surface plasmon resonance assay, for example, a BIACORE (registered trademark) assay, when sufficient time has passed, (i) the value of the response unit (RU) in the presence of the antibody and (ii) the value of the response unit (RU) in the absence of the antibody. The screening method may include comparing the value of (i) above and the value of (ii) above. The screening method may include selecting the antibody when the value of (i) above is lower than the value of (ii) above. The screening method may include identifying a "crossing time point", where the curve in the presence of Clq and the absence of the antibody crosses the curve in the presence of Clq and the antibody.As described above, multiple intersecting time points can be observed even in a single sensorgram, and any one of the multiple intersecting time points can be selected as the "intersecting time point". In some embodiments, the screening method may include measuring the value of the response unit (RU) at least 60s, 100s, 150s, 200s, 500s, 700s, 1000s, 1500s, or 2000s after the time point at which the antibody injection begins. Alternatively, the screening method may include measuring the value of the response unit (RU) at least 100s, 200s, 300s, 400s, 500s, 600s, 700s, 800s, 900s, 1000s, 3000s, 5000s, 7000s, or 10000s after the intersecting time point. In some embodiments, the screening method may include selecting an antibody that inhibits the interaction between Clq and the Clr2s2 complex or an antibody having a substitution function when the time point of crossover of the antibody is within 60s, 100s, 150s, 200s, 500s700s, 1000s, 1500s or 2000s after the start time point of antibody injection, as determined by, for example, the BIACORE (registered trademark) assay using the following conditions: the capture levels of the Clr2s2 complex and Clq are 200 resonance units (RU) and 200 resonance units (RU), respectively, and the antibody is injected as an analyte at 500nM, 10 microliters (μL) / min. In some embodiments, the screening method may include selecting an antibody that inhibits the interaction between Clq and the Clr2s2 complex or an antibody having a replacement function when substantially all (or all) Clq dissociates from the Clqrs complex within 100s, 300s, 500s, 700s, 1000s, 1500s, 2000s, 3000s, 5000s, 7000s or 10000s after the time point of starting antibody injection, as determined by, for example, BIACORE (registered trademark) assay using the following conditions: the capture levels of the Clr2s2 complex and Clq are 200 resonance units (RU) and 200 resonance units (RU), respectively, and the antibody is injected as an analyte at 500 nM, 10 microliters / minute. As described above, "substantially all (Clq)" refers to 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more percentages, and "all (Clq)" refers to 100%, and the percentage of dissociated Clq can be quantitatively determined by any assay described herein, including the BIACORE (registered trademark) assay.
[0345] (a2) BIACORE (registered trademark) / blocking concept
[0346] In one embodiment, the invention provides an antibody that inhibits the interaction between Clq and Clr2s2 complexes, wherein the antibody has a blocking function, so that the antibody binds Clr2s2 and inhibits the binding of Clq to Clr2s2. In a further embodiment, the antibody has a blocking rate of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more. The blocking function / activity or blocking rate can be determined by using BIACORE (registered trademark) assay. The following conditions can be used to assess the Clq blocking level: the capture level of Clr2s2 is for 50, 100, 200, 400 resonance units (RU). Antibody variants are injected at 250, 500, 1000, 2000 nM to saturate antibody binding, and then injected with 50, 100, 200 nM human Clq, with or without antibody variants 250, 500, 1000, 2000 nM. The blocking rate was calculated by the following formula: [1-(human Clq binding response in the presence of the antibody variant / human Clq binding response in the absence of the antibody variant)] x 100%.
[0347] (a3) pH dependence
[0348] In one embodiment, the isolated antibody specifically binds to Cls in a pH-dependent manner. In a preferred embodiment, the binding activity of the antibody to Cls is lower in the acidic pH range (eg, at pH 5.8) than in the neutral pH range (eg, at pH 7.4).
[0349] In the embodiment, in the acidic pH range, the binding of the antibody to Cls is quite low, and therefore, when the binding activity is measured by surface plasmon resonance and the dissociation constant (KD) value is calculated from the data, the KD value in the acidic pH range has a lower reliability or the binding activity to Cls cannot be detected in the acidic pH range; that is, in the case where the binding activity of the antibody to human and / or cynomolgus monkey Cls is determined by surface plasmon resonance,
[0350] i) KD values in the neutral pH range can be reliably calculated, whereas KD values in the acidic pH range cannot be reliably calculated due to the absence or very low binding activity, or
[0351] ii) Under the premise that both the KD values in the neutral pH range and the acidic pH range can be reliably calculated, the ratio of the KD value in the acidic pH range to the KD value in the neutral pH range, i.e. the acidic KD / neutral KD ratio, is greater than 10.
[0352] In embodiments, the ratio ii) of acidic KD / neutral KD is preferably 14 or more, 44 or more, 45 or more, 72 or more, 99 or more, 100 or more, 117 or more, 209 or more, 278 or more. In embodiments, the ratio ii) of acidic KD / neutral KD is more preferably 44 or more, 45 or more, 72 or more, 99 or more, 100 or more, 117 or more, 209 or more, 278 or more.
[0353] The term "reliably" in the case is as follows. The KD value of each sample at pH 7.4 and pH 5.8 was determined at 37°C using a BIACORE (registered trademark) T200 instrument (GE Healthcare). Purified mouse anti-human Ig κ light chain (GE Healthcare) can be fixed to all flow cells of a CM5 sensor chip using an amine coupling kit (GE Healthcare). A buffer containing 20mM ACES, 150mM NaCl, 1.2mM CaCl2, 1mg / mL bovine serum albumin (BSA) (IgG-free), 1mg / mL CMD (CM-dextran sodium salt), 0.05% Tween (registered trademark) 20 and 0.005% NaN3 (pH 7.4 or pH 5.8) was used as a running buffer. Each antibody can be captured on the sensor surface by anti-human Ig κ light chain. The antibody capture level was adjusted to 50 resonance units (RU). For KD values of pH 7.4, human Clr2s2 complexes are prepared so that the protein complex can be injected at 0, 25, 40, 100, 200, 400 nM, 0, 12.5, 25, 40, 100, 200 nM, or 0, 6.3, 12.5, 25, 50, 100 nM at 30 μl / min. For KD values of pH 5.8, human or cynomolgus monkey Clr2s2 complexes are prepared so that the protein complex can be injected at 0, 200, 400, 800, 1600, 3200 nM, or 0, 50, 100, 200, 400, 800 nM at 30 μl / min, for example using glycine pH 2.0 (GE Healthcare). The sensor surface is regenerated using, for example, glycine pH 2.0 (GE Healthcare) for each cycle. KD values were obtained using BIACORE (registered trademark) T200 Evaluation Software Version 2.0 (GE Healthcare). The KD value at pH 5.8 was compared with the KD value at pH 7.4 (acidic KD / neutral KD ratio). If the quality control results of the BIACORE (registered trademark) software mentioned that the "kinetic constant cannot be uniquely determined" for the antibody, we considered that the KD value of the antibody could not be reliably calculated.
[0354] In one embodiment of this case, the binding activity measured by surface plasmon resonance is performed at 37° C. using a sensor chip on which each antibody is captured by human Ig κ light chain at 50 resonance units and a running buffer comprising 20 mM ACES (N-(2-acetylamino)-2-aminoethanesulfonic acid), 150 mM NaCl, 1.2 mM CaCl2, 1 mg / mL goat serum albumin (BSA), 1 mg / mL CM-dextran sodium salt (CMD), 0.05% polysorbate 20, 0.005% NaN3.
[0355] In an embodiment, the antibodies do not include antibodies for which the KD value in the neutral pH range cannot be reliably calculated due to no binding activity or rather low binding activity.
[0356] In addition to binding to Cls in a pH-dependent manner, the effect of calcium on pH-dependent antibody affinity for Cls may be another important property. Cls forms dimers at high calcium concentrations, but dissociates into monomers at low calcium concentrations. When Cls is in a dimeric state, bivalent antibodies are able to form immune complexes by cross-linking multiple Cls molecules. This allows the antibody to bind to the Cls molecules in the complex through both affinity and avidity interactions, thereby increasing the apparent affinity of the antibody. In contrast, when Cls is in a monomeric state, the antibody binds to Cls only through avidity interactions. This means that pH-dependent Cls antibodies can form immune complexes with dimeric Cls in plasma, but once entering acidic endosomes, Cls dissociates into monomers. This leads to the dissociation of the immune complex, which then enhances the pH-dependent dissociation of the antibody from the antigen.
[0357] In one aspect, in the isolated anti-Cls antibody, when measured at high calcium concentration at neutral and acidic pH values, the ratio of the KD value of its Cls binding activity at acidic pH to the KD value of its Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral) pH)) is greater than 10. In one aspect, in the isolated anti-Cls antibody, when measured at high calcium concentration at neutral pH and low calcium concentration at acidic pH, the ratio of its KD value of its Cls binding activity at acidic pH to the KD value of its Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral) pH)) is greater than 10. In some embodiments, in the isolated anti-Cls antibody, the ratio of the KD value for Cls binding activity at acidic pH to the KD value for Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral) pH)) is greater than 10 when measured at neutral and acidic pH under low calcium concentration, wherein the anti-Cls antibody binds to the dimeric state of Cls.
[0358] Without being bound by a particular theory, if 1) the epitope structure of Cls bound to the antibody can be conformationally altered by the absence of calcium, thereby changing the affinity of the antibody or 2) the interaction (affinity or avidity) of the antibody can vary depending on the condition of Cls (monomeric state or dimeric state), measurements using specific conditions (high calcium concentration at neutral pH and low calcium concentration at acidic pH) can be used to estimate the ratio of KD values (KD(acidic pH) / KD(neutral pH)).
[0359] In other words, the antibody binds to Cls with a higher affinity at neutral pH than at acidic pH, as described in (i) or (ii) below:
[0360] (i) when measured at neutral and acidic pH with high calcium concentration, the ratio of the KD value for Cls binding activity at acidic pH to the KD value for Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral pH)) is greater than 10,
[0361] (ii) the ratio of the KD value of Cls binding activity at acidic pH to the KD value of Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral pH)) is greater than 10 when measured at neutral pH with high calcium concentration and acidic pH with low calcium concentration.
[0362] More generally, without being bound by a particular theory, if 1) the epitope structure of a certain antigen bound by an antibody can be conformationally altered by the absence of calcium, thereby changing the affinity of the antibody or 2) the interaction (affinity or avidity) of the antibody can be altered by the antigen condition (monomer state or dimeric state), measurements using specific conditions (high calcium concentration at neutral pH and low calcium concentration at acidic pH) can be used to estimate the ratio of KD values (KD(acidic pH) / KD(neutral pH)).
[0363] Thus, the antibody binds to the antigen with a higher affinity at neutral pH than at acidic pH, as shown below: the ratio of the KD value of the antigen-binding activity at acidic pH to the antigen-binding activity at neutral pH (KD(acidic pH) / KD(neutral pH)) is greater than 10 when measured at high calcium concentration at neutral pH and low calcium concentration at acidic pH.
[0364] The above KD ratio, i.e. KD (acidic pH) / KD (neutral pH), can be compared between a parent antibody (i.e., the original antibody before modification of the present invention) and an antibody into which one or more amino acid mutations (e.g., addition, insertion, deletion or substitution) have been introduced relative to the original (parent) antibody. The original (parent) antibody can be any known or newly isolated antibody, as long as it specifically binds to C1s. Thus, in one aspect, in the isolated anti-Cls antibody, the ratio of the KD value for Cls binding activity at acidic pH to the KD value for Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral pH)) is at least 1.2-fold, 1.4-fold, 1.6-fold, 1.8-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 5-fold, 8-fold, 10-fold higher than the ratio of the KD value for Cls binding activity at acidic pH to the KD value for Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral pH)) of the original (parental) antibody. In other words, the present invention provides an isolated anti-Cls antibody, wherein the isolated anti-Cls antibody has introduced one or more amino acid mutations (e.g., additions, insertions, deletions or substitutions) from a parent (original) antibody, and the ratio of the following (i) to (ii) is at least 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4, 5, 8 or 10: (i) the ratio of the KD value of the Cls binding activity of the isolated anti-Cls antibody at acidic pH to the KD value of the Cls binding activity at neutral pH (KD (acidic pH) / KD (neutral pH)); (ii) the ratio of the KD value of the Cls binding activity of the parent (original) antibody at acidic pH to the KD value of the Cls binding activity at neutral pH (KD (acidic pH) / KD (neutral pH)). These KD ratios can be measured at any (high or low) calcium concentration, for example at neutral and acidic pH at high calcium concentration, or at neutral pH at high calcium concentration and at acidic pH at low calcium concentration.
[0365] On the one hand, the antibody has different antigen binding activities between intracellular conditions and extracellular conditions. Intracellular and extracellular conditions refer to different intracellular and extracellular conditions. The types of conditions include, for example, ion concentrations, more specifically, metal ion concentrations, hydrogen ion concentrations (pH) and calcium ion concentrations. "Intracellular conditions" preferably refer to the environmental characteristics of the internal environment of the endosome, and "extracellular conditions" preferably refer to the environmental characteristics of the environment in the plasma. Antibodies with the property of antigen binding activity that varies according to ion concentration can be obtained by screening a large number of antibodies for the domain with such properties. For example, antibodies with the above-mentioned properties can produce antibodies with a large number of sequences that are different from each other by hybridoma methods or antibody library methods, and obtain them by measuring their antigen binding activities under different ion concentrations. The B cell cloning method is one of the examples of the method for screening such antibodies. In addition, as described below, specify at least one unique amino acid residue that can give antibodies the property of antigen binding activity that varies according to ion concentration, to prepare a library of a large number of antibodies with different sequences, while having a unique amino acid residue as a common structure. Such libraries can be screened to effectively separate antibodies with the above-mentioned properties.
[0366] In one aspect, the present invention provides an antibody that binds Cls with a higher affinity at neutral pH than at acidic pH. In another aspect, the present invention provides an anti-Cls antibody that exhibits pH-dependent binding to Cls. As used herein, the expression "pH-dependent binding" means "reduced binding at acidic pH compared to neutral pH", and the two expressions are interchangeable. For example, an anti-Cls antibody "having a pH-dependent binding property" includes an antibody that binds Cls with a higher affinity at neutral pH than at acidic pH.
[0367] In certain embodiments, the ratio of the KD value for Cls binding activity at acidic pH to the KD value for Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral pH)) is greater than 10 when measured at both neutral and acidic pH values at high calcium concentration. In specific embodiments, the antibody binds Cls with an affinity at least 11, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times greater at neutral pH than at acidic pH.
[0368] In certain embodiments, the ratio of the KD value for Cls binding activity at acidic pH to the KD value for Cls binding activity at neutral pH (KD(acidic pH) / KD(neutral pH)) when measured at high calcium concentration at neutral pH and low calcium concentration at acidic pH is greater than 10. In specific embodiments, the antibody binds Cls with an affinity at least 11, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times greater at neutral pH than at acidic pH.
[0369] In the above case, for example, the acidic pH is 5.8 and the neutral pH is 7.4, so KD (acidic pH) / KD (neutral pH) is KD (pH 5.8) / KD (pH 7.4). In this regard, examples of acidic pH and neutral pH will be described in detail later. In some embodiments, KD (acidic pH) / KD (neutral pH), such as KD (pH 5.8) / KD (pH 7.4), can be 11 to 10,000.
[0370] When the antigen is a soluble protein, the binding of the antibody to the antigen will result in an extension of the half-life of the antigen in plasma (i.e., a decrease in the clearance rate of the antigen from the plasma) because the antibody can have a longer half-life in plasma than the antigen itself and acts as a carrier of the antigen. This is due to the recycling of the antigen-antibody complex by FcRn through the endosomal pathway in the cell (Roopenian and Akilesh (2007) Nat Rev Immunol 7(9): 715-725). However, antibodies with pH-dependent binding properties, which bind to their antigens in a neutral extracellular environment and release the antigen into the acidic endosomal compartment after entering the cell, are expected to have superior properties in antigen neutralization and clearance relative to their counterparts that bind in a pH-independent manner (Igawa et al. (2010) Nature Biotechnol 28(11); 1203-1207; Devanaboyina et al. (2013) mAbs 5(6): 851-859; International Patent Application Publication No. WO 2009 / 125825).
[0371] In one aspect, the invention provides an antibody that binds Cls with a higher affinity under conditions of high calcium concentration than under conditions of low calcium concentration.
[0372] In one embodiment, preferred metal ions include, for example, calcium ions. Calcium ions are involved in regulating many biological phenomena, including contraction of muscles such as skeletal muscle, smooth muscle and cardiac muscle; activation of leukocyte movement, phagocytosis, etc.; activation of platelet shape changes, secretion, etc.; activation of lymphocytes; activation of mast cells, including the secretion of histamine; cellular responses mediated by catecholamine α receptors or acetylcholine receptors; exocytosis; release of transmitter substances from neuronal terminals; and axoplasmic flow in neurons. Known intracellular calcium ion receptors include troponin C, calmodulin, parvalbumin and myosin light chain, which have several calcium ion binding sites and are believed to be derived from a common origin in terms of molecular evolution. There are also many known calcium binding motifs. Such well-known motifs include, for example, cadherin domains, the EF-hand of calmodulin, the C2 domain of protein kinase C, the Gla domain of the coagulation protein Factor IX, C-type lectins of the acylglycoprotein receptor and the mannose binding receptor, the A domain of the LDL receptor, annexins, thrombospondin type 3 domains, and EGF-like domains.
[0373] In one embodiment, when the metal ion is a calcium ion, it is desirable that the antigen binding activity is lower under low calcium ion concentration conditions than under high calcium ion concentration conditions. Meanwhile, the intracellular calcium ion concentration is lower than the extracellular calcium ion concentration. On the contrary, the extracellular calcium ion concentration is higher than the intracellular calcium ion concentration. In one embodiment, the low calcium ion concentration is preferably 0.1 micromole (μM) to 30 micromole, more preferably 0.5 micromole to 10 micromole, particularly preferably 1 micromole to 5 micromole, close to the calcium ion concentration in the early endosome in vivo. Meanwhile, in one embodiment, the high calcium ion concentration is preferably 100 μM to 10 μM, more preferably 200 μM to 5mM, particularly preferably 0.5mM to 2.5mM, close to the calcium ion concentration in plasma (in blood). In one embodiment, preferably low calcium ion concentration is the calcium ion concentration in the endosome, and high calcium ion concentration is the calcium ion concentration in the plasma. When comparing the antigen binding activity level between low calcium ion concentration and high calcium ion concentration, it is preferred that the binding ratio of the antibody under high calcium ion concentration is stronger than that under low calcium ion concentration. In other words, the antigen binding activity of the preferred antibody is lower at low calcium ion concentrations than at high calcium ion concentrations. When the level of binding activity is represented by a dissociation constant (KD), the value of KD (low calcium ion concentration) / KD (high calcium ion concentration) is greater than 1, preferably 2 or more, more preferably 10 or more, more preferably 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. The upper limit of the value of KD (low calcium ion concentration) / KD (high calcium ion concentration) is not particularly limited, as long as the technician can manufacture it with technology, it can be any value such as 100, 400, 1000, 10000. The dissociation rate constant (kd) can be used instead of KD. When it is difficult to calculate the KD value, the activity can be assessed according to the binding reaction level in BIACORE (registered trademark) when the analyte passes through with the same concentration. When the antigen passes through the chip fixed with antigen binding molecules, the binding reaction under low calcium concentration is preferably 1 / 2 or less of the binding reaction under high calcium concentration, more preferably 1 / 3 or less, still more preferably 1 / 5 or less, particularly preferably 1 / 10 or less. It is known that the extracellular calcium ion concentration (e.g., in plasma) is high in vivo, while the intracellular calcium ion concentration (e.g., in endosome) is low. Therefore, in one embodiment, it is preferred that the extracellular condition is a high calcium ion concentration, and the intracellular condition is a low calcium ion concentration. In the case where the antigen binding activity under the intracellular calcium ion concentration condition is lower than the antigen binding activity under the extracellular calcium ion concentration condition and is given to antigen binding molecules (e.g., antibodies), the antigen bound to the antigen binding molecules of the present invention outside the cell dissociates from the intracellular antigen binding molecules, thereby enhancing the antigen from the extracellular incorporation into the cell. When applied to an organism, such antibodies can reduce the antigen concentration in plasma and reduce the physiological activity of the antigen in vivo. Therefore, antibodies are useful.The method for screening antigen binding regions or antibodies with lower antigen binding activity under low calcium ion concentration conditions than under high calcium ion concentration conditions includes, for example, the method described in WO2012 / 073992 (e.g., paragraphs 0200-0213). The method for imparting to the antigen binding region a property that is weaker in binding to the antigen under low calcium ion concentration conditions than under high calcium ion concentration conditions is not particularly limited and can be carried out by any method. Specifically, the method is described in Japanese Patent Application No. 2011-218006, and includes, for example, replacing at least one amino acid residue in the antigen binding region with an amino acid residue having metal chelating activity and / or inserting at least one amino acid residue having metal chelating activity into the antigen binding region. An antigen binding molecule in which at least one amino acid residue in the antigen binding region has been replaced by an amino acid residue having metal chelating activity and / or at least one amino acid residue having metal chelating activity has been inserted into the antigen binding region is a preferred embodiment of the antigen binding molecule.
[0374] The amino acid residue with metal chelating activity preferably includes, for example, serine, threonine, asparagine, glutamine, aspartic acid and glutamic acid. In addition, the amino acid residue that changes the antigen-binding activity of the antigen-binding region according to the calcium ion concentration preferably includes, for example, an amino acid residue that forms a calcium binding motif. Calcium binding motifs are well known to those skilled in the art and have been described in detail (e.g., Springer et al., (Cell (2000) 102, 275-277); Kawasaki and Kretsinger (Protein Prof. (1995)) 2, 305-490); Moncrief et al., (J. Mol. Evol. (1990) 30, 522-562); Chauvaux et al., (Biochem. J. (1990) 265, 261-265); Bairoch and Cox (FEBS Lett. (1990) 269, 454-456); Davis (New Biol. (1990) 2, 410-419); Schaefer et al., (Genomics (1995) 25, 638-643); Economou et al., (EMBO J. (1990) 9, 349-354); Wurzburg et al., (Structure. (2006) 14, 6, 1049-1058). The EF hand in troponin C, calmodulin, parvalbumin and myosin light chain; the C2 domain in protein kinase C; the Gla domain in the coagulation protein factor IX; the C-type lectins of the acylglycoprotein receptor and the mannose binding receptor, ASGPR, CD23 and DC-SIGN; the A domain in the low-density lipoprotein receptor; the annexin domain; the cadherin domain; the thrombospondin type 3 domain; and the EGF-like domain are preferably used as calcium-binding motifs.
[0375] The antigen binding region may include amino acid residues that change antigen binding activity according to calcium ion concentration, such as the above-mentioned amino acid residues with metal chelating activity and amino acid residues that form calcium binding motifs. The positions of these amino acid residues in the antigen binding region are not particularly limited, as long as the antigen binding activity changes according to the calcium ion concentration, they can be located at any position. At the same time, as long as the antigen binding activity changes according to the calcium ion concentration, these amino acid residues can be included alone or in a combination of two or more. The amino acid residue preferably includes, for example, serine, threonine, asparagine, glutamine, aspartic acid and glutamic acid. When the antigen binding region is an antibody variable region, the amino acid residue may be included in the heavy chain variable region and / or the light chain variable region. In a preferred embodiment, the amino acid residue may be included in the CDR3 of the heavy chain variable region, more preferably in the heavy chain variable region CDR3 according to the 95th, 96th, 100a and / or 101st of Kabat numbering.
[0376] In another preferred embodiment, the amino acid residue may be contained in the CDR1 of the light chain variable region, more preferably in the 30th, 31st and / or 32nd position according to Kabat numbering in the light chain variable region CDR1. In yet another preferred embodiment, the amino acid residue may be contained in the CDR2 of the light chain variable region, more preferably in the 50th position according to Kabat numbering in the light chain variable region CDR2. In yet another preferred embodiment, the amino acid residue may be contained in the CDR3 of the light chain variable region, more preferably in the 92nd position according to Kabat numbering in the light chain variable region CDR3.
[0377] In addition, the above embodiments can be combined. For example, the amino acid residue can be contained in two or three CDRs selected from CDR1, CDR2 and CDR3 of the light chain variable region, more preferably in any one or more positions of position 30, 31, 32, 50 and / or 92 according to Kabat numbering in the light chain variable region.
[0378] A large number of antigen-binding regions having different sequences and sharing the above-mentioned amino acid residues (which change antigen-binding activity according to calcium ion concentration) as a common structure are prepared as libraries. The library can be screened to efficiently obtain antigen-binding regions having binding activity to the desired antigen, wherein their antigen-binding activity changes according to calcium ion concentration.
[0379] For the purposes of this disclosure, the "affinity" of an antibody to Cls is expressed as the KD of the antibody. The KD of an antibody refers to the equilibrium dissociation constant of an antibody-antigen interaction. The greater the KD value of an antibody binding to its antigen, the weaker its binding affinity to that particular antigen. Therefore, as used herein, the expression "higher affinity at neutral pH than at acidic pH" (or the equivalent expression "pH-dependent binding") refers to an antibody having a KD at acidic pH that is greater than the KD of the antibody at neutral pH. For example, in the context of the present invention, if the KD at which an antibody binds to Cls at acidic pH is more than 10 times greater than the KD at which the antibody binds to Cls at neutral pH, the antibody is considered to bind to Cls at neutral pH with a higher affinity than at acidic pH. Thus, the invention includes antibodies that bind to Cls at acidic pH with a KD that is at least 11, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times greater than the KD of the antibody that binds to Cl at neutral pH. In another embodiment, the KD value of the antibody at neutral pH may be 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10-11 M, 10 -12 In another embodiment, the KD value of the antibody at acidic pH can be 10 -9 M, 10 -8 M, 10 -7 M, 10 -6 M or larger.
[0380] The binding properties of an antibody to a specific antigen can also be expressed by the antibody's kd. The antibody's kd refers to the dissociation rate constant of the antibody relative to the specific antigen, expressed in reciprocal seconds (sec -1 ). An increase in the kd value indicates that the antibody binds to its antigen more weakly. Thus, the present invention includes antibodies that bind to Cls with a higher kd value at acidic pH than at neutral pH. The present invention includes antibodies that have a kd for binding to Cls at acidic pH that is at least 11, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more times greater than the kd for binding to Cls at neutral pH. In another embodiment, the kd value of the antibody at neutral pH may be 10 -2 l / s, 10 -3 l / s, 10 -4 l / s, 10 -5 l / s, 10 -6 In another embodiment, the kd value of the antibody at acidic pH can be 10 -3 l / s, 10 -2 l / s, 10 -1 l / s or greater.
[0381] In some cases, "reduced binding at acidic pH compared to at neutral pH" is expressed as the ratio of the KD value of the antibody at acidic pH to the KD value of the antibody at neutral pH (or vice versa). For example, for the purposes of the present invention, an antibody may be considered to have "reduced binding to Cls at acidic pH compared to its binding at neutral pH" if it exhibits an acidic / neutral KD ratio of 10 or greater. In certain exemplary embodiments, the acidic / neutral KD ratio of the antibody may be 11, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. In another embodiment, the KD value of the antibody at neutral pH may be 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10-11 M, 10 -12 In another embodiment, the KD value of the antibody at acidic pH can be 10 -9 M, 10 -8 M, 10 -7 M, 10 -6 M or larger.
[0382] In some cases, "reduced binding at acidic pH compared to neutral pH" is expressed as the ratio of the antibody's Kd value at acidic pH to the antibody's Kd value at neutral pH (or vice versa). For example, for purposes of this disclosure, an antibody may be considered to have "reduced binding to Cls at acidic pH compared to its binding at neutral pH" if the antibody exhibits an acidic / neutral kd ratio of 2 or greater. In certain exemplary embodiments, the antibody's acidic / neutral Kd ratio may be 11, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or greater. In another embodiment, the antibody's kd value at neutral pH may be 10 -2 l / s, 10 -3 l / s, 10 -4 l / s, 10 -5 l / s, 10 - 6 In another embodiment, the kd value of the antibody at acidic pH can be 10 -3 l / s, 10 -2 l / s, 10 -1 l / s or greater.
[0383] As used herein, the expression "acidic pH" refers to a pH of 4.0 to 6.5. The expression "acidic pH" includes pH values of 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, and 6.5. In a specific aspect, the "acidic pH" is 5.8.
[0384] As used herein, the expression "neutral pH" refers to a pH of 6.7 to about 10.0. The expression "neutral pH" includes pH values of 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9 and 10.0. In a specific aspect, the "neutral pH" is 7.4.
[0385] As used herein, the expression "under high calcium concentration conditions" or "at a high calcium concentration" refers to 100 μM to 10 mM, more preferably 200 μM to 5 mM, particularly preferably 0.5 mM to 2.5 mM, which is close to the calcium ion concentration in plasma (blood). The expression "under high calcium concentration conditions" or "at high calcium concentration" includes calcium concentration values of 100 μM, 200 μM, 300 μM, 400 μM, 500 μM, 600 μM, 700 μM, 800 μM, 900 μM, 0.5 mM, 0.7 mM, 0.9 mM, 1 mM, 1.2 mM, 1.4 mM, 1.6 mM, 1.8 mM, 2.0 mM, 2.2 mM, 2.4 mM, 2.5 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM and 10 mM Ca. 2+ In certain aspects, "under conditions of high calcium concentration" or "at high calcium concentration" refers to 1.2 mM Ca 2+ .
[0386] As used herein, the expression "under low calcium concentration conditions" or "at a low calcium concentration" refers to 0.1 μM to 30 μM, more preferably 0.5 μM to 10 μM, particularly preferably 1 μM to 5 μM, which is close to the calcium ion concentration in the early endosome in vivo. The expression "under low calcium concentration conditions" or "at a low calcium concentration" includes calcium concentration values of 0.1 μM, 0.5 μM, 1 μM, 1.5 μM, 2.0 μM, 2.5 μM, 2.6 μM, 2.7 μM, 2.8 μM, 2.9 μM, 3.0 μM, 3.1 μM, 3.2 μM, 3.3 μM, 3.4 μM, 3.5 μM, 4.0 μM, 5.0 μM, 6.0 μM, 7.0 μM, 8.0 μM, 9.0 μM, 10 μM, 15 μM, 20 μM, 25 μM and 30 μM Ca 2+ In certain aspects, "under low calcium concentration conditions" or "at a low calcium concentration" refers to 3.0 μM Ca 2+ .
[0387] KD values and kd values as expressed herein can be determined using a surface plasmon resonance-based biosensor to characterize antibody-antigen interactions. (See, e.g., Example 3 herein). KD values and kd values can be determined at 25 degrees Celsius (C) or 37 degrees Celsius. The assay can be performed in the presence of 150 mM NaCl. In some embodiments, the assay can be performed using surface plasmon resonance technology, wherein the antibody is immobilized, the antigen is used as the analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate and 150 mM NaCl, 37 degrees Celsius (C).
[0388] On the one hand, the present invention provides a method for increasing the clearance rate of Cls in the plasma of an individual. In some embodiments, the method comprises administering an effective amount of an anti-Cls antibody to an individual to enhance the clearance rate of Cls from plasma. The present invention also provides a method for enhancing the clearance rate of Clr and Cls complexes from plasma in an individual. In some embodiments, the method comprises administering an effective amount of an anti-Cls antibody to an individual to enhance the clearance rate of Clr and Cls complexes from plasma. In some embodiments, the method comprises administering an effective amount of an anti-Cls antibody to an individual to enhance the clearance rate of Clr2s2 from plasma. In some embodiments, the method comprises administering an effective amount of an anti-Cls antibody to an individual to enhance the clearance rate of Clr2s2 from plasma rather than the clearance rate of Clq from plasma.
[0389] In another aspect, the invention provides a method for removing Cls from plasma, the method comprising: (a) identifying an individual in need of removing Cls from their plasma; (b) providing an antibody that binds to Cls via an antigen binding (Cls-binding) domain of the antibody and has a KD (pH 5.8) / KD (pH 7.4) value defined as a ratio of KD for Cls at pH 5.8 to KD for Cl at pH 7.4 of 11 to 10,000 when KD is determined using surface plasmon resonance technology, wherein the antibody binds to Cl in plasma in vivo and dissociates from bound Cls under conditions present in endosomes in vivo, and wherein the antibody is a human IgG or a humanized IgG; and (c) administering the antibody to the individual. In another aspect, this surface plasmon resonance technology can be used at 37 degrees Celsius and 150 mM NaCl. On the other hand, surface plasmon resonance techniques can be used where the antibody is immobilized, the antigen is used as the analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate, and 150 mM NaCl at 37 degrees Celsius.
[0390] In another aspect, the present invention provides a method for removing Cls from the plasma of a subject, the method comprising: (a) identifying a first antibody that binds to Cls via an antigen binding region of the first antibody; (b) identifying a second antibody that: (1) binds to Cls via an antigen binding (Cls-binding) domain of the second antibody, (2) is identical in amino acid sequence to the first antibody except that at least one amino acid in the variable region of the first antibody is replaced by histidine and / or at least one histidine is inserted into the variable region of the first antibody, and (3) has a KD(pH5.8) / KD(pH7.4) value that is higher than the KD(pH5.8) / KD(pH7.4) value of the first antibody and is between 11 and 10,000, wherein KD(pH5.8) / KD(pH7.4) is defined as pH when KD is determined using surface plasmon resonance technology. 5.8 for Cls to the KD for Cls at pH 7.4, (4) binds to Cls in plasma in vivo, (5) dissociates from bound Cls under conditions present in endosomes in vivo, and (6) is human IgG or humanized IgG; (c) identifying a subject in need of lowering his or her plasma Cls levels; and (d) administering a second antibody to the subject, thereby lowering the plasma level of Cls in the subject. In another aspect, this surface plasmon resonance technique can be used at 37 degrees Celsius and 150 mM NaCl. In another aspect, this surface plasmon resonance technique can be used at 37 degrees Celsius and 150 mM NaCl. In another aspect, such a surface plasmon resonance technique can be used wherein the antibody is immobilized, the antigen is used as the analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate and 150 mM NaCl, 37 degrees Celsius.
[0391] In another aspect, the present invention provides a method for removing Cls from the plasma of a subject, the method comprising: (a) identifying a first antibody that: (1) binds to Cls via an antigen binding region of the first antibody, (2) has an amino acid sequence identical to a second antibody that binds to Cls via an antigen binding (Cls-binding) domain of the second antibody, except that at least one variable region of the first antibody has at least one more histidine residue than the corresponding variable region of the second antibody, and (3) has a KD(pH5.8) / KD(pH7.4) value that is higher than the KD(pH5.8) / KD(pH7.4) value of the second antibody and is between 11 and 10,000, wherein KD(pH5.8) / KD(pH7.4) is defined as the KD for Cls at pH 5.8 divided by the KD at pH 7.4 when the KD is determined using surface plasmon resonance technology. 7.4 for Cls, (4) binds to Cls in plasma in vivo, (5) dissociates from bound Cls under conditions present in endosomes in vivo, and (6) is human IgG or humanized IgG; (b) identifying a subject in need of lowering his or her plasma Cls level; (c) administering the first antibody to the subject at least once to lower the subject's plasma Cls level. In another aspect, such surface plasmon resonance techniques can be used at 37 degrees Celsius and 150 mM NaCl. In another aspect, such surface plasmon resonance techniques can be used at 37 degrees Celsius and 150 mM NaCl. In another aspect, such surface plasmon resonance techniques can be used wherein the antibody is immobilized, the antigen is used as the analyte, and the following conditions are used: 10 mM MES buffer, 0.05% polyoxyethylene sorbitan monolaurate, and 150 mM NaCl at 37 degrees Celsius. In some cases, the antibody inhibits a component of the classical complement pathway; in some cases, the classical complement pathway component is Cls.
[0392] (a4) pI of the isolated antibody
[0393] In one embodiment of the isolated antibody, the pI of the antibody is less than 9.00, less than 8.90, less than 8.80, or 8.78 or less. The pI is preferably less than 8.90, more preferably less than 8.80, and further preferably 8.78 or less. When the pI is less than any of these, the half-life of the antibody in the blood will be extended. On the other hand, the possible minimum value of pI is generally 4.28 or greater.
[0394] In one embodiment, the pI of the antibody can be measured by capillary isoelectric focusing (cIEF). As an example of an embodiment, cIEF is performed on a Protein Simple iCE3 all-capillary imaging system using a capillary box with a fluorocarbon coating. The anolyte and cathode solutions are 0.08M phosphoric acid in 0.1% m / v methylcellulose (MC) and 0.1M sodium hydroxide in 0.1% m / v MC, respectively. All analyzed samples contain 0.5mg / mL working antibody, 0.3% m / v MC, 6mMIDA (iminodiacetic acid), 10mM arginine, 4M urea, pI markers (7.65 and 9.77), and one of the following v / v mixtures of 2% pharmalyte 8-10.5 and 2% pharmalyte 5-8. All samples are briefly vortexed and centrifuged before loading into the autosampler compartment. Before starting the measurement, the sample is incubated in the autosampler for 2 hours. Focusing was performed at 1.5 kV for 1 minute and then at 3.0 kV for 7 minutes. The autosampler compartment was maintained at 10 degrees C. Each sample was measured in duplicate and the pI value for each sample was obtained by calculating the average of n=2 measurements.
[0395] Alternatively, in one embodiment, the pI of the antibody can be measured by capillary isoelectric focusing (cIEF). As an example of an embodiment, cIEF is performed on a Protein Simple iCE3 all-capillary imaging system using a capillary box with a fluorocarbon coating. The anolyte and cathode solutions are 0.08M phosphoric acid in 0.1% m / v methylcellulose (MC) and 0.1M sodium hydroxide in 0.1% m / v MC, respectively. All analyzed samples contain 0.35% m / v MC, 4mM IDA (iminodiacetic acid), 10mM arginine, pI markers (3.21 or 4.22 or 4.65 or 5.12 or 5.85 or 6.14 or 6.61 or 7.05 or 7.65 or 8.40 or 8.79 or 9.46 or 9.77 or 10.1), and one of the following v / v mixtures of 4% pharmalyte 3-10. All samples were briefly vortexed and centrifuged before loading into the autosampler compartment. Focusing was performed at 1.5 kV for 1 minute and then at 3.0 kV for 8 minutes. The autosampler compartment was maintained at 10 degrees Celsius. Each sample was measured in duplicate and the pI value for each sample was obtained by calculating the average of n=2 measurements.
[0396] In one embodiment of the case, the pI is measured by capillary isoelectric focusing, wherein a solution containing 0.08 M phosphoric acid in 0.1% m / v methylcellulose (MC) is used as the anolyte solution, a solution containing 0.1 M sodium hydroxide in 0.1% m / v MC is used as the catholyte solution, and a solution containing 0.5 mg / mL antibody, 0.3% m / v MC, 6.0 mM iminodiacetic acid (IDA), 10 mM arginine, 4 M urea and pI markers (7.65 and 9.77) is used as a working solution for the cleavage antibody.
[0397] (a5) Antigen binding region
[0398] In one embodiment, the antibody comprises an antigen binding region. In a preferred embodiment, the antigen binding region can specifically bind to an epitope within the CUB1-EGF-CUB2 domain of Cls. In a further preferred embodiment, the antigen binding region can specifically bind to the CUB1-EGF-CUB2 domain of Cls. In these embodiments, Cls includes but is not limited to human Cls. Cls is preferably human Cls.
[0399] In one embodiment, the antigen binding region may be an antibody variable region. The antibody variable region may be all or part of the antibody variable region, as long as the antigen binding region does not destroy the properties of the isolated antibody, such as replacing function and / or blocking function, and the following binding activity of the antibody;
[0400] In the case where the binding activity of the antibody to human and / or cynomolgus monkey Cls is measured by surface plasmon resonance,
[0401] i) the dissociation constant (KD) values in the neutral pH range can be reliably calculated, whereas the KD values in the acidic pH range cannot be reliably calculated due to the absence of binding activity or very low binding activity, or
[0402] ii) On the premise that both the KD values in the neutral pH range and the acidic pH range can be reliably calculated, the ratio of the KD value in the acidic pH range to the KD value in the neutral pH range, i.e. the ratio of acidic KD / neutral KD, is greater than 10.
[0403] In an embodiment, the antibody variable region is humanized. The antigen binding region is preferably a humanized antibody variable region. When such a humanized antibody is used in medicine, it is expected that side effects can be avoided compared to non-humanized antibodies.
[0404] In one embodiment, the antigen binding region comprises a heavy chain variable region, the heavy chain variable region comprises HVR-H1, HVR-H2 and HVR-H3, the HVR-H1 comprises an amino acid sequence consisting of AYAMN (SEQ ID No. 1), the HVR-H2 comprises an amino acid sequence consisting of LIYGX1X2X3X4FYASWAX5X6 (SEQ ID No. 2), and the HVR-H3 comprises an amino acid sequence consisting of GRSX7NYX8SX9FHL (SEQ ID No. 3). In an embodiment, the antigen binding region comprises a light chain variable region, the light chain variable region comprises HVR-L1, HVR-L2 and HVR-L3, the HVR-L1 comprises an amino acid sequence consisting of QAX 10 X 11 X 12 LHD 13 NLA (SEQ ID No. 4), wherein HVR-L2 comprises X 14 ASX 15 X 16 ES (SEQ ID No. 5), wherein the HVR-L3 comprises X 17 GEFX 18 X 19 X 20 X 21 ADX 22 NX 23 (SEQ ID No.6). In the embodiment, X1 to X 23 Each of which is selected from naturally occurring amino acids.
[0405] In another embodiment of the present invention, the isolated anti-Cls antibody comprises a heavy chain variable region, a light chain variable region and an antibody constant region. In the embodiment, the heavy chain variable region comprises HVR-H1, HVR-H2 and HVR-H3, wherein the HVR-H1 comprises an amino acid sequence consisting of AYAMN (SEQ ID No. 1), the HVR-H2 comprises an amino acid sequence consisting of LIYGX1X2X3X4FYASWAX5X6 (SEQID No. 2), and the HVR-H3 comprises an amino acid sequence consisting of GRSX7NYX8SX9FHL (SEQ ID No. 3). In the embodiment, the light chain variable region comprises HVR-L1, HVR-L2 and HVR-L3, wherein the HVR-L1 comprises an amino acid sequence consisting of QAX 10 X 11 X 12 LHD 13 NLA (SEQ ID No. 4), wherein HVR-L2 comprises X 14ASX 15 X 16 ES (SEQ ID No. 5), wherein the HVR-L3 comprises X 17 GEFX 18 X 19 X 20 X 21 ADX 22 NX 23 (SEQ ID No.6). In the embodiment, X1 to X 23 Each of which is selected from naturally occurring amino acids.
[0406] These amino acid sequences include common sequences in the antibodies disclosed in the "Examples", COS0637pHv1 to COS0637pHv9, which were produced by recombination and characterization of chimeric antibodies produced in PCT / JP2019 / 015919 in the Examples. When the antigen-binding region comprises a heavy chain variable region and a light chain variable region, the antigen-binding region has a higher pH-dependent binding activity to human and / or cynomolgus monkey Cls than the chimeric antibody, even though the antigen-binding region is humanized.
[0407] In one embodiment, X1 to X 23 The amino acid is preferably selected from the following amino acids.
[0408] X1 is Lys or Ser,
[0409] X2 is Gly or Lys,
[0410] X3 is His or Ser,
[0411] X4 is Glu or Thr,
[0412] X5 is Glu or Lys,
[0413] X6 is Glu or Gly,
[0414] X7 is Lys or Val,
[0415] X8 is Asn or Val,
[0416] X9 is Asp or Gly,
[0417] X 10 is Asn, Gln or Ser,
[0418] X 11 is Gly or Gln,
[0419] X 12 It is Ile or Ser,
[0420] X 13 is Lys or Arg,
[0421] X 14 is Gly or Gln,
[0422] X 15 is Gln or Thr,
[0423] X 16 is Leu or Arg,
[0424] X 17 is His or Gln,
[0425] X 18 Is Pro or Ser,
[0426] X 19 is Cys or Tyr,
[0427] X 20 is Glu or Ser,
[0428] X 21 is Glu or Ser,
[0429] X 22 is Cys or Leu, and
[0430] X 23 It is Gln or Thr.
[0431] These amino acids are commonly present in the antibodies disclosed in the "Examples", COS0637pHv1 to COS0637pHv9. When the antigen-binding region comprises the amino acids, the antigen-binding region has a higher pH dependency of higher binding activity than the chimeric antibody, even though the antigen-binding region is humanized.
[0432] In one embodiment, HVR-H1 comprises an amino acid sequence consisting of SEQ ID No.7, HVR-H2 comprises any one of the amino acid sequences consisting of SEQ ID Nos.8 to 10, HVR-H3 comprises any one of the amino acid sequences consisting of SEQ ID Nos.11 to 13, HVR-L1 comprises any one of the amino acid sequences consisting of SEQ ID Nos.14 to 18, HVR-L2 comprises any one of the amino acid sequences consisting of SEQ ID Nos.19 to 22, and HVR-L3 comprises any one of the amino acid sequences consisting of SEQ ID Nos.23 to 28.
[0433] In one embodiment, the combination of amino acid sequences of HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3 is selected from the group consisting of 1) to 9) below;
[0434] 1) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0435] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 8,
[0436] HVR-H3, which comprises an amino acid sequence consisting of SEQ ID No 11,
[0437] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 14,
[0438] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0439] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 23;
[0440] 2) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0441] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 9,
[0442] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 12,
[0443] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 14,
[0444] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0445] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 23;
[0446] 3) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0447] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0448] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0449] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0450] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0451] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0452] 4) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0453] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0454] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0455] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0456] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0457] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0458] 5) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0459] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0460] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0461] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 16,
[0462] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 21, and
[0463] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 25;
[0464] 6) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0465] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0466] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0467] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 17,
[0468] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0469] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 26;
[0470] 7) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0471] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0472] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0473] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0474] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0475] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 27;
[0476] 8) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0477] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0478] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0479] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0480] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0481] HVR-L3, which comprises the amino acid sequence consisting of SEQ ID No. 27, and
[0482] 9) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0483] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0484] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0485] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0486] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 22, and
[0487] HVR-L3 comprises the amino acid sequence consisting of SEQ ID No.28.
[0488] In one embodiment, X 19 and / or X 22 Not Cys. When X 19 and / or X 22 When X is not Cys, the risk of heterogeneity of the isolated antibody produced will be reduced. In one embodiment, X 19 is Trp or Tyr, and X 22 is Leu or Met. 19 and / or X 22 When it is not Cys, in X 19 There is Trp or Tyr at X 22 The antigen binding region with Leu or Met at the position of the antigen binding region, such as other amino acids disclosed in Example 3, has higher binding activity to human and / or cynomolgus monkey Cls and higher pH dependence. In the embodiment, X 19 Preferably, Tyr, X 22 Preferably Leu. The selection of Tyr and Leu at this position can prevent X 19 and X 22 The amino acids are oxidized. These amino acids are common in the antibodies disclosed in the "Examples", COS0637pHv3 to COS0637pHv9.
[0489] In one embodiment, X1 to X 23 The amino acid is preferably selected from the following amino acids.
[0490] X1 is Ser,
[0491] X2 is Gly,
[0492] X3 is His,
[0493] X4 is Glu,
[0494] X5 is Glu,
[0495] X6 is Glu,
[0496] X7 is Lys,
[0497] X8 is Asn or Val,
[0498] X9 is Asp or Gly,
[0499] X 10 is Asn, Gln or Ser,
[0500] X 11 is Gly or Gln,
[0501] X 12 It's Ile.
[0502] X 13 is Lys or Arg,
[0503] X 14 is Gly or Gln,
[0504] X 15 is Gln or Thr,
[0505] X 16 is Leu or Arg,
[0506] X 17 It's His,
[0507] X18 is Pro or Ser,
[0508] X 19 It's Tyr.
[0509] X 20 is Glu or Ser,
[0510] X 21 is Glu or Ser,
[0511] X 22 is Leu, and
[0512] X 23 It is Gln or Thr.
[0513] These amino acids are common in the antibodies disclosed in the "Examples", COS0637pHv3 to COS0637pHv9. When the antigen binding region comprises amino acids, the heterogeneity and X in the isolated antibodies produced 19 and X 22 The risk of amino acid oxidation is reduced, and the antigen-binding region has a higher pH dependence than the chimeric antibody in terms of binding activity to human and / or cynomolgus monkey Cls.
[0514] In a preferred embodiment, HVR-H1 comprises an amino acid sequence consisting of SEQ ID No.7, HVR-H2 comprises an amino acid sequence consisting of SEQ ID No.10, HVR-H3 comprises an amino acid sequence consisting of SEQ ID No.11 or 13, HVR-L1 comprises any one of the amino acid sequences consisting of SEQ ID Nos.15 to 18, HVR-L2 comprises any one of the amino acid sequences consisting of SEQ ID Nos.19 to 22, and HVR-L3 comprises any one of the amino acid sequences consisting of SEQ ID Nos.24 to 28.
[0515] In a further preferred embodiment, the combination of amino acid sequences of HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3 is selected from the group consisting of 3) to 9) below;
[0516] 3) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0517] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0518] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0519] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0520] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0521] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0522] 4) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0523] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0524] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0525] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0526] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0527] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0528] 5) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0529] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0530] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0531] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 16,
[0532] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 21, and
[0533] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 25;
[0534] 6) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0535] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0536] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0537] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 17,
[0538] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0539] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 26;
[0540] 7) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0541] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0542] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0543] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0544] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0545] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 27;
[0546] 8) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0547] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0548] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0549] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0550] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0551] HVR-L3, which comprises the amino acid sequence consisting of SEQ ID No. 27, and
[0552] 9) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0553] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0554] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0555] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0556] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 22, and
[0557] HVR-L3 comprises the amino acid sequence consisting of SEQ ID No.28.
[0558] Among these combinations, the combination of the amino acid sequences of HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3 is preferably selected from the group consisting of the following four combinations, because these four have less immunogenic potential and are less likely to induce morphological changes in immune cells such as PBMCs;
[0559] 3) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0560] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0561] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0562] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 15,
[0563] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 20, and
[0564] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 24;
[0565] 5) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0566] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0567] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 13,
[0568] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 16,
[0569] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 21, and
[0570] HVR-L3, which comprises an amino acid sequence consisting of SEQ ID No. 25;
[0571] 8) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0572] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0573] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0574] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0575] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 19, and
[0576] HVR-L3, which comprises the amino acid sequence consisting of SEQ ID No. 27, and
[0577] 9) HVR-H1, which comprises the amino acid sequence consisting of SEQ ID No. 7,
[0578] HVR-H2 comprises an amino acid sequence consisting of SEQ ID No. 10,
[0579] HVR-H3, which comprises the amino acid sequence consisting of SEQ ID No. 11,
[0580] HVR-L1, which comprises the amino acid sequence consisting of SEQ ID No. 18,
[0581] HVR-L2, which comprises the amino acid sequence consisting of SEQ ID No. 22, and
[0582] HVR-L3 comprises the amino acid sequence consisting of SEQ ID No.28.
[0583] In one embodiment, the amino acid sequence of the heavy chain variable region is selected from the group consisting of the amino acid sequence consisting of SEQ ID No. 40, 41, 98, 99 and 100. In one embodiment, the amino acid sequence of the light chain variable region is selected from the group consisting of the amino acid sequence consisting of SEQ ID No. 38, 101, 102, 103, 104, 105 and 106. In a preferred embodiment, the combination of the amino acid sequences of the heavy chain variable region and the light chain variable region is selected from the group consisting of the amino acid sequence combination consisting of SEQ ID No. 40 and 38, SEQ ID No. 41 and 38, SEQ ID No. 98 and 101, SEQ ID No. 99 and 101, SEQ ID No. 99 and 102, SEQ ID No. 99 and 103, SEQ ID. No100 and 104, SEQ ID No. 100 and 105, and SEQ ID No. 100 and 106.
[0584] In one embodiment, the amino acid sequence of the heavy chain variable region is selected from the group consisting of the amino acid sequence consisting of SEQ ID No. 98, 99 and 100. In one embodiment, the amino acid sequence of the light chain variable region is selected from the group consisting of the amino acid sequence consisting of SEQ ID No. 101, 102, 103, 104, 105 and 106. In a preferred embodiment, the combination of the amino acid sequences of the heavy chain variable region and the light chain variable region is selected from the group consisting of the amino acid sequence combination consisting of SEQ ID No. 98 and 101, SEQ ID No. 99 and 101, SEQ ID No. 99 and 102, SEQ ID No. 99 and 103, SEQ ID No. 100 and 104, SEQ ID No. 100 and 105, and SEQ ID No. 100 and 106.
[0585] (a6) Antibody constant region
[0586] In one embodiment, the antibody constant region in the isolated antibody includes but is not limited to the constant region of a human antibody. The constant region of a human antibody may include a heavy chain and a light chain. Human antibodies include but are not limited to human IgG1. The human antibody is preferably human IgG1.
[0587] In one embodiment, the antibody constant region comprises at least one amino acid that increases the ability of the isolated antibody to bind to FcRn in an acidic pH range compared to an isolated antibody without the at least one amino acid.
[0588] In an embodiment, the constant region comprises
[0589] (a) according to EU numbering, Ala at position 434; Glu, Arg, Ser or LVs at position 438; and Glu, Asp or Gln at position 440;
[0590] (b) according to EU numbering, Ala at position 434; Arg or Lys at position 438; and Glu or Asp at position 440;
[0591] (c) according to EU numbering, Ile or Leu at position 428; Ala at position 434; Ile, Leu, Val, Thr or Phe at position 436; Glu, Arg, Ser or Lys at position 438; Glu, Asp or Gln at position 440;
[0592] (d) according to EU numbering, Ile or Leu at position 428; Ala at position 434; Ile, Leu, Val, Thr or Phe at position 436; Arg or Lys at position 438; and Glu or Asp at position 440;
[0593] (e) according to EU numbering, Leu at position 428; Ala at position 434; Val or Thr at position 436; Glu, Arg, Ser or Lys at position 438; Glu, Asp or Gln at position 440; or
[0594] (f) According to EU numbering, Leu at position 428; Ala at position 434; Val or Thr at position 436; Arg or Lys at position 438; and Glu or Asp at position 440.
[0595] WO2013 / 046704 specifically reports double amino acid residue substitutions according to EU numbering Q438R / S440E, Q438R / S440D, Q438K / S440E and Q438K / S440D, which when combined with amino acid substitutions that increase FcRn binding under acidic conditions, lead to a significant reduction in rheumatoid factor binding.
[0596] In an embodiment, the constant region preferably comprises a combination of amino acid substitutions selected from the group consisting of:
[0597] (I) According to EU numbers: (a) N434A / Q438R / S440E; (b) N434A / Q438R / S440D; (c) N434A / Q438K / S440E; (d) N434A / Q438K / S440D; (e) N434A / Y436T / Q438R / S440E; (f) N434A / Y436T / Q438R / S440D; (g) N434A / Y436T / Q438K / S440E; (h) N434A / Y436T / Q438K / S440D; (i) N434A / Y436V / Q438R / S440E; (j) N434A / Y436V / Q438R / S440D; (k) N434A / Y436V / Q438K / S440E; (l) N434A / Y436V / Q438K / S440D; (m) N434A / R435H / F436T / Q438R / S440E; (n) N434A / R435H / F436T / Q438R / S440D; (o) N434A / R435H / F436T / Q438K / S440E; (p) N434A / R435H / F436T / Q438K / S440D; (q) N434A / R435H / F436V / Q438R / S440E; (r) N434A / R435H / F436V / Q438R / S440D; (s) N434A / R435H / F436V / Q438K / S440E; (t) N434A / R435H / F436V / Q438K / S440D; (u) M428L / N434A / Q438R / S440E; (v) M428L / N434A / Q438R / S440D; (w) M428L / N434A / Q438K / S440E; (x) M428L / N434A / Q438K / S440D; (y) M428L / N434A / Y436T / Q438R / S440E; (z) M428L / N434A / Y436T / Q438R / S440D; (aa) M428L / N434A / Y436T / Q438K / S440E; (ab) M428L / N434A / Y436T / Q438K / S440D; (ac) M428L / N434A / Y436V / Q438R / S440E; (ad) M428L / N434A / Y436V / Q438R / S440D; (ae) M428L / N434A / Y436V / Q438K / S440E; (af) M428L / N434A / Y436V / Q438K / S440D;(ag)L235R / G236R / S239K / M428L / N434A / Y436T / Q438R / S440E; or;
[0598] (II) According to EU numbering (a) N434A / Q438R / S440E; (b) N434A / Y436T / Q438R / S440E; (c) N434A / Y436V / Q438R / S440E; (d) M428L / N434A / Q438R / S440E; (e) M428L / N434A / Y436T / Q438R / S440E; f)M428L / N434A / Y436V / Q438R / S440E; (g)L235R / G236R / S239K / M428L / N434A / Y436T / Q4 38R / S440E; and (h) L235R / G236R / A327G / A330S / P331S / M428L / N434A / Y436T / Q438R / S440E.
[0599] In another embodiment, the constant region preferably comprises at least one amino acid selected from the group consisting of Leucine at position 428, Alanine at position 434, and Threonine at position 436 (all numbering according to the EU numbering system). In an embodiment, the constant region more preferably comprises Leucine at position 428, Alanine at position 434, and Threonine at position 436 (all numbering according to the EU numbering system).
[0600] In one embodiment, the constant region comprises at least one amino acid that increases the ability of the isolated antibody to bind to an Fcγ receptor in the neutral pH range, compared to a second reference antibody.
[0601] In an embodiment, the constant region preferably comprises at least one or more amino acids selected from the group consisting of, according to EU numbering, in the constant region site:
[0602] Either Lys or Tyr at amino acid position 221;
[0603] any one of Phe, Trp, Glu and Tyr at amino acid position 222;
[0604] any one of Phe, Trp, Glu and Lys at amino acid position 223;
[0605] any one of Phe, Trp, Glu and Tyr at amino acid position 224;
[0606] any one of Glu, Lys and Trp at amino acid position 225;
[0607] any one of Glu, Gly, Lys and Tyr at amino acid position 227;
[0608] any one of Glu, Gly, Lys and Tyr at amino acid position 228;
[0609] any one of Ala, Glu, Gly and Tyr at amino acid position 230;
[0610] any one of Glu, Gly, Lys, Pro and Tyr at amino acid position 231;
[0611] any one of Glu, Gly, Lys and Tyr at amino acid position 232;
[0612] any one of Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 233;
[0613] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 234;
[0614] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 235;
[0615] any one of Ala, Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 236;
[0616] any one of Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 237;
[0617] any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 238;
[0618] any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp and Tyr at amino acid position 239;
[0619] Any one of Ala, Ile, Met and Thr at amino acid position 240;
[0620] any one of Asp, Glu, Leu, Arg, Trp and Tyr at amino acid position 241;
[0621] any one of Leu, Glu, Leu, Gln, Arg, Trp and Tyr at amino acid position 243;
[0622] His at amino acid position 244;
[0623] Ala at amino acid position 245;
[0624] any one of Asp, Glu, His and Tyr at amino acid position 246;
[0625] any one of Ala, Phe, Gly, His, Ile, Leu, Met, Thr, Val and Tyr at amino acid position 247;
[0626] any one of Glu, His, Gln and Tyr at amino acid position 249;
[0627] Either Glu or Gln at amino acid position 250;
[0628] Phe at amino acid position 251;
[0629] any one of Phe, Met and Tyr at amino acid position 254;
[0630] any one of Glu, Leu and Tyr at amino acid position 255;
[0631] Any one of Ala, Met and Pro at amino acid position 256;
[0632] any one of Asp, Glu, His, Ser and Tyr at amino acid position 258;
[0633] any one of Asp, Glu, His and Tyr at amino acid position 260;
[0634] Any one of Ala, Glu, Phe, Ile and Thr at amino acid position 262;
[0635] Any one of Ala, Ile, Met and Thr at amino acid position 263;
[0636] any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Trp and Tyr at amino acid position 264;
[0637] any one of Ala, Leu, Phe, Gly, His, Ile, LVs, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 265;
[0638] Any one of Ala, Ile, Met and Thr at amino acid position 266;
[0639] any one of Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp and Tyr at amino acid position 267;
[0640] any one of Asp, Glu, Phe, Gly, Ile, Lys, Leu, Met, Pro, Gln, Arg, Thr, Val and Trp at amino acid position 268;
[0641] any one of Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 269;
[0642] any one of Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Gln, Arg, Ser, Thr, Trp and Tyr at amino acid position 270;
[0643] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 271;
[0644] any one of Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 272;
[0645] Either Phe or Ile at amino acid position 273;
[0646] any one of Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 274;
[0647] Either Leu or Trp at amino acid position 275;
[0648] any one of Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 276;
[0649] any one of Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, and Trp at amino acid position 278;
[0650] Ala at amino acid position 279;
[0651] any one of Ala, Gly, His, Lys, Leu, Pro, Gln, Trp and Tyr at amino acid position 280;
[0652] any one of Asp, Lys, Pro and Tyr at amino acid position 281;
[0653] any one of Glu, Gly, Lys, Pro and Tyr at amino acid position 282;
[0654] any one of Ala, Gly, His, Ile, Lys, Leu, Met, Pro, Arg and Tyr at amino acid position 283;
[0655] any one of Asp, Glu, Leu, Asn, Thr and Tyr at amino acid position 284;
[0656] any one of Asp, Glu, Lys, Gln, Trp and Tyr at amino acid position 285;
[0657] any one of Glu, Gly, Pro and Tyr at amino acid position 286;
[0658] any one of Asn, Asp, Glu and Tyr at amino acid position 288;
[0659] any one of Asp, Gly, His, Leu, Asn, Ser, Thr, Trp and Tyr at amino acid position 290;
[0660] any one of Asp, Glu, Gly, His, Ile, Gln and Thr at amino acid position 291;
[0661] any one of Ala, Asp, Glu, Pro, Thr and Tyr at amino acid position 292;
[0662] any one of Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 293;
[0663] any one of Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 294;
[0664] any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 295;
[0665] any one of Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr and Val at amino acid position 296;
[0666] any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 297;
[0667] any one of Ala, Asp, Glu, Phe, His, Ile, Lys, Met, Asn, Gln, Arg, Thr, Val, Trp and Tyr at amino acid position 298;
[0668] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Val, Trp and Tyr at amino acid position 299;
[0669] any one of Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, and Trp at amino acid position 300;
[0670] any one of Asp, Glu, His and Tyr at amino acid position 301;
[0671] Ile at amino acid position 302;
[0672] Any one of Asp, Gly and Tyr at amino acid position 303;
[0673] any one of Asp, His, Leu, Asn and Thr at amino acid position 304;
[0674] any one of Glu, Ile, Thr and Tyr at amino acid position 305;
[0675] any one of Ala, Asp, Asn, Thr, Val and Tyr at amino acid position 311;
[0676] Phe at amino acid position 313;
[0677] Leu at amino acid position 315;
[0678] Either Glu or Gln at amino acid position 317;
[0679] any one of His, Leu, Asn, Pro, Gln, Arg, Thr, Val and Tyr at amino acid position 318;
[0680] any one of Asp, Phe, Gly, His, Ile, Leu, Asn, Pro, Ser, Thr, Val, Trp and Tyr at amino acid position 320;
[0681] any one of Ala, Asp, Phe, Gly, His, Ile, Pro, Ser, Thr, Val, Trp and Tyr at amino acid position 322;
[0682] Ile at amino acid position 323;
[0683] any one of Asp, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Thr, Val, Trp and Tyr at amino acid position 324;
[0684] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 325;
[0685] any one of Ala, Asp, Glu, Gly, Ile, Leu, Met, Asn, Pro, Gln, Ser, Thr, Val, Trp and Tyr at amino acid position 326;
[0686] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Thr, Val, Trp and Tyr at amino acid position 327;
[0687] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 328;
[0688] any one of Asp, Glu, Phe, Gly, His, Tle, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 329;
[0689] any one of Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 330;
[0690] any one of Asp, Phe, His, Ile, Leu, Met, Gln, Arg, Thr, Val, Trp and Tyr at amino acid position 331;
[0691] any one of Ala, Asp, Glu, Phe, Gly, His, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr at amino acid position 332;
[0692] any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Ser, Thr, Val and Tyr at amino acid position 333;
[0693] any one of Ala, Glu, Phe, Ile, Leu, Pro and Thr at amino acid position 334;
[0694] any one of Asp, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Val, Trp and Tyr at amino acid position 335;
[0695] any one of Glu, Lys and Tyr at amino acid position 336;
[0696] any one of Glu, His and Asn at amino acid position 337;
[0697] any one of Asp, Phe, Gly, Ile, Lys, Met, Asn, Gln, Arg, Ser and Thr at amino acid position 339;
[0698] Either Ala or Val at amino acid position 376;
[0699] Either Gly or Lys at amino acid position 377;
[0700] Asp at amino acid position 378;
[0701] Asn at amino acid position 379;
[0702] Any one of Ala, Asn and Ser at amino acid position 380;
[0703] Either Ala or Ile at amino acid position 382;
[0704] Glu at amino acid position 385;
[0705] Thr at amino acid position 392;
[0706] Leu at amino acid position 396;
[0707] Lys at amino acid position 421;
[0708] Asn at amino acid position 427;
[0709] Either Phe or Leu at amino acid position 428;
[0710] Met at amino acid position 429;
[0711] Trp at amino acid position 434;
[0712] Ile at amino acid position 436; and
[0713] Any one of Gly, His, Ile, Leu and Tyr at the 440th amino acid.
[0714] In an embodiment, the constant region more preferably comprises, according to EU numbering, in the constant region site, at least one or more of the following:
[0715] Asp at amino acid position 238; and
[0716] Glu at the 328th amino acid.
[0717] In an embodiment, the constant region further preferably includes at least one of the following amino acids: tyrosine at position 234, tryptophan at position 235, asparagine at position 236, aspartic acid at position 238, valine at position 250, isoleucine at position 264, aspartic acid at position 268, leucine at position 295, proline at position 307, threonine at position 326, lysine at position 330 (all numbering is according to the EU numbering system).
[0718] The constant region further preferably includes the following amino acids (a) or (b);
[0719] (a) tryptophan at position 235, asparagine at position 236, aspartic acid at position 268, leucine at position 295, threonine at position 326, and lysine at position 330, or
[0720] (b) tyrosine at position 234, aspartic acid at position 238, valine at position 250, isoleucine at position 264, proline at position 307 and lysine at position 330 (all numbering according to the EU numbering system).
[0721] In one embodiment, the isoelectric point (pI) of the separated antibody is increased by changing the constant region. In an embodiment, the separated antibody with increased pI includes at least two amino acid changes in the constant region compared to its parent constant region. In a further embodiment, each amino acid change increases the isoelectric point (pI) of the constant region compared to the parent constant region. In a further embodiment, amino acids can be exposed on the surface of the region. In a further embodiment, the separated antibody includes a constant region and an antigen-binding domain. In a further embodiment, the antigen-binding activity of the antigen-binding domain changes according to ion concentration conditions.
[0722] In a further embodiment, the constant region with increased pi of the invention comprises at least two amino acid changes at at least two positions selected from the group consisting of: 285, 311, 312, 315, 318, 333, 335, 337, 341, 342, 343, 384, 385, 388, 390, 399, 400, 401, 402, 413, 420, 422 and 431, according to EU numbering. In a further embodiment, the constant region with increased pi comprises Arg or Lys at each of the selected positions.
[0723] In a specific embodiment, the constant region with increased pi includes an arginine at position 311 and an arginine at position 343 (both numberings are according to the EU numbering system).
[0724] In one embodiment, the isoelectric point (pI) of the antibody of separation is reduced by changing the heavy chain variable region and / or the light chain variable region. In embodiments, compared with its parent region, the antibody of separation with reduced pI comprises at least one amino acid change in the heavy chain variable region and / or the light chain variable region. This pI reduced by changing the heavy chain variable region and / or the light chain variable region can contribute to improving the PK of the antibody of separation.
[0725] In an embodiment, the constant region in the heavy chain comprises at least one amino acid that can reduce the binding ability to C1q compared to the human antibody constant region without the at least one amino acid. When the unnecessary binding of the constant region to C1q in the separated antibody is reduced by this amino acid, when the separated antibody is used in medicine, the side effects causing unnecessary binding are avoided. The relevant amino acids that reduce the binding of the antibody constant region to C1q are, for example, shown in WO2014163101. In a specific embodiment, the amino acid that can reduce the binding ability to C1q is Asp at position 238 in the EU numbering system.
[0726] In one embodiment, the binding activity of the constant region in the isolated antibody to all activated FcγRs, especially FcγRIIa (R type), can be reduced compared to an isolated antibody comprising a naturally occurring IgG antibody constant region as disclosed in WO2014163101, while their FcγRIIb binding activity is maintained. Through this binding activity of the constant region, the inflammatory immune response inhibitory signal generated by the phosphorylation of ITIM (immunoreceptor tyrosine-based inhibitory motif) of FcγRIIb can be enhanced under the condition that the property of eliminating immune complexes by FcγRIIb is maintained to a similar degree to that of naturally occurring IgG. In addition, by giving the constant region the property of selectively binding to FcγRIIb, anti-antibody production can be suppressed. In addition, by reducing the binding to the activated FcγR, platelet activation mediated by the interaction between FcγRIIa on platelets and immune complexes, as well as dendritic cell activation caused by cross-linking of activated FcγRs can be avoided.
[0727] In an embodiment, the constant region in the heavy chain includes at least one amino acid that can selectively bind to FcγRIIb compared to the constant region of a human antibody without the at least one amino acid. In an embodiment, the ratio of the KD value of the constant region in the heavy chain to human FcγRIIa to the KD value of human FcγRIIb (KD(hFcγRIIa / KD(hFcγRIIb)) is higher than the KD value ratio of the constant region of a human antibody without the at least one amino acid. Exemplary amino acids in the constant region with the property of selectively binding to FcγRIIb are shown, for example, in WO2014163101. In a specific embodiment, the constant region in the heavy chain includes Tyr at position 234 of the EU numbering system, Asp at position 238 of the EU numbering system, Ile at position 264 of the EU numbering system, and Lys at position 330 of the EU numbering system.
[0728] In a specific embodiment, the constant region in the heavy chain includes at least one selected from the group consisting of: Arg at position 214 of the EU numbering system, Val at position 250 of the EU numbering system, Pro at position 307 of the EU numbering system, Arg at position 311 of the EU numbering system, Arg at position 343 of the EU numbering system, Leu at position 428 of the EU numbering system, Ala at position 434 of the EU numbering system, Thr at position 436 of the EU numbering system, Arg at position 438 of the EU numbering system, and Glu at position 440 of the EU numbering system. In a preferred embodiment, the constant region in the heavy chain includes at least one selected from the group consisting of: Arg at position 214 of the EU numbering system, Tyr at position 234 of the EU numbering system, Asp at position 238 of the EU numbering system, Val at position 250 of the EU numbering system, Ile at position 264 of the EU numbering system, Pro at position 307 of the EU numbering system, Arg at position 311 of the EU numbering system, Lys at position 330 of the EU numbering system, Arg at position 343 of the EU numbering system, Leu at position 428 of the EU numbering system, Ala at position 434 of the EU numbering system, Thr at position 436 of the EU numbering system, Arg at position 438 of the EU numbering system, and Glu at position 440 of the EU numbering system. In a preferred embodiment, the constant region in the heavy chain comprises Arg at position 214 of the EU numbering system, Tyr at position 234 of the EU numbering system, Asp at position 238 of the EU numbering system, Val at position 250 of the EU numbering system, Ile at position 264 of the EU numbering system, Pro at position 307 of the EU numbering system, Arg at position 311 of the EU numbering system, Lys at position 330 of the EU numbering system, Arg at position 343 of the EU numbering system, Leu at position 428 of the EU numbering system, Ala at position 434 of the EU numbering system, Thr at position 436 of the EU numbering system, Arg at position 438 of the EU numbering system, and Glu at position 440 of the EU numbering system. When the amino acids in these embodiments are combined with the above-mentioned antigen-binding region, the isolated antibody has less immunogenic potential and / or less potential to induce morphological changes in immune cells (e.g., PBMCs).
[0729] In one embodiment, the C-terminal lysine (position 447 in the EU numbering system) or C-terminal glycine-lysine (positions 446 and 447 in the EU numbering system) of the constant region of the heavy chain can be removed to reduce heterogeneity in the isolated antibodies produced as disclosed in WO2009041613. In a preferred embodiment, the amino acids at positions 446 and 447 in the EU numbering system in the constant region are deleted.
[0730] Fc region variants
[0731] (Cleaning Technology)
[0732] In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of the antibodies provided herein, thereby producing Fc region variants. The Fc region variant comprises a human Fc region sequence (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc region) comprising an amino acid modification (e.g., replacement) at one or more amino acid positions. In some embodiments, the Fc region is the Fc region of human IgG1.
[0733] In order to enhance the reduction of plasma antigen concentration and / or improve the pharmacokinetics of antibodies, the amino acid residues of the site of binding to FcRn in the IgG Fc region can be modified to enhance their uptake in cells. When an antibody with pH dependence is modified in this way, the mutant will be a "sweeping" antibody that can bind to FcRn more firmly and allow the antigen to be efficiently transferred to the endosome (where the pH is acidic) and then degraded, but can itself be more efficiently recycled to the cell surface. Compared with the unmodified original (parent) antibody, this modified "sweeping" antibody can bind to FcRn firmly at neutral pH and on the cell surface, and enhance the uptake and degradation of antigens. (Semin Immunopathol. 2018; 40(1): 125-140).
[0734] In some aspects, the antibody is an Fc region having at least one amino acid modification in the Fc region to enhance reduction of plasma antigen concentration and / or improve the pharmacokinetics of the antibody.
[0735] In some embodiments, the Fc region is a human Fc region that has stronger binding activity to activated Fcγ receptors than to the Fc region of native human IgG1. As mentioned in 2013 / 047752, in order to enhance the binding activity to the activated Fcγ receptor, one or more amino acids selected from the group consisting of the amino acids at the following positions in the Fc region can be modified to be different from the amino acids at the corresponding positions in the Fc region of the natural human IgG1 as the parent (original) antibody: 221, 222, 223, 224, 225, 227, 228, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 246, 247, 249, 250, 251, 254, 255, 256, 258, 260, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273 , 274, 275, 276, 278, 279, 280, 281, 282, 283, 284, 285, 286, 288, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 311, 313, 315, 317, 318, 32 0, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 339, 376, 377, 378, 379, 380, 382, 385, 392, 396, 421, 427, 428, 429, 434, 436 and 440 (EU numbering).
[0736] In some embodiments, the Fc region is a human Fc region that has stronger binding activity to inhibitory Fcγ receptors than to activating Fcγ receptors. As mentioned in, for example, WO 2013 / 125667, in order to enhance the binding activity to inhibitory Fcγ receptors, one or more amino acids selected from the group consisting of amino acids at the following positions in the Fc region can be modified to be different from the amino acids at the corresponding positions in the Fc region of natural human IgG1: 244, 245, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 260, 262, 265, 270, 272, 279, 283, 285, 286, 288, 293, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325 5, 307, 308, 309, 311, 312, 314, 316, 317, 318, 332, 339, 340, 341, 343, 356, 360, 362, 375, 376, 377, 378, 380, 382, 385, 386, 387, 388, 389, 400, 413, 415, 423, 424, 427, 428, 430, 431, 433, 434, 435, 436, 438, 439, 440, 442 and 447 (EU numbering).
[0737] In some embodiments, the Fc region is a human Fc region that has a stronger binding activity to FcRn at neutral pH than that of the Fc region of native human IgG1. As mentioned in, for example, WO 2011 / 122011, in order to enhance the binding activity to FcRn at neutral pH, one or more amino acids selected from the group consisting of amino acids at the following positions in the Fc region can be modified to be different from the amino acids at the corresponding positions in the Fc region of native human IgG1: 237, 238, 239, 248, 250, 252, 254, 255, 256, 257, 258, 265, 270, 286, 289, 297, 298, 303, 305, 307, 308, 309, 311, 312, 314, 315, 317, 325, 332, 334, 360, 376, 380, 382, 384, 385, 386, 387, 389, 424, 428, 433, 434 and 436 (EU numbering).
[0738] In certain embodiments, the present invention contemplates an antibody variant that has some but not all effector functions, making it an ideal candidate for applications where the half-life of the antibody in vivo is important but certain effector functions (e.g., complement and ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduction / depletion of CDC and / or ADCC activity. For example, an Fc receptor (FcR) binding assay can be performed to ensure that the antibody lacks FcγR binding (and therefore may lack ADCC activity) but retains FcRn binding ability. Primary cells used to mediate ADCC, NK cells, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-492 (1991) Table 3 on page 464 summarizes FcR expression on hematopoietic cells. Non-limiting examples of in vitro assays for assessing ADCC activity of molecules of interest are described in U.S. Pat. Nos. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assays can be used (see, e.g., the ACT1 (registered trademark) non-radioactive cytotoxicity assay for flow cytometry (Cell Technology, Inc. Mountain View, CA; and the CytoTox 96 (registered trademark) non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the target molecule can be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). A Clq binding assay can also be performed to confirm that the antibody cannot bind Clq and therefore lacks CDC activity. See, e.g., Clq and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402.To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, MS et al., Blood 101: 1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103: 2738-2743 (2004). FcRn binding and in vivo clearance / half-life assays can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18(12): 1759-1769 (2006)).
[0739] Antibodies with reduced effector function include antibodies with one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 substituted (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc mutants in which residues 265 and 297 are substituted with alanine (U.S. Pat. No. 7,332,581).
[0740] Certain antibody variants with increased or decreased binding to FcRs have been described (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001)).
[0741] In certain embodiments, the antibody variants include an Fc region with one or more amino acid substitutions that improve ADCC, eg, substitutions at positions 298, 333, and / or 334 of the Fc region (EU numbering of residues).
[0742] In some embodiments, changes are made in the Fc region that result in altered (ie, increased or decreased) Clq binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al. J. Immunol. 164:4178-4184 (2000).
[0743] US2005 / 0014934A1 (Hinton et al.) describes antibodies with increased half-life and increased binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117: 587 (1976) and Kim et al., J. Immunol. 24: 249 (1994)). Those antibodies comprise an Fc region with one or more substitutions therein that increase the binding of the Fc region to FcRn. Such Fc variants include those having substitutions at one or more Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826). See also Duncan & Winter, Nature 322: 738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94 / 29351, for other examples of Fc region variants.
[0744] (a7) Other Implementation Schemes
[0745] (Antibody Variants)
[0746] In certain embodiments, amino acid sequence variants of antibodies provided herein are contemplated. For example, it may be necessary to improve the binding affinity and / or other biological properties of the antibody. The amino acid sequence variants of the antibody can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues in the antibody amino acid sequence. Any combination of deletions, insertions and substitutions can be performed to obtain the final construct, provided that the final construct has the desired characteristics, such as antigen binding.
[0747] a7-1) Substitution, insertion and deletion variants
[0748] In certain embodiments, antibody variants with one or more amino acid substitutions are provided. The target sites for substitution mutagenesis include HVR and FR. Conservative substitutions are in Table 1 under the heading "Preferred Substitutions". More substantial changes are provided in Table 1 under the heading "Exemplary Substitutions" and are further described below with reference to the amino acid side chain classes. Amino acid substitutions can be introduced into the target antibody, and the product can be screened to obtain the desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.
[0749] [Table 1]
[0750]
[0751] Amino acids can be grouped based on common side chain properties:
[0752] (1) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
[0753] (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
[0754] (3) Acidic: Asp, Glu;
[0755] (4) Basic: His, Lys, Arg;
[0756] (5) Residues that affect chain orientation: Gly, Pro;
[0757] (6) Aromatic: Trp, Tyr, Phe.
[0758] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
[0759] One type of substitutional variant involves replacing one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Typically, the resulting variant selected for further study will have modifications (e.g., improvements) and / or will substantially retain certain biological properties of the parent antibody in terms of certain biological properties (e.g., increased affinity, reduced immunogenicity). Exemplary substitutional variants are affinity-matured antibodies that can be easily produced, for example, using affinity maturation techniques based on phage display, such as those described herein. In short, one or more HVR residues are mutated, and variant antibodies are displayed on phage and screened for specific biological activity (e.g., binding affinity).
[0760] Changes (e.g., substitutions) can be made in HVRs, for example, to improve antibody affinity. For example, changes can be made in HVR "hot spots," residues encoded by codons that are highly mutated during somatic maturation (see, e.g., Chowdhury, Methods Mol. Biol. 207: 179-196 (2008)), and / or residues that contact antigen, and the resulting variant VH or VL is tested for binding affinity. Affinity maturation by construction of secondary libraries and reselection from the secondary libraries has been described, for example, in Hoogenboom et al., Methods in Molecular Biology 178: 1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, (2001). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves an HVR-directed approach in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 are particularly often targeted.
[0761] In certain embodiments, substitutions, insertions or deletions may occur within one or more HVRs, as long as such changes do not significantly reduce the ability of the antibody to bind to antigen. For example, conservative changes (e.g., conservative substitutions provided herein) that do not significantly reduce binding affinity may be made in HVRs. For example, such changes may be outside the antigen contact residues in HVRs. In some embodiments of the variant VH and VL sequences provided above, each HVR is either unchanged or contains no more than one, two or three amino acid substitutions.
[0762] As described in Cunningham and Wells (1989) Science, 244: 1081-1085, a useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis". In this method, a residue or a group of target residues (e.g., charged residues such as Arg, Asp, His, Lys and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitutions. Alternatively or additionally, the crystal structure of the antigen-antibody complex can be analyzed to identify contact points between the antibody and the antigen. Such contact residues and adjacent residues can be targeted or eliminated as substitution candidates. Variants can be screened to determine whether they contain the desired properties.
[0763] Amino acid sequence insertions include amino and / or carboxyl terminal fusions of polypeptides ranging in length from one residue to one hundred or more residues, and intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with N-terminal methionyl residues. Other insertion variants of antibody molecules include fusions of enzymes (e.g., for ADEPT) or polypeptides that increase the plasma half-life of antibodies to the N- or C-termini of the antibody.
[0764] a7-2) Glycosylation variants
[0765] In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent of antibody glycosylation. Addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence to create or remove one or more glycosylation sites.
[0766] In the case where the antibody includes an Fc region, the carbohydrates attached thereto may be altered. Natural antibodies produced by mammalian cells typically include branched biantennary oligosaccharides that are typically attached to Asn297 of the CH2 domain of the Fc region via an N-bond. See, e.g., Wright et al. TIBTECH 15: 26-32 (1997). Oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, the oligosaccharides in the antibodies of the invention may be modified to produce antibody variants with certain improved properties.
[0767] In one embodiment, an antibody variant having a carbohydrate structure is provided that lacks fucose (directly or indirectly) attached to the Fc region. For example, the amount of fucose in such an antibody may be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297 relative to the sum of all sugar structures (e.g., complex, hybrid, and high mannose structures) attached to Asn 297, as measured by MALDI-TOF mass spectrometry, for example, as described in WO 2008 / 077546. Asn297 refers to an asparagine residue located at about position 297 in the Fc region (EU numbering of Fc region residues); however, due to minor sequence variations of antibodies, Asn297 may also be located about + / -3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylated variants may have improved ADCC function. See, e.g., U.S. Patent Publication Nos. US 2003 / 0157108 (Presta, L.); US 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include: US 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; US 2003 / 0115614; US 2002 / 0164328; US 2004 / 0093621; US 2004 / 0132140; US 2004 / 0110704; US 2004 / 0110282; US 2004 / 0109865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO2005 / 035778; WO2005 / 053742; WO2002 / 031140; Okazaki et al. J. Mol. Biol. 336: 1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249: 533-545 (1986); U.S. Patent Application No. US 2003 / 0157108 A1, Presta, L; and WO 2004 / 056312 A1, Adams et al., especially in Example 11), and knockout cell lines, such as α-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4): 680-688 (2006); and WO 2003 / 085107).
[0768] Further provide bisected oligosaccharides for antibody variants, for example, wherein the biantennary oligosaccharides connected to the Fc region of the antibody are bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described in, for example, WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US 2005 / 0123546 (Umana et al.). Antibody variants having at least one galactose residue in the oligosaccharide connected to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described in, for example, WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.).
[0769] a7-3) Cysteine engineered antibody variants
[0770] In certain embodiments, it may be desirable to produce cysteine engineered antibodies, such as "thioMAbs," in which one or more residues of an antibody are replaced by cysteine residues. In a specific embodiment, the replaced residues appear at accessible sites of the antibody. By replacing those residues with cysteine, reactive thiol groups are thus positioned at accessible sites of the antibody and can be used to conjugate the antibody to other moieties (e.g., drug moieties or linker-drug moieties) to produce immunoconjugates, as further described herein. In certain embodiments, any one or more of the following residues may be replaced by cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) in the heavy chain Fc region. Cysteine engineered antibodies can be produced as described in U.S. Patent No. 7,521,541.
[0771] a7-4) Antibody derivatives
[0772] In certain embodiments, the antibodies provided herein may be further modified to include other non-proteinaceous parts known in the art and easily available. Suitable parts for derivatized antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol / propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers) and dextran or poly-(n-vinyl pyrrolidone) polyethylene glycol, polypropylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylene polyols (e.g., glycerol), polyvinyl alcohol and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. Polymers may have any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if the attached polymer is more than one, they may be the same or different molecules. In general, the amount and / or type of polymer used for derivatization can be determined based on considerations including, but not limited to, the specific property or function of the antibody to be improved, whether the antibody derivative will be used therapeutically under defined conditions, etc.
[0773] In another embodiment, a conjugate of an antibody and a non-protein moiety that can be selectively heated by exposure to radiation is provided. In one embodiment, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength, and includes but is not limited to wavelengths that do not harm normal cells but heat the non-protein to a temperature close to that at which the cells of the antibody-non-protein moiety are killed.
[0774] B. Recombinant Methods and Compositions
[0775] Recombinant methods and compositions can be used to produce antibodies, for example, as described in U.S. Patent No. 4,816,567. In one embodiment, an isolated nucleic acid encoding an anti-Cls antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the amino acid sequence of the VL of the antibody and / or an amino acid sequence comprising the amino acid sequence of the VH of the antibody (e.g., the light chain and / or heavy chain of the antibody). In another embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acids are provided. In another embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, the host cell includes (e.g., transformed with): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is a eukaryotic cell, such as a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., a YO, NSO, Sp2 / O cell). In one embodiment, a method for preparing an anti-Cls antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody as provided above under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
[0776] For the recombinant production of anti-Cls antibodies described herein, nucleic acids encoding antibodies, such as those described above, are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids can be easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to genes encoding antibody heavy and light chains).
[0777] Suitable host cells for cloning or expressing antibody encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199 and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing expression of antibody fragments in Escherichia coli.) After expression, antibodies can be separated from bacterial cell paste in the soluble portion and can be further purified.
[0778] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized" to produce antibodies with partially or fully human glycosylation patterns. See Gemgross, Nat. Biotech. 22: 1409-1414 (2004) and Li et al., Nat. Biotech. 24: 210-215 (2006).
[0779] Suitable host cells for expressing glycosylated antibodies also come from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
[0780] Plant cell cultures can also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES (registered trademark) technology for producing antibodies in transgenic plants).
[0781] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted for growth in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells, as described in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse trophoblast cells (TM4 cells, as described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described in Mather et al., Annals NY Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (, Urlaub et al., Proc. Natl. Acad. Sci. USA 77: 4216 (1980)); and myeloma cell lines, such as YO, NSO and Sp2 / O. For a review of certain mammalian host cell lines suitable for antibody production, see Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).
[0782] Antibodies with pH-dependent characteristics can be obtained by using screening methods and / or mutagenesis methods, for example, as described in WO2009 / 125825. The screening method may include any process for identifying antibodies with pH-dependent binding characteristics in an antibody population specific for a specific antigen. In certain embodiments, the screening method may include measuring one or more binding parameters (e.g., KD or kd) of a single antibody in an initial antibody population at acidic pH and neutral pH. The binding parameters of the antibody can be measured using, for example, surface plasmon resonance or any other analytical method that allows quantitative or qualitative assessment of the binding properties of an antibody to a specific antigen. In certain embodiments, the screening method may include identifying antibodies that bind to an antigen with an acidic KD / neutral KD ratio of 2 or more. Alternatively, the screening method may include identifying antibodies that bind to an antigen with an acidic kd / neutral kd ratio of 2 or more.
[0783] In another embodiment, the mutagenesis method includes the deletion, substitution or addition of amino acids incorporated into the heavy chain and / or light chain of the antibody to enhance the pH-dependent binding of the antibody to the antigen. In certain embodiments, mutagenesis is performed in one or more variable domains of the antibody, such as in one or more HVRs (e.g., CDRs). For example, mutagenesis includes replacing an amino acid in one or more HVRs (e.g., CDRs) of the antibody with another amino acid. In certain embodiments, mutagenesis includes replacing one or more amino acids in at least one HVR (e.g., CDR) of the antibody with histidine. In certain embodiments, "enhanced pH-dependent binding" refers to a mutant form of an antibody that exhibits a greater acidic KD / neutral KD ratio than the original "parent" (i.e., less pH-dependent) form of the antibody before mutagenesis, or a greater acidic kd / neutral kd ratio. In certain embodiments, the mutant form of the antibody has an acidic KD / neutral KD ratio of 2 or greater. Alternatively, the mutant form of the antibody has an acidic kd / neutral kd ratio of 2 or greater.
[0784] Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized (e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor) using a bifunctional or derivatizing agent (e.g., maleimidobenzoyl sulfosuccinimide ester (conjugated through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl2, or R1N=C=NR, wherein R and R1 are different alkyl groups).
[0785] Animals (usually non-human mammals) are immunized against the antigen, immunogenic conjugate or derivative by combining, for example, 100 micrograms or 5 micrograms of protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant, and the solution is injected intradermally at multiple sites. One month later, the animals are boosted with 1 / 5 to 1 / 10 of the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. After 7 to 14 days, the animals are bled and the antibody titer of the serum is determined. The animals are boosted until the titer stabilizes. Preferably, the animals are boosted with conjugates of the same antigen, but conjugated to different proteins and / or through different cross-linking agents. The conjugates can also be made into protein fusions in recombinant cell culture. In addition, agglutinating agents such as alum are also suitable for enhancing immune responses.
[0786] A monoclonal antibody is obtained from a substantially homogeneous antibody population, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.
[0787] For example, monoclonal antibodies can be prepared using the hybridoma method first described by Kohler et al., Nature 256(5517): 495-497 (1975). In the hybridoma method, mice or other suitable host animals, such as hamsters, are immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the protein used for immunization. Alternatively, lymphocytes can be immunized in vitro.
[0788] Immunizing agents generally include antigenic proteins or fusion variants thereof. Typically, if cells of human origin are required, peripheral blood lymphocytes (PBL) are used, and if non-human mammalian sources are required, spleen cells or lymph node cells are used. Lymphocytes are then fused with immortalized cell lines using a suitable fusing agent such as polyethylene glycol to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press (1986), pp. 59-103).
[0789] Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, cattle and human origin. Rat or mouse myeloma cell lines are usually used. The hybridoma cells thus prepared are inoculated and grown in a suitable culture medium, which preferably contains one or more substances that inhibit the growth or survival of the unfused parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium of the hybridoma will usually contain hypoxanthine, aminopterin and thymidine (HAT culture medium), which are substances that prevent the growth of HGPRT-deficient cells.
[0790] Preferred immortalized myeloma cells are those that fuse efficiently, support stable high-level production of antibodies by selected antibody-producing cells, and are sensitive to culture media (e.g., HAT culture media). Among them, preferred are murine myeloma lines, such as MOPC-21 and MPC-11 mouse tumors derived from the Salk Institute Cell Distribution Center, San Diego, California, USA, and SP-2 cells (and derivatives thereof, e.g., X63-Ag8-653) available from the American Type Culture Collection, Manassas, Virginia, USA. Human myeloma and mouse-human heteromyeloma cell lines have also been described for the production of human monoclonal antibodies (Kozbor et al. J. Immunol. 133(6):3001-3005 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, pp. 51-63 (1987)).
[0791] For the production of monoclonal antibodies against the antigen, the culture medium in which the hybridoma cells are grown is assayed. Preferably, the binding specificity of the monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). Such techniques and assays are known in the art. For example, binding affinity can be determined by Scatchard analysis of Munson, Anal. Biochem. 107 (1): 220-239 (1980).
[0792] After identifying hybridoma cells that produce antibodies with the desired specificity, affinity and / or activity, clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 culture media. In addition, hybridoma cells can be grown as tumors in mammals.
[0793] The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
[0794] III. Determination
[0795] The anti-Cls antibodies provided herein can be identified, screened or characterized for their physical / chemical properties and / or biological activities by various assays known in the art.
[0796] A. Binding and Other Assays
[0797] In one aspect, the antigen binding activity of the antibodies of the invention is tested, for example, by known methods such as ELISA, Western blot, and the like.
[0798] On the other hand, competition assays can be used to identify antibodies that compete with any anti-Cls antibody described herein for binding to Cls, or to identify antibodies that bind to the same epitope as any anti-Cls antibody described herein. In certain embodiments, when such a competing antibody is present in excess, it blocks (e.g., reduces) the binding of a reference antibody to Cls by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or more. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or conformational epitope) as any anti-Cls antibody described herein. Morris (1996) "Epitope Mapping Protocols", Methods in Molecular Biology Volume 66 (Humana Press, Totowa, NJ) provides detailed exemplary methods for mapping epitopes to which antibodies bind. In certain embodiments, such a competition assay can be performed under neutral pH conditions. In some embodiments, the competition assay is a tandem competition assay using, for example, the Octet (registered trademark) system.
[0799] In an exemplary competition assay, fixed Cls is incubated in a solution comprising a first labeled antibody (e.g., one of the antibodies described herein) that binds to Cl and a second unlabeled antibody that is tested for its ability to compete with the first antibody for binding to Cls. The second antibody may be present in a hybridoma supernatant. As a control, fixed Cls is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that allow the first antibody to bind to Cls, excess unbound antibody is removed and the amount of label associated with fixed Cls is measured. If the amount of label associated with fixed Cls is significantly reduced in the test sample compared to the control sample, it indicates that the second antibody is competing with the first antibody for binding to Cls. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
[0800] On the other hand, antibodies that bind to the same epitope as the anti-Cls antibodies provided herein or compete with the anti-Cls antibodies provided herein for binding to Cls can be identified using sandwich assays. Sandwich assays involve the use of two antibodies, each of which is capable of binding to different immunogenic portions or epitopes of the protein to be detected. In a sandwich assay, the test sample analyte is bound to a first antibody that is fixed to a solid support, and then a second antibody is bound to the analyte to form an insoluble three-part complex. See David & Greene, U.S. Patent No. 4,376,110. The second antibody itself can be labeled with a detectable portion (direct sandwich assay) or can be measured using an anti-immunoglobulin antibody labeled with a detectable portion (indirect sandwich assay). For example, a sandwich assay is an ELISA assay, in which case the detectable portion is an enzyme. Antibodies that simultaneously bind to Cls with the anti-Cls antibodies provided herein can be determined as antibodies that bind to epitopes different from the anti-Cls antibodies. Therefore, antibodies that do not simultaneously bind to Cls with the anti-Cls antibodies provided herein can be determined as antibodies that bind to the same epitope as the anti-Cls antibodies or compete with the anti-Cls antibodies for binding to Cls.
[0801] B. Activity Assay
[0802] On the one hand, an assay for identifying anti-Cls antibodies having biological activity is provided. The biological activity can include blocking the activation of the classical pathway and the generation of cleavage products C2a, C2b, C3a, C3b, C4a, C4b, C5a and C5b caused by the activation of the pathway. Antibodies with this biological activity in vivo and / or in vitro are also provided.
[0803] In certain embodiments, such biological activities of the antibodies of the present invention are tested. In some embodiments, the ability of the antibodies of the present invention to inhibit complement-mediated hemolysis of sheep red blood cells (RBC) can be assessed, and the sheep red blood cells (RBC) have been sensitized with antibodies to sheep RBC antigens, i.e., using RBC assays. In some embodiments, the ability of the antibodies of the present invention to inhibit complement-mediated hemolysis of chicken red blood cells (cRBC) can be assessed, and the chicken red blood cells have been sensitized with antibodies to cRBC antigens. Using human serum as a source of complement proteins, the activity of the antibodies of the present invention can be determined by measuring the amount of released hemoglobin by spectrophotometry.
[0804] The RBC assay can be suitably performed using known methods, such as the method disclosed in J. Vis. Exp. 2010; (37): 1923. The article describes how to perform a 50% hemolytic complement (CH50) assay as an RBC lysis assay. In short, the assay measures activation of the classical complement pathway and detects reduction, loss or inactivation of any component of the pathway. It assesses the activity of complement components in serum to lyse red blood cells. When antibodies are incubated with test serum, the pathway is activated and causes hemolysis. If one or more components of the classical pathway are reduced, the CH50 value will decrease. The CH50 assay is not exactly the same as the assay used in the examples herein, which measures the percentage inhibition of cell lysis by complement components; however, the concept and basic setup are essentially the same as the present invention. In an embodiment, the RBC assay is performed as follows. Human serum is pre-incubated with the antibody of interest (e.g., incubated at 37 degrees Celsius (°C) for 3 hours). The serum is then added to an equal volume of sensitized sheep red blood cells and incubated (e.g., at 37°C for 1 hour) to lyse the red blood cells. The reaction is then stopped. The mixture was centrifuged to precipitate the unlysed cells, the supernatant was removed, and the OD at 630 nm was subtracted from the absorbance (OD) at 415 nm for analysis of the release of hemoglobin. In order to calculate the inhibition percentage of erythrocyte lysis, 0% inhibition was set to the condition of no addition of antibody (buffer only), and 100% inhibition was set to the condition of adding EDTA at a final concentration of 5 mM (see, e.g., Example 7). When an antibody shows an inhibition percentage of erythrocyte lysis, this means that the antibody has neutralizing activity on human serum complement, e.g., has an activity of inhibiting the interaction between Clq and Clr2s2 complexes.
[0805] Therefore, the RBC assay can be used to assess the neutralizing activity of antibodies against human serum complement to assess the activity of inhibiting the interaction between Clq and the Clr2s2 complex. In an embodiment, the invention provides an isolated antibody that inhibits the interaction between Clq and the Clr2s2 complex, wherein the antibody has at least 70% neutralizing activity against human serum complement in the RBC assay.
[0806] C. Assessment of immunogenic potential
[0807] As described in WO2018 / 124005 (Kubo C. et al.), the immunogenic potential of antibodies was determined by using CD4 T cells that secrete IL-2 prior to active proliferation. + The proportion of T cells was evaluated as an indicator. Specifically, CD8 - CD25 low PBMC (peripheral blood mononuclear cells) were prepared from human PBMC and cultured in the presence of antibodies for 67 hours.
[0808] IV. Immunoconjugates
[0809] The present invention also provides an immunoconjugate comprising an anti-Cls antibody herein conjugated to one or more cytotoxic agents such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant or animal origin or fragments thereof), or radioactive isotopes.
[0810] In one embodiment, the immunoconjugate is an antibody-drug conjugate (ADC) in which the antibody is conjugated to one or more drugs, including but not limited to maytansinoids (see U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235) B1); auristatins, such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483 and 5,780,588 and 7,498,298); caudatelin; calicheamicin or its derivatives (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001 and 5,877,296; Hinman et al., Cancer Res. 53: 3336-3342 (1993); and Lode et al., Cancer Res. 58: 2925-2928 (1998); anthracyclines, such as daunomycin or doxorubicin (see Kratz et al., Current Med. Chem. 13: 477-523 (2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16: 358-362 (2006); Torgov et al., Bioconj. Chem. 16: 717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834 (2000); Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532 (2002); King et al., J. Med. Chem. 45:4336-4343 (2002); and U.S. Pat. No. 6,630,579); methotrexate; vindesine; taxanes, such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecenes; and CC1065.
[0811] In another embodiment, the immunoconjugate comprises an antibody described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, a nonbinding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, tricholoma toxin A chain, alpha-sarcin, Aleurites fordii proteins, dianthus proteins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, phytoncidin inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
[0812] In another embodiment, the immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes can be used to produce radioconjugates. Examples include 211 At 131 I. 125 I. 90 Y. 186 Re, 188 Re, 153 Sm, 212 Bi, 32 p. 212 When the radioconjugate is used for detection, it may contain a radioactive atom such as Tc-99m or 123 I, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
[0813] Conjugates of antibodies and cytotoxic agents can be prepared using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexyl-1-carboxylate (SMCC), iminothiophene (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate) and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionuclides to antibodies. See WO94 / 11026. The linker can be a "cleavable linker" that promotes release of the cytotoxic drug in the cell. For example, an acid-labile linker, a peptidase-sensitive linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker can be used (Chari et al., Cancer Res. 52: 127-131 (1992); U.S. Pat. No. 5,208,020).
[0814] The immunoconjugates or ADCs herein specifically contemplate, but are not limited to, such conjugates prepared with cross-linkers including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinyl sulfone) benzoate), which is commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL, USA).
[0815] V. Methods and compositions for diagnosis and detection
[0816] In certain embodiments, any anti-Cls antibody provided herein can be used to detect the presence of Cls in a biological sample. As used herein, the term "detection" includes quantitative or qualitative detection. In certain embodiments, the biological sample comprises cells or tissues, such as serum, whole blood, plasma, biopsy samples, tissue samples, cell suspensions, saliva, sputum, oral fluid, cerebrospinal fluid, amniotic fluid, ascites, milk, colostrum, mammary secretions, lymph, urine, sweat, tears, gastric juice, synovial fluid, peritoneal fluid, lens fluid or mucus.
[0817] In one embodiment, an anti-Cls antibody for use in a diagnostic or detection method is provided. In another aspect, a method for detecting the presence of Cls in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-Cls antibody as described herein under conditions that allow the anti-Cls antibody to bind to Cls, and detecting whether a complex is formed between the anti-Cls antibody and Cls. This method can be an in vitro or in vivo method. In one embodiment, the anti-Cls antibody is used to select a subject suitable for treatment with an anti-Cls antibody, for example, where Cls is a biomarker for selecting a patient.
[0818] Exemplary disorders that can be diagnosed using the antibodies of the invention include, but are not limited to, age-related macular degeneration, Alzheimer's disease, amyotrophic lateral sclerosis, allergic reactions, argyrophilic dementia, arthritis (e.g., rheumatoid arthritis), asthma, atherosclerosis, atypical hemolytic uremic syndrome, autoimmune diseases, Barraquer-Simons syndrome, Behcet's disease, British amyloid angiopathy, bullous pemphigoid, thromboangiitis obliterans, Clq nephropathy, cancer, catastrophic antiphospholipid syndrome, cerebral amyloid angiopathy, cold agglutinin disease, corticobasal degeneration, Creutzfeldt-Jakob disease, Crohn's disease, cryoglobulinaemic vasculitis, dementia pugilistica, dementia with Lewy bodies (DLB), diffuse neurofibrillary tangles with calcifications, discoid lupus erythematosus, Down syndrome, focal segmental glomerulosclerosis, formal thought disorder, frontotemporal dementia (FTD), frontotemporal dementia with Parkinson's disease associated with chromosome 17, ... Temporal lobar degeneration, Gerstmann-Straussler-Scheinker disease, Guillain-Barre syndrome, Hallervorden-Spatz disease, hemolytic uremic syndrome, hereditary angioedema, hypophosphastasis, idiopathic pneumonia syndrome, immune complex disease, inclusion body myositis, infectious diseases (e.g., those caused by bacteria (e.g., Neisseria meningitidis or Streptococcus), viruses (e.g., human immunodeficiency virus (HIV)), or other infectious agents), inflammatory diseases, ischemia / reperfusion injury, mild cognitive impairment, immune thrombocytopenic purpura (ITP), molybdenum cofactor deficiency (MoCD) type A, membranoproliferative glomerulonephritis (MPGN) I, membranoproliferative glomerulonephritis (MPGN) II (dense deposit disease), membranous nephritis, multi-infarct dementia, lupus (e.g.,Systemic lupus erythematosus (SLE), glomerulonephritis, Kawasaki disease, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, myasthenia gravis, myocardial infarction, myotonic dystrophy, neuromyelitis optica, Niemann-Pick disease type C, non-Guamanian motor neuron disease with neurofibrillary tangles, Parkinson's disease, Parkinson's disease with dementia, paroxysmal nocturnal hemoglobinuria, pemphigus vulgaris, Pick's disease, postencephalitic Parkinson's disease, polymyositis, prion amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, psoriasis, sepsis, Shiga toxin-producing Escherichia coli (STEC)-H uS, spinal muscular atrophy, stroke, subacute sclerosing panencephalitis, tangled dementia only, transplant rejection, vasculitis (e.g., ANCA-associated vasculitis), Wegener's granulomatosis, sickle cell disease, cryoglobulinemia, mixed cryoglobulinemia, essential mixed cryoglobulinemia, mixed cryoglobulinemia type II, mixed cryoglobulinemia type III, nephritis, drug-induced thrombocytopenia, lupus nephritis, bullous pemphigoid, epidermolysis bullosa acquisita, delayed hemolytic transfusion reaction, hypocomplementary urticarial vasculitis syndrome, pseudophakic bullous keratopathy, and platelet refractory. ,
[0819] In certain embodiments, labeled anti-Cls antibodies are provided. Labels include, but are not limited to, directly detected labels or moieties (e.g., fluorescent, chromogenic, electron-dense, chemiluminescent, and radioactive labels), and, for example, moieties that are indirectly detected by enzyme reactions or molecular interactions, such as enzymes or ligands. Exemplary labels include, but are not limited to, radioisotopes. 32 P. 14 C. 125 I. 3 H and 131 I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, such as firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinedione, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, sugar oxidases, such as glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase, heterocyclic oxidases (such as uricase and xanthine oxidase), those combined with enzymes that use hydrogen peroxide to oxidize dye precursors (such as HRP, lactoperoxidase or microperoxidase), biotin / avidin, spin labels, phage labels, stable free radicals, and the like.
[0820] VI. Pharmaceutical preparations
[0821] Pharmaceutical preparations of the anti-Cls antibodies described herein are prepared by mixing such antibodies having the desired purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)) in the form of a lyophilized formulation or an aqueous solution. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptide; protein, such as serum albumin, gelatin or immunoglobulin; hydrophilic polymer, such as polyvinyl pyrrolidone; amino acid, such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharide, disaccharide and other carbohydrate, including glucose, mannose or dextrin; chelating agent, such as EDTA; sugar, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterion, such as sodium; metal complex (such as Zn-protein complex); and / or nonionic surfactant, such as polyethylene glycol (PEG). The pharmaceutically acceptable carrier herein further includes an interstitial drug dispersant, such as a soluble neutral active hyaluronidase glycoprotein (sHASEGP), such as a human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 (HYLENEX (registered trademark), Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.
[0822] Exemplary lyophilized antibody formulations are described in US Pat. No. 6,267,958. Aqueous antibody formulations include those described in US Pat. No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.
[0823] The formulations herein may also contain more than one active ingredient, preferably those with complementary activities and which do not adversely affect each other, if necessary for treating a specific indication. For example, it may be desirable to further provide a formulation for combined therapy. Such active ingredients may be present in combination in an amount effective for the intended purpose.
[0824] The active ingredient can be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0825] Sustained release preparations may be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules.
[0826] Preparations for in vivo administration are generally sterile. Sterility can be easily achieved, for example, by filtration through sterile filtration membranes.
[0827] VII. Treatment Methods and Compositions
[0828] Any of the anti-Cls antibodies provided herein can be used in therapeutic methods.
[0829] In one aspect, anti-Cls antibodies for use as a medicament are provided. In other aspects, anti-Cls antibodies for use in treating complement-mediated diseases or conditions are provided. In certain embodiments, anti-Cls antibodies for use in methods of treatment are provided. In certain embodiments, the present invention provides anti-Cls antibodies for use in methods of treating individuals suffering from complement-mediated diseases or conditions, the method comprising administering an effective amount of the anti-Cls antibody to the individual. In one such embodiment, the method further comprises administering an effective amount of at least one additional therapeutic agent to the individual.
[0830] In a further embodiment, the present invention provides an anti-Cls antibody for use in treating a complement-mediated disease or condition. In a further embodiment, the anti-Cls antibody can be used to enhance the clearance of Cls from plasma. In a further embodiment, the anti-Cls antibody can be used to enhance the clearance of Clr2s2 from plasma. In a further embodiment, the anti-Cls antibody can be used to enhance the clearance of Clr2s2 from plasma rather than the clearance of Clq from plasma. In some cases, the antibody inhibits a component of the classical complement pathway; in some cases, the classical complement pathway component is Cls. In certain embodiments, the present invention provides an anti-Cls antibody for use in a method for treating a complement-mediated disease or condition. In certain embodiments, the present invention provides an anti-Cls antibody for use in a method for increasing the clearance of Cls from plasma. In certain embodiments, the present invention provides an anti-Cls antibody for use in a method for enhancing the clearance of Clr2s2 from plasma. In certain embodiments, the present invention provides an anti-Cls antibody for use in a method for enhancing the clearance of Clr2s2 from plasma rather than the clearance of Clq from plasma. In certain embodiments, the invention provides anti-Cls antibodies for use in a method of inhibiting a component of the classical complement pathway; in some cases, the classical complement pathway component is Cls. An "individual" according to any of the above embodiments is preferably a human.
[0831] In one aspect, the present disclosure provides a method for regulating complement activation. In some embodiments, the method inhibits complement activation, such as reducing the production of C4b2a. In some embodiments, the present disclosure provides a method for regulating complement activation in an individual suffering from a complement-mediated disease or condition, the method comprising administering an anti-Cls antibody of the present disclosure or a pharmaceutical composition of the present disclosure to the individual, wherein the pharmaceutical composition comprises an anti-Cls antibody of the present disclosure. In some embodiments, this method inhibits complement activation. In some embodiments, the individual is a mammal. In some embodiments, the individual is a human. It can be administered by any route known to those skilled in the art, including those disclosed herein. In some embodiments, administration is intravenous or subcutaneous. In some embodiments, administration is intrathecal.
[0832] A complement-mediated disease or disorder is a disorder characterized by abnormal amounts of complement Cls or abnormal levels of complement Cls proteolytic activity in cells, tissues or body fluids of an individual.
[0833] In some cases, the complement-mediated disease or condition is characterized by the presence of an elevated (higher than normal) amount of Cls or an elevated level of complement Cls activity in a cell, tissue, or body fluid. For example, in some cases, the complement-mediated disease or condition is characterized by the presence of elevated amounts and / or elevated activity of Cls in brain tissue and / or cerebrospinal fluid. The "higher than normal" amount of Cls in a cell, tissue, or body fluid represents that the amount of Cls in the cell, tissue, or body fluid is higher than the normal control level, for example, higher than the normal control level for an individual or group of individuals in the same age group. The "higher than normal" level of Cls activity in a cell, tissue, or body fluid indicates that the proteolytic cleavage that acts by Cls in a cell, tissue, or body fluid is higher than the normal control level, for example, higher than the normal control level for an individual or group of individuals in the same age group. In some cases, an individual suffering from a complement-mediated disease or condition exhibits one or more additional symptoms of such a disease or condition.
[0834] In other cases, the complement-mediated disease or condition is characterized by the presence of a lower than normal amount of Cls or a lower level of complement Cls activity in a cell, tissue or body fluid. For example, in some cases, the complement-mediated disease or condition is characterized by the presence of a lower amount and / or lower activity of Cls in brain tissue and / or cerebrospinal fluid. The "lower than normal" amount of Cls in a cell, tissue or body fluid indicates that the amount of Cls in the cell, tissue or body fluid is lower than the normal control level, for example, lower than the normal control level for an individual or group of individuals in the same age group. The "lower than normal" level of Cls activity in a cell, tissue or body fluid indicates that the proteolytic cleavage that acts by Cls in a cell, tissue or body fluid is lower than the normal control level, for example, lower than the normal control level for an individual or group of individuals in the same age group. In some cases, an individual suffering from a complement-mediated disease or condition exhibits one or more additional symptoms of such a disease or condition.
[0835] A complement-mediated disease or condition is a disease or condition in which the amount or activity of complement Cls causes a disease or condition in an individual. In some embodiments, a complement-mediated disease or condition is selected from the group consisting of autoimmune diseases, cancers, blood diseases, infectious diseases, inflammatory diseases, ischemia-reperfusion injury, neurodegenerative diseases, neurodegenerative disorders, eye diseases, kidney diseases, transplant rejection, vascular diseases, and vasculitis. In some embodiments, a complement-mediated disease or condition is an autoimmune disease. In some embodiments, a complement-mediated disease or condition is cancer. In some embodiments, a complement-mediated disease or condition is an infectious disease. In some embodiments, a complement-mediated disease or condition is an inflammatory disease. In some embodiments, a complement-mediated disease or condition is a blood disease. In some embodiments, a complement-mediated disease or condition is an ischemia-reperfusion injury. In some embodiments, a complement-mediated disease or condition is an eye disease. In some embodiments, a complement-mediated disease or condition is a kidney disease. In some embodiments, the complement-mediated disease or condition is transplant rejection. In some embodiments, the complement-mediated disease or condition is antibody-mediated transplant rejection. In some embodiments, the complement-mediated disease or condition is a vascular disease. In some embodiments, the complement-mediated disease or condition is a vasculitis condition. In some embodiments, the complement-mediated disease or condition is a neurodegenerative disease or condition. In some embodiments, the complement-mediated disease is a neurodegenerative disease. In some embodiments, the complement-mediated condition is a neurodegenerative condition. In some embodiments, the complement-mediated disease or condition is a tauopathy.
[0836] Examples of complement-mediated diseases or disorders include, but are not limited to, age-related macular degeneration, Alzheimer's disease, amyotrophic lateral sclerosis, allergic reactions, argyrophilic dementia, arthritis (e.g., rheumatoid arthritis), asthma, atherosclerosis, atypical hemolytic uremic syndrome, autoimmune diseases, Barraquer-Simons syndrome, Behcet's disease, British amyloid angiopathy, bullous pemphigoid, thromboangiitis obliterans , Clq nephropathy, cancer, catastrophic antiphospholipid syndrome, cerebral amyloid angiopathy, cold agglutinin disease, corticobasal degeneration, Creutzfeldt-Jakob disease, Crohn's disease, cryoglobulinemic vasculitis, dementia pugilistica, dementia with Lewy bodies (DLB), diffuse neurofibrillary tangles with calcifications, discoid lupus erythematosus, Down syndrome, focal segmental glomerulosclerosis, formal thought disorder, frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism associated with chromosome 17, frontotemporal lobar degeneration, Gerstmann-Straussler-Scheinker disease, Guillain-Barre syndrome, Hallervorden-Spatz disease, hemolytic uremic syndrome, hereditary angioedema, hypophosphastasis, idiopathic pneumonia syndrome, immune complex disease, inclusion body myositis, infectious diseases (e.g., caused by bacteria (e.g., Neisseria meningitidis or Streptococcus) viruses (e.g., human immunodeficiency virus (HIV)), or other infectious agents, inflammatory diseases, ischemia / reperfusion injury, mild cognitive impairment, immune thrombocytopenic purpura (ITP), molybdenum cofactor deficiency (MoCD) type A, membranoproliferative glomerulonephritis (MPGN) I, membranoproliferative glomerulonephritis (MPGN) II (dense deposit disease), membranous nephritis, multi-infarct dementia, lupus (e.g.,Systemic lupus erythematosus (SLE), glomerulonephritis, Kawasaki disease, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, myasthenia gravis, myocardial infarction, myotonic dystrophy, neuromyelitis optica, Niemann-Pick disease type C, non-Guamanian motor neuron disease with neurofibrillary tangles, Parkinson's disease, Parkinson's disease with dementia, paroxysmal nocturnal hemoglobinuria, pemphigus vulgaris, Pick's disease, postencephalitic Parkinson's disease, polymyositis, prion amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, psoriasis, sepsis, Shiga toxin-producing Escherichia coli (STEC)- HuS, spinal muscular atrophy, stroke, subacute sclerosing panencephalitis, tangled dementia only, transplant rejection, vasculitis (e.g., ANCA-associated vasculitis), Wegener's granulomatosis, sickle cell disease, cryoglobulinemia, mixed cryoglobulinemia, essential mixed cryoglobulinemia, mixed cryoglobulinemia type II, mixed cryoglobulinemia type III, nephritis, drug-induced thrombocytopenia, lupus nephritis, bullous pemphigoid, epidermolysis bullosa acquisita, delayed hemolytic transfusion reaction, hypocomplementary urticarial vasculitis syndrome, pseudophakic bullous keratopathy, and platelet refractory. ,
[0837] Alzheimer's disease and certain forms of frontotemporal dementia (Pick's disease, sporadic frontotemporal dementia and frontotemporal dementia of Parkinson's disease associated with chromosome 17) are the most common forms of tauopathy. Accordingly, the present invention relates to any method as described above, wherein the tauopathy is frontotemporal dementia of Alzheimer's disease, Pick's disease, sporadic frontotemporal dementia and Parkinson's disease associated with chromosome 17. Other tauopathies include, but are not limited to, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and subacute sclerosing panencephalitis.
[0838] Neurodegenerative tauopathies include Alzheimer's disease, amyotrophic lateral sclerosis / parkinsonism-dementia syndrome, argyrophilic dementia, British amyloid angiopathy, cerebral amyloid angiopathy, corticobasal degeneration, Creutzfeldt-Jakob disease, dementia pugilistica, diffuse neurofibrillary tangles with calcifications, Down syndrome, frontotemporal dementia, frontotemporal dementia with Parkinson disease associated with chromosome 17, frontotemporal lobar degeneration, Gerstmann-Straussler-Scheinker disease, Halle Vorden-Spatz disease, inclusion body myositis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian motor neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic Parkinsonism, prion amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, dementia with tangles only, multi-infarct dementia, ischemic stroke, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), and stroke.
[0839] The present disclosure also provides methods for treating synucleinopathies, such as Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA), etc. For example, PD with dementia (PDD) can be treated using the methods of the present disclosure.
[0840] In some embodiments, the complement-mediated disease or condition comprises Alzheimer's disease. In some embodiments, the complement-mediated disease or condition comprises Parkinson's disease. In some embodiments, the complement-mediated disease or condition comprises transplant rejection. In some embodiments, the complement-mediated disease or condition is antibody-mediated transplant rejection.
[0841] In some embodiments, the anti-Cls antibodies of the present disclosure prevent or delay the onset of at least one symptom of a complement-mediated disease or condition in an individual. In some embodiments, the anti-Cls antibodies of the present disclosure reduce or eliminate at least one symptom of a complement-mediated disease or condition in an individual. Examples of symptoms include, but are not limited to, symptoms associated with autoimmune diseases, cancers, blood diseases, infectious diseases, inflammatory diseases, ischemia-reperfusion injury, neurodegenerative diseases, neurodegenerative conditions, kidney disease, transplant rejection, eye diseases, vascular diseases, or vasculitis. Symptoms can be neurological symptoms, such as impaired cognitive function, impaired memory, loss of motor function, etc. Symptoms can also be the activity of Cls proteins in cells, tissues, or body fluids of an individual. Symptoms can also be the degree of complement activation in cells, tissues, or body fluids of an individual.
[0842] In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual modulates complement activation in the individual's cells, tissues, or body fluids. In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual inhibits complement activation in the individual's cells, tissues, or body fluids. For example, in some embodiments, when administered at one or more doses as a monotherapy or combination therapy to an individual suffering from a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure inhibits complement activation in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to complement activation in the individual before treatment with the anti-Cls antibody.
[0843] In some embodiments, the anti-Cls antibodies of the present disclosure reduce the deposition of C3 on red blood cells; for example, in some embodiments, the anti-Cls antibodies of the present disclosure reduce the deposition of C3b, iC3b, etc. on RBCs. In some embodiments, the anti-Cls antibodies of the present disclosure inhibit complement-mediated erythrocyte lysis.
[0844] In some embodiments, the anti-Cls antibodies of the present disclosure reduce the deposition of C3 on platelets; for example, in some embodiments, the anti-Cls antibodies of the present disclosure reduce the deposition of C3b, iC3b, etc. on platelets.
[0845] In some embodiments, administration of an anti-Cls antibody of the present disclosure results in a result selected from the group consisting of: (a) reduced complement activation; (b) improved cognitive function; (c) reduced neuronal loss; (d) reduced levels of phosphorylated Tau in neurons; (e) reduced glial activation; (f) reduced lymphocyte infiltration; (g) reduced macrophage infiltration; (h) reduced antibody deposition, (i) reduced glial cell loss; (j) reduced oligodendrocyte loss; (k) reduced dendritic cell infiltration; (l) reduced neutrophil infiltration; (m) reduced erythrocyte lysis; (n) reduced erythrocyte phagocytosis; (o) reduced platelet phagocytosis; (p) reduced platelet lysis; (q) reduced ) improved graft survival; (r) reduced macrophage-mediated phagocytosis; (s) improved vision; (t) improved motor control; (u) improved thrombosis; (v) improved coagulation; (w) improved renal function; (x) reduced antibody-mediated complement activation; (y) reduced autoantibody-mediated complement activation; (z) improved anemia; (aa) reduced demyelination; (ab) reduced eosinophilia; (ac) reduced deposition of C3 on erythrocytes (e.g., reduced deposition of C3b, iC3b, etc. on erythrocytes); and (ad) reduced deposition of C3 on platelets (e.g., reduced deposition of C3b, iC3b, etc. on platelets); and (ae) reduced anaphylatoxins (af) decreased autoantibody-mediated blister formation; (ag) decreased autoantibody-induced pruritus; (ah) decreased autoantibody-induced erythema; (ai) decreased autoantibody-mediated skin erosions; (aj) decreased red blood cell destruction due to transfusion reactions; (ak) decreased red blood cell lysis due to alloantibodies; (al) decreased hemolysis due to transfusion reactions; (am) decreased alloantibody-mediated platelet lysis; (an) decreased platelet lysis due to transfusion reactions; (ao) decreased mast cell activation; (ap) decreased mast cell histamine release; (aq) decreased vascular permeability; (ar) decreased edema; (as) decreased complement deposition on the graft endothelium; ( at) reduced production of anaphylatoxins in the graft endothelium; (au) reduced separation of the dermal-epidermal junction; (av) reduced production of anaphylatoxins at the dermal-epidermal junction; (aw) reduced alloantibody-mediated complement activation in the graft endothelium; (ax) reduced antibody-mediated loss of the neuromuscular junction; (ay) reduced complement activation at the neuromuscular junction; (az) reduced production of anaphylatoxins at the neuromuscular junction; (ba) reduced complement deposition at the neuromuscular junction; (bb) reduced paralysis; (be) reduced numbness; (bd) increased bladder control; (be) increased bowel control; (bf) reduced mortality associated with autoantibodies; and (bg) reduced morbidity associated with autoantibodies.
[0846] In some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or disorder, the anti-Cls antibodies of the present disclosure are effective in achieving at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90% reduction in one or more of the following outcomes compared to the level or extent of the outcome in the individual prior to treatment with the anti-Cls antibody: (a) complement activation; (b) cognitive decline; (c) neuronal loss; (d) neuronal Phosphorylated Tau levels in neurons; (e) glial cell activation; (f) lymphocyte infiltration; (g) macrophage infiltration; (h) antibody deposition, (i) glial cell loss; (j) oligodendrocyte loss; (k) dendritic cell infiltration; (l) neutrophil infiltration; (m) erythrocyte lysis; (n) erythrocyte phagocytosis; (o) platelet phagocytosis; (p) platelet lysis; (q) graft rejection; (r) macrophage-mediated phagocytosis; (s) visual loss; (t) antibody-mediated complement activation; (u) autoantibody-mediated complement activation; (v) demyelination; (w) eosinophilia.
[0847] In some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or disorder, the anti-Cls antibodies of the present disclosure are effective in achieving an improvement of at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90% in one or more of the following outcomes as compared to the level or extent of the outcome in the individual prior to treatment with the anti-Cls antibody: a) cognitive function; b) graft survival; c) vision; d) motor control; e) thrombosis; f) coagulation; g) renal function; and h) hematocrit (red blood cell count).
[0848] In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual reduces complement activation in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces complement activation in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to complement activation in the individual prior to treatment with the anti-Cls antibody.
[0849] In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual improves cognitive function of the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure improves cognitive function of the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to the cognitive function of the individual before treatment with the anti-Cls antibody.
[0850] In some embodiments, administering an anti-Cls antibody of the present disclosure to an individual reduces the rate of cognitive decline in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces the rate of cognitive decline in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90% compared to the rate of cognitive decline in the individual before treatment with the anti-Cls antibody.
[0851] In some embodiments, administering an anti-Cls antibody of the present disclosure to an individual reduces neuronal loss in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces neuronal loss in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to neuronal loss in the individual before treatment with the anti-Cls antibody.
[0852] In some embodiments, administering an anti-Cls antibody of the present disclosure to an individual reduces the level of phosphorylated Tau in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces the phosphorylated Tau level of the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90% compared to the level of phosphorylated Tau in the individual before treatment with the anti-Cls antibody.
[0853] In some embodiments, administering an anti-Cls antibody of the present disclosure to an individual reduces glial cell activation in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces glial cell activation in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to glial cell activation in the individual before treatment with the anti-Cls antibody. In some embodiments, the glial cell is an astrocyte or a microglia.
[0854] In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual reduces lymphocyte infiltration in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces lymphocyte infiltration in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to lymphocyte infiltration in the individual before treatment with the anti-Cls antibody.
[0855] In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual reduces macrophage infiltration in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces macrophage infiltration in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90% compared to macrophage infiltration in the individual prior to treatment with the anti-Cls antibody.
[0856] In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual reduces antibody deposition in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, an anti-Cls antibody of the present disclosure reduces antibody deposition in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to antibody deposition in the individual prior to treatment with the anti-Cls antibody.
[0857] In some embodiments, administration of an anti-Cls antibody of the present disclosure to an individual reduces the production of anaphylatoxins (e.g., C3a, C4a, C5a) in the individual. For example, in some embodiments, when administered at one or more doses as a monotherapy or in combination therapy to an individual with a complement-mediated disease or condition, the anti-Cls antibody of the present disclosure reduces the production of anaphylatoxins in the individual by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, compared to the production of anaphylatoxins in the individual before treatment with the anti-Cls antibody.
[0858] In some embodiments, the present disclosure provides the use of an anti-Cls antibody of the present disclosure or a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for treating an individual suffering from a complement-mediated disease or condition. In some embodiments, the present disclosure provides the use of an anti-Cls antibody of the present disclosure in treating an individual suffering from a complement-mediated disease or condition. In some embodiments, the present disclosure provides the use of a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient in treating an individual suffering from a complement-mediated disease or condition.
[0859] In some embodiments, the disclosure provides use of an anti-Cls antibody of the disclosure in the preparation of a medicament for treating an individual suffering from a complement-mediated disease or disorder.
[0860] In some embodiments, the present disclosure provides the use of an anti-Cls antibody of the present disclosure or a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for inhibiting complement activation. In some embodiments, the present disclosure provides the use of an anti-Cls antibody of the present disclosure or a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient in inhibiting complement activation in an individual suffering from a complement-mediated disease or condition. In some embodiments, the present disclosure provides the use of an anti-Cls antibody of the present disclosure in inhibiting complement activation in an individual suffering from a complement-mediated disease or condition. In some embodiments, the present disclosure provides the use of a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient in inhibiting complement activation in an individual suffering from a complement-mediated disease or condition.
[0861] In some embodiments, the present disclosure provides the use of an anti-Cls antibody of the present disclosure in the preparation of a medicament for modulating complement activation. In some embodiments, the medicament inhibits complement activation. In some embodiments, the medicament inhibits complement activation in an individual suffering from a complement-mediated disease or disorder.
[0862] In some embodiments, the present disclosure provides an anti-Cls antibody of the present disclosure or a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for use in medical treatment. In some embodiments, the present disclosure provides an anti-Cls antibody of the present disclosure for use in medical treatment. In some embodiments, the present disclosure provides a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for use in medical treatment.
[0863] In some embodiments, the present disclosure provides an anti-Cls antibody of the present disclosure or a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for treating an individual suffering from a complement-mediated disease or condition. In some embodiments, the present disclosure provides an anti-Cls antibody of the present disclosure for treating an individual suffering from a complement-mediated disease or condition. In some embodiments, the present disclosure provides a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for treating an individual suffering from a complement-mediated disease or condition.
[0864] In some embodiments, the present disclosure provides an anti-Cls antibody of the present disclosure or a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for regulating complement activation. In some embodiments, the present disclosure provides an anti-Cls antibody of the present disclosure for regulating complement activation. In some embodiments, the present disclosure provides a pharmaceutical composition comprising an anti-Cls antibody of the present disclosure and a pharmaceutically acceptable excipient for regulating complement activation. In some embodiments, the anti-Cls antibody inhibits complement activation.
[0865] On the other hand, the present invention provides the use of anti-Cls antibodies in the manufacture or preparation of drugs. In one embodiment, the drug is used to treat a complement-mediated disease or condition. In a further embodiment, the drug is used in a method for treating a complement-mediated disease or condition, comprising administering an effective amount of the drug to an individual suffering from a complement-mediated disease or condition. In one such embodiment, the method further comprises administering an effective amount of at least one additional therapeutic agent to the individual, for example, as described below. In a further embodiment, the drug is used to enhance the clearance (or removal) of Cls from plasma. In a further embodiment, the drug is used to enhance the clearance (or removal) of Clr2s2 from plasma. In a further embodiment, the drug is used to enhance the clearance (or removal) of Clr2s2 from plasma rather than the clearance (or removal) of Clq from plasma. In a further embodiment, the drug is used to inhibit components of the classical complement pathway; in some cases, the components of the classical complement pathway are Cls.
[0866] In a further embodiment, the medicament is for use in a method of treating an individual suffering from a complement-mediated disease or disorder, comprising administering to the individual an effective amount of the medicament.The "individual" according to any of the above embodiments may be a human.
[0867] In a further aspect, the invention provides a method for treating a complement-mediated disease or condition. In one embodiment, the method administers an effective amount of an anti-Cls antibody to an individual suffering from such a complement-mediated disease or condition. In one such embodiment, the method further comprises administering an effective amount of at least one additional therapeutic agent to the individual, as described below. According to any of the above embodiments, an "individual" can be a human.
[0868] In a further aspect, the invention provides methods for enhancing the clearance (or removal) of Cls from the plasma of an individual. In a further aspect, the invention provides methods for enhancing the clearance (or removal) of Clr2s2 from the plasma of an individual. In another aspect, the invention provides methods for enhancing the clearance (or removal) of Clr2s2 from the plasma but not the clearance (or removal) of Clq from the plasma of an individual. In some cases, the invention provides methods for inhibiting a component of the classical complement pathway in an individual; in some cases, the classical complement pathway component is Cls. In one embodiment, the "individual" is a human.
[0869] In a further aspect, the invention provides a pharmaceutical preparation comprising any anti-Cls antibody provided herein, e.g., for use in any of the above-mentioned methods of treatment. In one embodiment, the pharmaceutical preparation comprises any anti-Cls antibody provided herein and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical preparation comprises any anti-Cls antibody provided herein and at least one additional therapeutic agent, e.g., as described below.
[0870] The antibodies of the invention can be used alone or in combination with other agents in therapy. For example, the antibodies of the invention can be co-administered with at least one additional therapeutic agent.
[0871] Such combination therapies described above include combined administration (wherein two or more therapeutic agents are contained in the same or separate formulations) and separate administration, in which case the administration of the antibodies of the present invention may be prior to, concurrently with, and / or subsequent to the administration of the additional one or more therapeutic agents. In one embodiment, the administration of the anti-Cls antibody and the administration of the additional therapeutic agent occur within about one month of each other, or within about one, two, or three weeks, or within about one, two, three, four, five, or six days. The antibodies of the present invention may also be used in combination with radiation therapy.
[0872] The antibodies of the present invention (and any additional therapeutic agents) can be administered by any suitable means, including parenteral, intrapulmonary and intranasal, and if local treatment is desired, can be administered intralesionally. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. Administration can be by any suitable route, such as by injection, such as intravenous or subcutaneous injection, depending in part on whether the administration is short-lived or long-term. Various dosing regimens including but not limited to single or multiple administrations at different time points, bolus administration and pulse infusions are contemplated herein.
[0873] The antibodies of the present invention will be formulated, dosed and applied in a manner consistent with good medical practice. Factors considered in this case include the specific condition being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the condition, the delivery site of the agent, the method of administration, the time schedule of administration, and other factors known to the physician. The antibody need not be but is optionally formulated with one or more agents currently used to prevent or treat the condition in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of condition or treatment, and the other factors mentioned above. These are generally used with the same dosage and route of administration as described herein, or with about 1% to 99% of the dosage described herein, or with any dosage and any route determined to be suitable by experience / clinical practice.
[0874] For the prevention or treatment of a disease, the appropriate dose of the antibody of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is for preventive or therapeutic purposes, previous treatment, the patient's clinical history and response to the antibody, and the judgment of the attending physician. The antibody is suitable for administration to the patient at one time or in a series of treatments. Depending on the type and severity of the disease, an antibody of about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg-10 mg / kg) can be an initial candidate dose for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. Depending on the above factors, a typical daily dose may be in the range of about 1 μg / kg to 100 mg / kg or more. For repeated administration for several days or longer, depending on the condition, treatment will generally continue until the desired suppression of disease symptoms occurs. An exemplary dose of the antibody will be in the range of about 0.05 mg / kg to about 10 mg / kg. Therefore, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg or 10 mg / kg (or any combination thereof) can be administered to the patient. Such doses can be administered intermittently, for example, weekly or every three weeks (for example, so that the patient receives about 2 to about 20 doses, or for example, about 6 doses of antibody). An initial higher loading dose can be administered, followed by one or more lower doses. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
[0875] It will be appreciated that any of the above-described formulations or treatment methods may be performed using an immunoconjugate of the invention in place of or in addition to an anti-Cls antibody.
[0876] VIII. Products
[0877] In another aspect of the present invention, an article containing materials for treating, preventing and / or diagnosing the above-mentioned diseases is provided. The article includes a container and a label on the container or a package insert associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be made of a variety of materials such as glass or plastic. The container holds a composition, which is itself or in combination with another composition that is effective in treating, preventing and / or diagnosing the condition, and can have a sterile access port (for example, the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). At least one active ingredient in the composition is an antibody of the present invention. The label or package insert indicates that the composition is used to treat the selected condition. In addition, the article may include (a) a first container containing a composition, wherein the composition comprises an antibody of the present invention; and (b) a second container containing a composition, wherein the composition contains further cytotoxic or other therapeutic agents. The article in this embodiment of the present invention may further include a package insert, which indicates that the composition can be used to treat a specific condition. Alternatively or additionally, the article of manufacture may further include a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.
[0878] It will be understood that any of the above-described articles of manufacture may include an immunoconjugate of the invention in place of or in addition to an anti-Cls antibody. Example
[0879] The following are examples of methods and compositions of the present invention.It should be understood that various other embodiments may be practiced, given the general description provided above.
[0880] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, these descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patents and scientific literature cited herein are expressly incorporated by reference in their entirety.
[0881] Example 1
[0882] Preparation of recombinant Clr2s2
[0883] 1.1. Expression and purification of cynomolgus monkey Clr2s2 His / FLAG (registered trademark) tetramer
[0884] The sequences used for expression and purification were: cynomolgus monkey Cls with a C-terminal GGGGS linker and a FLAG (registered trademark) tag (SEQ ID NO: 29) and cynomolgus monkey Clr with a C-terminal GGGGS linker and an 8x histidine tag. The cynomolgus monkey Clr sequence had a R463Q S654A mutation (SEQ ID NO: 30). For expression of recombinant cynomolgus monkey Clr2s2 His / FLAG (registered trademark) tetramers, FreeStyle (registered trademark) 293-F cell line (Thermo Fisher, Carlsbad, CA, USA) was used to transiently co-express cynomolgus monkey Cls-FLAG (registered trademark) and cynomolgus monkey Clr-His. Conditioned medium expressing recombinant cynomolgus monkey Clr2s2 His / FLAG (registered trademark) tetramers was applied to anti-FLAG (registered trademark) M2 affinity resin (Sigma) and eluted with FLAG (registered trademark) peptide (Sigma). The fraction containing recombinant cynomolgus monkey Clr2s2 His / FLAG (registered trademark) tetramer was subjected to an IMAC column (GE Healthcare) and eluted with an imidazole gradient. The eluted fraction containing recombinant Clr2s2 His / FLAG (registered trademark) tetramer was collected and concentrated, and then subjected to a Superdex (registered trademark) 200 gel filtration column (GE Healthcare) equilibrated with 1X TBS, 2mM CaCl2 buffer. The fractions containing recombinant cynomolgus monkey Clr2s2 His / FLAG (registered trademark) were then combined, concentrated and stored at -80°C.
[0885] 1.2. Expression and purification of human Clr2s2 tetramer
[0886] The sequences used for expression and purification were: human Cls (NCBI Reference Sequence: NP_958850.1) (SEQ ID NO: 31) and human Clr (NCBI Reference Sequence: NP_001724.3). The human Clr sequence had a R463Q S654A mutation (SEQ ID NO: 32). For expression of recombinant human Clr2s2 tetramers, HEK293 (Expi293 (registered trademark)) cell lines (ThermoFisher, Carlsbad, CA, USA) or FreeStyle (registered trademark) 293-F cell lines (Thermo Fisher, Carlsbad, CA, USA) were used to transiently co-express human Cls and human Clr. The conditioned medium expressing recombinant human Clr2s2 was diluted to one third with MilliQ (registered trademark) water, 1M CaCl2 was added to a final 2mM, the pH was adjusted to 8 with 1N NaOH, and then loaded onto a Q agarose HP anion exchange chromatography column (GE healthcare) with 50mM Tris-HCl, 2mM CaCl2 pH8.0, and eluted with a NaCl gradient. The eluted fractions containing recombinant human Clr2s2 tetramers were collected and concentrated, and then subjected to a Superdex (registered trademark) 200 gel filtration column (GE Healthcare) equilibrated with 1XTBS, 2mM CaCl2 buffer. The fractions containing recombinant human Clr2s2 tetramers were then combined, concentrated if necessary, and stored at -80°C.
[0887] 1.3. Expression and purification of cynomolgus monkey Clr2s2 tetramer
[0888] The sequences used for expression and purification were: cynomolgus monkey Cls (SEQ ID NO: 33) and cynomolgus monkey Clr. The cynomolgus monkey Clr sequence had a R463Q S654A mutation (SEQ ID NO: 34). For expression of recombinant cynomolgus monkey Clr2s2 tetramers, HEK293 (Expi293 (registered trademark)) cell line (Thermo Fisher, Carlsbad, CA, USA) was used to transiently co-express cynomolgus monkey Cls and cynomolgus monkey Clr. The conditioned medium expressing recombinant cynomolgus monkey Clr2s2 was diluted to one-third with MilliQ (registered trademark) water, 0.1 M CaCl2 was added to a final 2 mM, the pH was adjusted to 8 with 1 N NaOH, loaded onto a HiTrap (registered trademark) Q HP anion exchange chromatography column (GE healthcare), and eluted with a NaCl gradient. The eluted fractions containing the recombinant human Clr2s2 tetramer were collected, concentrated, and then subjected to a Superdex (registered trademark) 200 gel filtration column (GE Healthcare) equilibrated with 1X TBS, 2 mM CaCl2 buffer. The fractions containing the recombinant cynomolgus monkey Clr2s2 tetramer were then combined and stored at -80°C.
[0889] Example 2
[0890] Preparation of anti-Cls antibody
[0891] 2.1. Generation and preparation of optimized antibodies from COS0637cc
[0892] In order to reduce the potential immunogenicity of the antibody, the variable regions of some anti-Cls antibodies COS0637cc (VH, SEQ ID NO: 35; VL, SEQ ID NO: 36, as described in WO2019 / 198807) were humanized. The complementary determining regions (CDRs) of anti-Cls rabbit antibodies were transplanted to the homologous human antibody framework (FR) using conventional CDR transplantation methods (Nature 321: 522-525 (1986)). Thus, humanized variable regions COS0637h (VH, SEQ ID NO: 37; VL, SEQ ID NO: 38) were generated.
[0893] The amino acids in the CDR region of COS0637cc were completely replaced by histidine. An effective mutation, K101H in HCDR3, was found and applied to COS0637h. The variable regions of the pH-dependent humanized anti-Cls antibody COS0637temp were generated (VH, SEQ ID NO: 39; VL, SEQ ID NO: 38).
[0894] Many mutations and combinations of mutations were examined to identify mutations and combinations of mutations that improve the binding properties of the lead antibody. Multiple mutations were then introduced into the variable region of COS0637temp to enhance the binding affinity with Cls (human Clr2s2 or cynomolgus monkey Clr2s2 or cynomolgus monkey Clr2s2 His / FLAG (registered trademark)) at neutral pH, or to reduce the binding affinity with Cls at acidic pH. Therefore, the optimized variants COS0637pHv1 and COS0637pHv2 were generated from COS0637temp. The sequence ID numbers of VH, VL, HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3 of the two antibodies are listed in Table 2.
[0895] [Table 2]
[0896]
[0897] Although humanized pH-dependent anti-Cls antibodies were produced, COS0637pHv1 and COS0637pHv2 have the potential risk of forming heterogeneous products due to the cysteine at positions 94 and 95d (kabat numbering) in the light chain. In order to reduce the risk of heterogeneity, comprehensive single amino acid substitutions were performed at the two positions of COS0637temp to find amino acids that retain binding ability. The sequence ID numbers of the VH and VL of the 38 antibodies and their mutations (kabat numbering) are listed in Table 3.
[0898] [Table 3]
[0899]
[0900] However, any variant with a single amino acid substitution did not show a binding reaction in the SPR (surface plasmon resonance) assay, and each single substitution combination of COS0637temp was performed. The sequence ID numbers of VH and VL of 18 antibodies and their mutations (kabat numbering) are listed in Table 4. Three antibodies (AL0737, AL0743, AL0744) among the 18 antibodies showed a slight binding reaction. In order to exclude the potential risk of methionine and tryptophan oxidation, AL0743 (containing C94Y and C95dL substitutions) was selected as a template for further optimization.
[0901] [Table 4]
[0902]
[0903] Since the binding affinity of AL0743 is weak, many mutation combinations were introduced into AL0743 to improve the binding properties (affinity at pH 7.4 and pH dependence). In addition, further engineering was performed to reduce their pI below COS0637pHv1 and COS0637pHv2. Thus, 7 engineered antibodies were generated. The sequence numbers of VH, VL, HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 are listed in Table 5-1.
[0904] [Table 5-1]
[0905]
[0906] The gene encoding VH was synthesized and combined with the human IgG1 heavy chain constant region (CH) (SG1, SEQ ID NO: 107), modified human IgG1 CH (e.g., SG1077R (SEQ ID NO: 108), TT91R (SEQ ID NO: 109), and SG1148 (SEQ ID NO: 110). The gene encoding VL was synthesized and combined with human CL (SK1, SEQ ID NO: 111) and modified human CL (KOMC, SEQ ID NO: 112), and the gene of the combined sequence was cloned into an expression vector.
[0907] The antibodies were expressed in HEK293 cells co-transfected with a mixture of heavy chain and light chain expression vectors and purified by protein A. If necessary, gel filtration was further performed. The names of the prepared antibodies are listed in Table 5-2. AH0813-SG1 was used as a control for the assay in Example 5.
[0908] [Table 5-2]
[0909]
[0910] Preparation of IPN009VH2VK3-SG1148
[0911] The polynucleotides of the heavy and light chain variable regions of the anti-Cls antibody, IPN009VH2 (SEQ TD NO: 113) and IPN009VK3 (SEQ ID NO: 114) (as described in WO2019 / 098212) were synthesized. The heavy and light chain variable regions were cloned into expression vectors containing the heavy chain constant region SG1148 (SEQ ID NO: 110) and the light chain constant region SK1 (SEQ ID No: 111), respectively.
[0912] According to the manufacturer's instructions, anti-Cls antibody IPN009VH2VK3-SG1148 was transiently expressed using Expi293 (registered trademark) F cells (Life Technologies). Recombinant antibodies were purified using protein A (GE Healthcare) and eluted in D-PBS, Tris buffered saline (TBS) or His buffer (20 mM histidine, 150 mM NaCl, pH 6.0). If necessary, size exclusion chromatography was further performed to remove high molecular weight and / or low molecular weight components.
[0913] Example 3
[0914] Binding characterization of anti-Cls antibodies
[0915] 3.1. BIACORE (registered trademark) screening for cysteine substitution in LCDR3 of COS0637temp
[0916] The analysis of the interaction between the antibody variants and the human Clr2s2 prepared as above was performed using a BIACORE (registered trademark) T200 instrument (GE Healthcare) or a BIACORE (registered trademark) 4000 (GE Healthcare) at pH 7.4 and 37°C. ProL (BioVision) was fixed to a CM4 sensor chip using an amine coupling kit (GE Healthcare) according to the settings recommended by GE Healthcare. Antibodies and analytes were diluted to their respective running buffers ACES pH 7.4 (20 mM ACES (N-(2-acetylamino)-2-aminoethanesulfonic acid), 150 mM NaCl, 1.2 mM CaCl2, 1 mg / ml bovine serum albumin BSA), 1 mg / ml CMD (CM-dextran sodium salt), 0.05% Tween (registered trademark) 20 (polysorbate 20), 0.005 w / v% NaN3). ProL captured each antibody to the sensor surface. Antibody capture levels were for 200 resonance units (RU). Then, recombinant human Clr2s2 was injected at concentrations of 25 and 100 nM and then dissociated at pH 7.4. The surface was regenerated using 10 mM glycine-HCl, pH 1.5. The sensorgrams for all antibodies at an antigen concentration of 100 nM are shown in Figure 2. Figure 1 , 2 and 3. Figure 1 Sensorgrams of single amino acid substitution variants at position 94 (kabat numbering) in the light chain of COS0637temp are shown. Figure 2 Sensorgrams of single amino acid substitution variants at position 95d (kabat numbering) in the light chain of COS0637temp are shown. Figure 3The sensorgrams of double amino acid substitution variants at positions 94 and 95d (Kabat numbering) in the light chain of COS0637temp are shown. Slight binding reactions were observed in three antibodies (AL0737, AL0743, AL0744). Figure 3 Highlighted with an arrow.
[0917] 3.2. Evaluation of Binding Activity to Clr2s2 at pH 7.4 and pH 5.8 Using BIACORE (registered trademark) sensorgrams
[0918] Comparison of BIACORE sensorgrams at pH 7.4 and pH 5.8
[0919] The binding properties of each sample at pH 7.4 and pH 5.8 were determined using a BIACORE (registered trademark) T200 instrument (GE Healthcare) at 37°C. Purified mouse anti-human Ig κ light chain (GE Healthcare) can be fixed to all flow cells of a CM5 sensor chip using an amine coupling kit (GE Healthcare). 20mM ACES, 150mM NaCl, 1.2mM CaCl2, 1mg / mL BSA (IgG-free), 1mg / mL CMD, 0.05% Tween (registered trademark) 20, 0.005% NaN3, pH 7.4 or pH 5.8 buffer were used as running buffer. Each antibody can be captured on the sensor surface by anti-human Ig κ light chain. Antibody capture levels were for 50 resonance units (RU). Human and cynomolgus Clr2s2 were prepared and can be injected at, for example, 800 or 1600 nM at 30 μl / min (1600 nM for COS0637temp-TT91R and 800 nM for the others). The sensor surface was regenerated using, for example, glycine pH 2.0 (GE Healthcare) for each cycle. Sensorgrams were obtained using BIACORE (registered trademark) T200 evaluation software version 2.0 (GE Healthcare). Figures 4-1 to 4-12 ). Each sensorgram is represented as follows: the solid line is human Clr2s2 at pH 7.4, the dotted line is human Clr2s2 at pH 5.8, the dashed line is cynomolgus monkey Clr2s2 at pH 7.4, and the dotted line is cynomolgus monkey Clr2s2 at pH 5.8. Although COS637cc-TT91R and COS0637h-TT91R showed comparable binding responses under both pH 7.4 and pH 5.8 conditions, the variants engineered for pH dependence showed significantly less binding under acidic conditions.
[0920] 3.3. Evaluation of pH-dependent binding to human Clr2s2 using kinetic scoring
[0921] The KD values (dissociation constants) of each sample at pH 7.4 and pH 5.8 were determined using a BIACORE (registered trademark) T200 instrument (GE Healthcare) at 37°C. Purified mouse anti-human Ig κ light chains (GE Healthcare) can be fixed to all flow cells of a CM5 sensor chip using an amine coupling kit (GE Healthcare). 20mM ACES, 150mM NaCl, 1.2mM CaCl2, 1mg / mL BSA (IgG-free), 1mg / mL CMD, 0.05% Tween (registered trademark) 20, 0.005% NaN3, pH 7.4 or pH 5.8 buffer were used as running buffer. Each antibody can be captured on the sensor surface by anti-human Ig κ light chains. Antibody capture levels were for 50 resonance units (RU). For KD values with pH 7.4, human Clr2s2 was prepared and can be injected at 0, 25, 40, 100, 200, 400 nM or 0, 12.5, 25, 40, 100, 200 nM or 0, 6.3, 12.5, 25, 50, 100 nM at 30 microliters per minute. For KD values with pH 5.8, human Clr2s2 was prepared and can be injected at 0, 200, 400, 800, 1600, 3200 nM or 0, 50, 100, 200, 400, 800 nM at 30 microliters per minute using, for example, glycine pH 2.0 (GE Healthcare). The sensor surface was regenerated using, for example, glycine pH 2.0 (GE Healthcare) for each cycle. KD values were obtained using BIACORE (registered trademark) T200 evaluation software version 2.0 (GE Healthcare). The KD values with pH 5.8 were compared with the pH 7.4 KD ((KD with pH 5.8) / (KD with pH 7.4)) (Table 6). KD values were rejected if the quality control results of the BIACORE (registered trademark) software mentioned that the "kinetic constants could not be uniquely determined" for the antibody and were described as ND (not detectable) in Table 6. The KD (pH 5.8) / KD (pH 7.4) scores of the engineered variants were higher than those of COS637cc-TT91R and COS0637h-TT91R. All COS0637 variants were described to have stronger pH dependence than COS0637cc-TT91R.
[0922] [Table 6]
[0923]
[0924] *ND: Not Detectable
[0925] 3.4. Evaluation of the Clq substitution function of anti-Cls antibodies
[0926] The Clq replacement function of antibody is proved by using BIACORE (registered trademark) T200 instrument (GE Healthcare) at 37 degrees Celsius Clr2s2 capture method. Anti-human Clr2s2 antibody IPN009VH2Vk3-SG1148 is fixed to CM5 sensor chip using amine coupling kit (GE Healthcare). Antibody, recombinant human Clr2s2 tetramer and natural human Clq (CompTech) are prepared in pH 7.4 buffer (20mM ACES, 150mM NaCl, 1.2mM CaCl2, 1mg / mL BSA (IgG-free), 1mg / mL CMD, 0.05% Tween (registered trademark) 20, 0.005% NaN3, pH 7.4). Recombinant human Clr2s2 tetramer is first captured to sensor surface by anti-Clr2s2 antibody. Capture level is for 200 resonance units (RU). Then, native human Clq was injected at approximately 100 nM, follow...
Claims
1. An isolated antibody comprising an antigen binding region and an antibody constant region, wherein The antibody promotes the dissociation of Clq from the Clqrs complex and / or inhibits the binding of Clq to Clr2s2, wherein In the case where the binding activity of the antibody to human and / or cynomolgus monkey C1s is measured by surface plasmon resonance, i) the dissociation constant (KD) values in the neutral pH range can be reliably calculated, whereas the KD values in the acidic pH range cannot be reliably calculated due to the absence of binding activity or very low binding activity, or ii) Under the premise that both the KD values in the neutral pH range and the acidic pH range can be reliably calculated, the ratio of the KD value in the acidic pH range to the KD value in the neutral pH range, i.e. the acidic KD / neutral KD ratio is greater than 10, Wherein the antibody comprises: 1) the VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:38; 2) the VH sequence of SEQ ID NO:41 and the VL sequence of SEQ ID NO:38; 3) the VH sequence of SEQ ID NO:98 and the VL sequence of SEQ ID NO:101; 4) the VH sequence of SEQ ID NO:99 and the VL sequence of SEQ ID NO:101; 5) the VH sequence of SEQ ID NO:99 and the VL sequence of SEQ ID NO:102; 6) the VH sequence of SEQ ID NO:99 and the VL sequence of SEQ ID NO:103; 7) the VH sequence of SEQ ID NO: 100 and the VL sequence of SEQ ID NO: 104; 8) the VH sequence of SEQ ID NO: 100 and the VL sequence of SEQ ID NO: 105; or 9) VH sequence of SEQ ID NO:100 and VL sequence of SEQ ID NO:
106.
2. The antibody of claim 1, wherein the binding activity is measured by surface plasmon resonance at 37 degrees Celsius using a sensor chip and a running buffer, each antibody being captured on the sensor chip with 50 resonance units by human Igκ light chain, and the running buffer comprises 20mM ACS (N-(2-acetylamino)-2-aminoethanesulfonic acid), 150mM NaCl, 1.2mM CaCl2, 1mg / mL bovine serum albumin (BSA), 1mg / mL CM-dextran sodium salt (CMD), 0.05% polysorbate 20, and 0.005% NaN3.
3. The antibody of claim 1 or 2, wherein the pi of the antibody is less than 9.00, and 4.28 or greater.
4. The antibody according to claim 1 or 2, wherein The antigen binding region specifically binds to the CUB1-EGF-CUB2 domain of human C1s.
Citation Information
Patent Citations
Two-layer type cold insulating implement
JP2011218006A
Encryption data generating device, decryption data generating device, authentication cryptosystem with additional data, and method and program therefor
JP2019015919A
Process for purifying antibody
US20020164328A1
Antibody composition-producing cell
US20030115614A1
Glycoprotein compositions
US20030157108A1
